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General Section

11. Introduction
1. 1. Peptide binding and cleavage
Proteins and peptides consist of 20 amino acid with different side chain functional
groups, thus their possibilities to form diverse structures are immense.[1] Because of this
large structural variety, proteins fulfil a wide range of functions in nature. Examples are
the use of proteins as structural material or for the storage of nitrogen. Probably the most
important function of proteins is the catalysis of chemical reactions as enzymes.
Selective interactions between proteins are crucial not only for enzyme function but also
for signal transduction. The principles that govern such intermolecular interactions are
still not fully understood because of the complexity of protein structures. Studies on small
model systems might lead to a better understanding of these complex interactions.
Therefore, the development of small receptors for peptides has attracted much attention in
recent years.[2-5] Apart from serving as a model for the study of complex protein-protein
interactions, such receptors have many potential applications. These include the use as
stationary phases for the separation of peptides[6], the development of selective sensors[7]
as well as the use as pharmaceutical drugs.
Although selective receptors for single amino acids have been rationally designed,[8] the
binding of small peptides is a much more challenging task. The reason for this lies in the
conformational flexibility of peptides, that complicates the design of a suitable receptor.
An example that demonstrates the difficulty to predict selective peptide binding is the
antibiotic vancomycin.[9] It is a macrotricyclic glycopeptide that binds with high affinity
2to the C-terminal peptide motif D-Ala-D-Ala. This sequence plays an important role in the
cell wall crosslinking of gram positive bacteria. When this peptide is blocked, the bacteria
are not able to build up their cell wall and cannot survive.
Resistant bacteria appeared that use D-Ala-D-Lac instead of D-Ala-D-Ala.[10]  This small
modification (just one atom is changed) results in a 1000 fold decrease of the binding
affinity.[11] The reason is a repulsive electrostatic interaction of the oxygen instead of a
hydrogen bond in case of D-Ala-D-Ala (figure 1.1.). This clarifies what big consequences
a minute structural change can have on the selectivity and strength of intermolecular
binding.
Figure 1.1.:  Intermolecular interactions between vancomycin and D-Ala-D-Lac
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3In analogy, the rational design of a receptor for a given peptide is very difficult.  At this
point, where rational design reaches its limits, an empirical approach using combinatorial
chemistry proves to be helpful. This concept relies on random mutations and selection of
the best binding partner out of a big pool of different compounds.
Using combinatorial chemistry, Ellman and co-workers found selective receptors for D-
Ala-D-Lac varying a vancomycin fragment combinatorially.[12] A more general concept
for peptide receptors is given by tweezer like receptors.[13-17] It involves two arms with
possible sites for interactions that are bound to a structure defining backbone.
Figure 1.2.: Scematic structure of tweezer like receptors and two examples
There are several examples of tweezer-like receptors that bind to peptides selectively
(figure 1. 2.).[13-17]  However, the existing tweezer-like peptide receptors bear certain
drawbacks, such as the lack of possibility to introduce molecular diversity (1) or difficult
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4synthesis (2). Thus, we were interested in the development of a novel class of tweezer
like receptors.
An even larger challenge than the selective binding is the selective cleavage of peptides
since amide bonds are very stable. In nature, this is accomplished by proteases.[1]   They
lower the activation barrier for amide hydrolysis and also assure that peptide bonds are
cleaved specifically.  While proteases provide for the controled cleavage of peptide
bonds, also undesired peptide cleavage occurs in nature, for example by radical mediated
damage catalyzed by metals.[18]
One example is the Fenton reaction. Although first described already in 1894,[19] it was
about 40 years later, that its mechanism was studied thoroughly by Haber and Weiss
among others. They were able to show that the iron(II) dependent formation of hydroxyl
radicals from hydrogen peroxide is only the first step in a complex cascade of radical
formation.[20, 21]
Fe(II)     +     H2O2 Fe(III)     +     OH   +     OH
Figure 1.3.: The Fenton reaction
Since iron is a very important metal in nature for example as part of the active centre of
many enzymes, the Fenton reaction occurs also in living organisms. The highly reactive
radicals produced can then attack biomolecules such as lipids, DNA or proteins and cause
damage.[22] Protein damage initiated by hydroxyl radicals involves side chain
modifications as well as backbone cleavage. This damage is believed to play an important
role in several diseases like diabetes, athereosclerosis, neurodegenerative diseases and
5ageing.[23]  For that reason, the effect of the Fenton reaction on biomolecules has been
studied intensely for many years. The reaction of single amino acids with radicals
generated by the Fenton reaction has been studied[24] as well as the mechanistic pathways
of protein oxidation.[25] However, almost no studies have addressed the influence of the
peptide sequence on the extent of the oxidative damage. Davies and coworkers studied
oxidative damage of collagen by a Fenton like reaction using copper focussing on site
specificity of the radical attack caused by binding of the metal to the protein.[26]
However, so far there exist to the best of our knowledge no systematic studies of the
sequence dependence of the Fenton reaction.
1. 2.  Research project
The task of this thesis is on one hand to develop a class of receptors that are able to bind
peptides selectively and on the other hand to examine whether peptides are cleaved
selectively under Fenton conditions.
In the first part the class of diketopiperazine receptors is presented. Their binding
properties are studied by combinatorial on-bead screenings against a tripeptide library in
organic solvents as well as in water. Furthermore, the importance of the central
diketopiperazine as a template for two-armed receptors is emphasised. Structural
prerequisites of two armed receptors are studied by exchanging the central
diketopiperazine against other templates as well as by conformational analysis of the
diketopiperazine template.
6In the second part the sequence dependence of peptide cleavage under Fenton conditions
is examined by combinatorial screenings of a peptide library where each peptide is
flanked by a fluorophore and a quencher.
72. Combinatorial Chemistry
The advent of combinatorial chemistry in the early 1990s has revolutionised the
discovery process of new therapeutics.[27] While it was first applied mainly in bioorganic
and medicinal chemistry it has since spread to other fields like material science[28]  and
catalyst development.[29, 30]
The principle of combinatorial chemistry is to synthesise a large number of different
molecules ("library"), screen them simultaneously and select the active members. This
can be viewed as an attempt to imitate natures' evolution principles of random mutation
and survival of the fittest. Combinatorial chemistry is an excellent tool where rational
prediction reaches its limits. The success of a combinatorial method relies on two factors,
firstly on the capacity to produce a large variety of molecules and on the other hand on
the existence of effective screening methods to identify active members of the library.  A
very simple method to create molecular diversity is the "split-and-mix synthesis" that was
presented by Furka and Lam in 1991.[31-34] Although many other methods have been
introduced[35, 36] split-and-mix synthesis is still one of the most elegant methods.
2. 1. Split-and-mix synthesis
Split-and-mix synthesis allows for the synthesis of a huge number of different molecules
on solid phase with relatively few reaction steps as shown in figure 2.1. It starts with a
pool of solid phase resin that is split into several equal portions (In the example three).
Then, in each individual reaction vessel a different reaction (A, B or C) is performed.
8Afterwards, the resin is recombined leading to a mixture of three different types of beads.
The resin is split up again for the second cycle of the synthesis, reactions D, E and F are
performed and the beads are mixed again. In our simple example with just three different
reactions per cycle we end up with a library of 9 compounds but this number increases
exponentially with an increasing number of reaction cycles. After x reaction cycles with n
different reactions performed in each cycle the maximal number of compounds equals nx.
It must be pointed out that each single bead carries just one compound ("one bead one
compound").
Figure 2.1.: split-and-mix synthesis
9The analysis is limited by the amount of compound on a single bead, which is usually
around 100 pmol. This allows for the analysis by Edman degradation but this method is
restricted to linear peptides. Mass spectrometry[37-39] as well as 13C-NMR and 1H-NMR[40,
41] 
 (only with especially large beads) are possible but the distinction of compounds with
identical mass is rather difficult if not impossible by these methods. An alternative to the
direct analysis is the use of encoding.[42]
2. 2. Encoded split-and-mix synthesis
The concept of encoding relies on the attachment of tags to the beads in the course of the
synthesis. These tags can later be analysed easily and unequivocally. Each reaction step is
thus encoded and the tags can later tell the "history" of the corresponding bead. A further
advantage of encoding is the fact that the analysis can even be performed when the
compound of interest has been modified during the screening.
The tag molecules should ideally have the following properties: They should be inert
under various reaction conditions, detectable on a very small scale and they should be
easily attached and detached from the solid support.
 Figure 2.2.: Tag alcohols used for library encoding
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All these requirements are fulfilled by the polyhalogenated aromatic alcohols (figure 2.2.)
introduced by Still et al.[43, 44] These molecules can be analysed on a 1 pM scale by gas
chromatography using electron capture detection (ECGC) since this detection method is
very sensitive to halogenated aromates.  The varying halogenation patterns as well as the
differing chainlengths result in different retention times in the GC. The tags can either be
attached to the solid support via a photocleavable[43]  or an oxidatively cleavable linker.[44]   
Figure 2.3.: Linkers to attach the tags to the solid support
The tags are coupled either via a carbonate bond to 3-nitro-4-hydroxymethyl-benzoic
acid or via an ether bond to vanillic acid. Via the acid functionality, the linkers can be
attached to the solid support via amide or ester bonds. Irradiation with UV-light in case of
the nitrobenzoic acid or oxidation with ceric ammonium nitrate (CAN) releases the tag
alcohols that are then analysed by ECGC after silylation of the alcohol function.
The detection sensitivity (1 pmol) of these tags is so high, that 1-2% of tags in respect to
the bead loading is sufficient for analysis. Therefore, in peptide libraries the tags can
normally be attached to the free N-terminus before the amino acid is coupled. The
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resulting capping of a few percent of the peptides can usually be afforded. However, by
attaching the tags at a parallel chain, this capping and the resulting inhomogenity of the
product peptides can be avoided.
Figure 2.4.: Encoded split synthesis
For encoding of the reactions, a binary code is used: Each reaction is encoded by an array
of tags rather than by one single tag. In our example (figure 1.8.), tag 1 encodes for
reaction A and tag 2 for reaction B while the combination of tag 1 and tag 2 can be used
to encode for reaction C (rather than a third tag). Thus, binary encoding allows to encode
2N-1 reactions with N different tags.
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2. 3. Screening of combinatorial libraries
The real power of combinatorial chemistry lies within the possibility to screen thousands
of compounds simultaneously in "on bead screenings" rather than testing each compound
individually. An experiment is needed to identify the active compounds in a readily
detectable way. Here, two screening methods that are relevant for this work are
presented.
2. 3. 1. Screening for selective binding
To visualise selective binding of a receptor to a substrate, the receptor is marked with a
dye, a fluorophore[45] or with radioactivity.[46] A solution of this (for example) dye-marked
Figure 2.5.: On bead screening of a dye marked receptor against an encoded library
EQUILIBRATION
ADDITION OF A SOLUTION
OF A DYE MARKED RECEPTOR
TO A LIBRARY
ISOLATION OF COLOURED 
BEADS AND TAG ANALYSIS
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receptor is then equilibrated with an on-bead library. When a library member interacts
with the receptor, the receptor and therefore the dye accumulates on the corresponding
bead.  In case of selective binding, only few beads will pick up the colour. For analysis,
the red beads are then isolated and the tags are cleaved and analysed.
2. 3. 2. Screening for Selective Cleavage
On bead detection of selective peptide cleavage can be achieved by a fluorophore
quencher library: A fluorescent molecule is attached to a solid support and an adequate
quencher is linked to it over a combinatorially varied peptide chain. Fluorescence will not
occur as long as the peptide is unharmed. Cleavage of the peptide will lead to removal of
the quencher. This, in turn will make the bead appear fluorescent.[47]
                  
QuencherAA1 AA2 AA3 Fluorophore AA1 AA2
selective peptide cleavage
fluorescence quenched QuencherAA3-
Fluorophore
Figure 2.6.: Screening for selective peptide cleavage
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3. Selective Binding of Peptides by Diketopiperazine Receptors
3. 1. Receptor design
In order to find a selective receptor for any desired peptide sequence we need a receptor
type that can be easily varied combinatorially at sites where such variations have
considerable effects on the binding selectivity. A library of such a receptor family should
contain receptors for any peptide. As demonstrated in previous studies on synthetic
receptors,[13-17] a suitable receptor type has to fulfil certain prerequisites:
-The receptor should possess a certain rigidity
-It should contain functionalities that allow for non covalent interactions with a substrate
-These functionalities should be easily variable
Furthermore, a rather straightforward synthesis that can be transferred to the solid phase
is also desirable with respect to the generation of an on-bead library.
Two-armed peptidic molecules with a general structure 3 as shown in Figure 3.1. fulfil all
these requirements. The central diproline diketopiperazine restricts the flexibility of the
molecule and directs the peptidic arms in positions that should allow for intermolecular
interactions with a peptidic guest. The amino acid sidechains of the peptidic arms provide
for functionalities that can interact with a peptidic substrate. Since peptide synthesis is
well established, these functionalities can be varied combinatorially.
Also the synthesis of the diketopiperazine template should be rather straightforward,
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Figure 3.1.: General structure 3 of the cis-diketopiperazine receptors
since diketopiperazines are known to form easily. Because the proline diketopiperazine is
the essential structural element we termed these molecules "diketopiperazine receptors".
The denotation of the template can be further specified in terms of the stereochemistry of
Cγ of the proline (the C atom carrying the substituents and thus the arms): This work
focuses on diketopiperazines with substituents at Cα and Cγ that are on the same side;
these receptors were termed "cis-diketopiperazine receptors" or short "cis-receptors".
This is in contrast to the corresponding trans-receptors with inverse stereochemistry on
Cγ that will be introduced later in this chapter.
In order to study the binding properties of this receptor type towards peptides we first
synthesised several dye-marked cis-receptor prototypes and screened them against a
tripeptide library.
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3. 2. Synthesis of the cis-diketopiperazine template
The synthesis of the template starts with commercially available N-Boc protected trans-γ-
hydroxy-L-proline 4. After esterification of the acid group using caesium carbonate and
methyl iodide, the hydroxyl functionality of 5 was activated with mesyl chloride. The
mesylate was then substituted by an azide under inversion of the configuration at Cγ.
The methyl ester 6 was then hydrolysed with sodium hydroxide and the acid was
activated as a pentafluorophenyl ester 7.
a: i. 0.55 eq CsCO3, MeOH/H2O (5:1), r.t., 1 h; ii. 2 eq MeI, DMF, r.t., 1.5 h; b: 1.2 eq MsCl, 1.2 eq NEt3,
CH2Cl2, 0°C, 0.5 h; c: 5 eq NaN3, DMF, 80°C, 3 h; d: 1.2 eq NaOH in H2O, MeOH/THF (1:1), r.t., 1.5 h; e:
1.1 eq C6F5OH, 1.1 eq EDC, CH2Cl2, r.t., 1h; f: TFA/CH2Cl2(1:3), r.t., 1.5 h ; g: 2 eq iPr2NEt, THF, r.t., 60
h; h: 10 % Pd/C, H2, 3 eq Boc2O, MeOH, r.t., 2 h.
Figure 3.2.: Synthesis of the bis-Boc-protected diketopiperyzine template 9
After deprotection of the Boc group by TFA, the cyclisation to the diketopiperazine 8
was performed in CH2Cl2 in the presence of Hünigs base at a concentration of 0.3 M.
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Reduction of the azide groups with in situ Boc protection of the amino groups gave the
well storable N-Boc protected diketopiperazine 9 in an overall yield of 29%.
3. 3. Synthesis of five dye-marked receptor prototypes
To study the binding properties of two-armed receptors based on the cis-diketopiperazine
template, we synthesised a series of dye-marked receptor prototypes in order to screen
them against an on-bead peptide library.
For the prototypes, the peptidic arms were chosen to be symmetrical in order to simplify
the synthesis. For all prototypes, either D- or L-tyrosine was attached to the template as
first amino acids of the arms. Phenylalanine and either trityl protected asparagine or
glutamine was chosen as amino acids for positions 2 and 3. We chose tyrosine because a
dye, that is required for the combinatorial screening, can be easily attached to its phenolic
hydroxyl group. As a dye Disperse red 1 was chosen that could be attached to the
tyrosine via an ether linkage. It is known, that Disperse red 1 does not bind to peptides.[48]
We were particularly interested how the binding properties are affected by small changes
in the sequences of the peptidic arms. Therefore, the sequences of the receptor arms of
the prototypes were chosen to be very similar with only slight differences:
Namely the prototypes 10 and 11 differ only in the configuration of the first amino acid
tyrosine. The order of amino acids at positions 2 and 3 are changed in receptors 11 and
12. Receptor 13 differs from receptor 10 by the exchange of asparagine by the one
methylene group longer glutamine.  The same is the case for receptors 12 and 14.
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Figure 3.3.: Structures of prototypes 10 - 14
The prototypes were synthesised by removal of the Boc groups of 9 and coupling of the
dye-marked pentafluorophenylester of N-Boc-D- or L-tyrosine 16 or 16a to yield 17 or
17a respectively. 16 and 16a were prepared by coupling Disperse red 1 to the phenolic
group of N-Boc-protected tyrosine allyl ester 15 or 15a via a Mitsunobu reaction with
subsequent activation as a pentafluorophenylester. After Boc-deprotection of 17, 17a
respectively, the two other amino acids of the arms were assembled by standard
couplings of FMOC-amino acids using EDC as coupling reagent and TAEA for FMOC-
deprotections.[49, 50] After the removal of the FMOC group of the third amino acid, the
aminogroups were acetylated with Ac2O in the presence of NEt3 to yield receptor
prototypes 10 - 14. The binding selectivities of these receptor prototypes towards
peptides were now determined by combinatorial on-bead screenings.
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a: 1 eq Disperse Red 1 (dye), 1 eq PPh3, 1 eq DEAD, toluene, r.t., 16 h, %; b: i. 1.2 eq NaOH in H2O,
MeOH/THF (1:1), r.t., 1.5 h; ii. 1.1 eq C6F5OH, 1.1 eq EDC, CH2Cl2, r.t., 1h, %; c: i. TFA/CH2Cl2 (1:3),
r.t., 1h; ii. 1 eq 16 or 16a, 4 eq iPr2NEt, CH2Cl2, r.t., 16h; d: i. 4M HCl in dioxan, MeOH, r.t., 1 h; ii. 3 eq
iPr2NEt, CH2Cl2, r.t.; e: 3 eq FMOC-amino acid, 3 eq EDC, CH2Cl2, r.t. 0.5 h; f: TAEA, CH2Cl2, r.t. 1 h;
repetition of (e) and (f); h: 5 eq Ac2O, 5 eq NEt3, CH2Cl2, r.t., 1 h.
Figure 3.4.: Synthesis of the receptor prototypes 10 - 14
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3. 4. Binding properties of the receptor prototypes
In order to test the binding properties of the receptors, we screened them against an
encoded tripeptide library.[43] The library we used (18) consisted of 29 different side chain
deprotected D- and L- amino acids in each position leading to a maximal variety of 293 =
24389 different peptides. The library had been synthesised on polystyrene resin and the N
terminus was acetylated. The general structure is shown in figure 3.5.
Figure 3.5.: General structure of the tripeptide library 18, AA1 - AA3   =   Gly, L-Ala,
D-Ala, L-Leu, D-Leu, L-Val, D-Val, L-Pro, D-Pro, L-Phe, D-Phe, L-Ser, D-Ser, L-Thr,
D-Thr, L-Asn, D-Asn, L-Gln, D-Gln, L-His, D-His, L-Asp, D-Asp, L-Glu, D-Glu, L-Lys,
D-Lys, L-Arg, D-Arg.
The screenings were performed in chloroform (filtered over aluminium oxide) at a
receptor concentration of ~30 µM. For the screenings, five theoretical copies of the
library were used to ensure that every sequence was present at least once in every
assay.[51, 52] After two days of equilibration, in the assays of 10 and 13, about one bead out
of 1500 picked up the red colour of the receptor (figure 3.6.). In contrast, no red beads
were observed in the screenings of 11, 12 and 14 even when the concentration was
augmented up to 500 µM indicating that these two-armed molecules don't bind to any of
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the 24389 different peptides of the library.[53]  Remarkably, both prototypes with an L-Tyr
in the first position of the arms bind to peptides with high selectivity, all the prototypes
with a D-Tyr as first amino acid do not bind to any of the 24389 peptides within the
library. Thus, the amino acid that is directly attached to the template has the largest
influence on the binding properties. This phenomenon will further be investigated in
chapter 4.9.
                        
Figure 3.6.: Screening of receptor 10 against the tripeptidelibrary 18 in chloroform
The sequences of the peptides bound to 10 and 13 were elucidated by separating the red
beads manually, cleaving and analysing the encoding tags on these beads. Table 3.1.
shows the sequence on the red beads of the assays of 10 and 13.
Both receptors preferentially select peptides with a D-histidine in position AA1 followed
by two hydrophobic D-amino acids. Furthermore the two receptors although differing
only in a single methylene group show certain differences in the binding selectivities.
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Table 3.1.: Binding specifities of the receptors 10 and 13 against the tripeptide library
AA3 AA2 AA3 Frequeny
found[a]
[%]
Frequency
expected[b]
[%]
10 D-Hph[c] D-Hph[c] D-His 59 0.10
D-Ala L-Asn D/L-Hph[c] 26 0.04
D-Asn D-Hph[c] D-Val/Gly 9 0.04
13 D-Val D-Hph[c] D-His 56 0.02
D-Phe/D-Ala D-Phe/D-Ala D-His 19 0.02
D-Gln D-Val/D-Phe D-Val/D-Leu 19 0.02
[a] The frequency found column lists the percentage of the corresponding peptide sequence among the
selected beads [b] The frequency expected column lists the percentage of the corresponding peptide
sequence among all the library beads. Comparison between the frequency found and the frequency
expected gives a measure for the selectivity of the receptor [c] Hph = hydrophobic amino acid. Can either
be Gly, Ala, Val, Leu or Phe
Receptor 10 also selects for peptides with an L-Asn in position AA2 or AA3 together
with hydrophobic D-amino acids while receptor 13 shows a further preference for
peptides with a D-Gln at the N-terminal position in combination with two hydrophobic D-
amino acids in the other two positions. Most importantly, diketopiperazine-receptors are
indeed able to bind to peptides selectively and small differences in the arms can alter the
binding selectivities.
To get an idea about the nature as well as the strength of these interactions we attempted
to perform NMR binding studies with receptor 13 and a representative peptide with the
D-Hph-D-Hph-D-His sequence. We chose receptor 13 rather than receptor 10 because of
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its better solubility in chloroform. However, the peptides Ac-D-Val-D-Val-D-His-
NH(CH2)7CH3 as well as Ac-D -Phe-D-Phe-D-His-NH(CH2)7CH3 were insoluble in
chloroform, thus preventing binding studies with 1H-NMR spectroscopy.
Because of these solubility problems the binding affinities were measured by solid phase
binding assays.[54] In table 3.2. the ∆G of receptors 10 and 13 against the peptides Ac-D-
Val-D-Val-D-His-resin and Ac-D-Phe-D-Phe-D-His-resin are shown. The affinities lie in
the range of ~ 5 kcal/mol which is a reasonable strong affinity for a small receptor.
Table 3.2. Binding affinities (∆G = -RTlnKa)
Receptor Ac-D-Val-D-Val-D-His-resin Ac-D-Phe-D-Phe-D-His-resin
10 - 5.6 - 5.3
13 - 4.9 - 4.9
Each measurement was repeated multiple times to ascertain the accuracy of the binding affinities within
errors of ±0.2 kcal/mol.. Resin = polystyrene ( loading 28 µmol/g)
3. 5. How does the length of the peptidic arms influence the binding properties?
To investigate the influence of changes in the length of the receptor arms, two variations
of receptor 10 were synthesised with one amino acid more or less in each arm. The arms
of prototype 19 consist of one amino acid less than 10, in prototype 20 the arms are
elongated by one asparagine. These two prototypes were screened against the tripeptide
library 18 in chloroform. While two-armed molecule 19 didn't show any selective
binding, several beads turned red in the assay with receptor 20. In Table 3 the binding
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selectivities of 20 are shown. It is apparent that the bound sequences differ substantially
from the peptides bound by receptor 10. Although 20 binds to sequences containing
asparagine combined with hydrophobic amino acids that were also bound by 10, the most
abundant sequence found in the assay of 10, the D-Hph-D-Hph-D-His motif, is not
recognized by receptor 20.
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Figure 3.7.: Variation of the number of arm amino acids
These results indicate that three amino acids in the arm are minimally necessary to
observe selective binding to peptides.  By adding one amino acid, the binding selectivity
changes.
So far, we have concentrated on the effect of changes in the receptor arms. In the
following, we will examine the influence of the backbone by replacing the
diketopiperazine with other diamines.
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Table 3.3.: Sequences bound by receptor 20
AA3 AA2 AA1 Frequeny
found[a]
[%]
Frequency
expected[b]
[%]
20 L-Asn L-Hph L-Asn 55 0.02
D-Hph D-Asn D-Hph/D-Asn 18 0.13
D-Asn/Gly L-Hph L-Asn 18 0.04
[a] The frequency found column lists the percentage of the corresponding peptide sequence among the
selected beads [b] The frequency expected column lists the percentage of the corresponding peptide
sequence among all the library beads. Comparison between the frequency found and the frequency
expected gives a measure for the selectivity of the receptor [c] Hph = hydrophobic amino acid. Can either
be Gly, Ala, Val, Leu or Phe
3. 6. Changing the configuration of the template from cis to trans
First we wanted to investigate the effect of a relatively small change in the template on
the binding properties of the corresponding receptors. We were therefore interested in the
diastereomeric trans-diketopiperazine with inversed stereochemistry at Cγ.
Based on the trans-template, receptor prototypes 10' - 14' analogue to 10 - 14 were
synthesised by attaching the same sequences as receptor arms.[55] The trans-receptors 10'
and 13' bound to similar peptide sequences as the corresponding cis-receptors 10 and 13.
More surprisingly also receptors 11', 12' and 13 ' showed highly selective binding
towards peptides in contrast to their cis-diastereomeric analogues 11, 12 and 13 that don't
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Figure 3.8.: The two diastereomeric diketopiperazine templates
bind towards peptides. Thus, the change from L- to D- in the configuration of the first
tyrosine residue has not the same dramatic effect on the binding ability for the trans-
receptors as it has on the cis-receptors.
We thus showed that representatives of two-armed molecules based on both the cis-
diketopiperazine template and the trans diketopiperazine template are able to bind to
similar peptides selectively. This gives rise to the question if any template that can anchor
two peptidic arms is good enough to serve as a backbone for two-armed receptors.
3. 7. Can a simpler diamino template replace the diketopiperazine?
To address this question we synthesised two-armed molecules based on several diamines.
In addition to the commercially available diaminocyclohexane 21 , bis-
aminomethylcyclohexane 22[56] and 1,7 diaminoheptan 23, diketodiazabicyclooctan 24[57]
was used.
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The templates 21 - 24 differ not only in the distance of the two amino groups that serve as
anchors for the arms but also in their rigidity. While the templates 21 and 24 are rigid, the
direction of the amino groups is not fixed in 22. The diaminoheptane 23 is completely
flexible and was chosen because the distance between the two amino groups is the same
as in the diketopiperazine.
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receptor arms 21 22 23 24
Ac-L-Phe- L-Asn(Trt)- L-Tyr(dye)- 25 26 27 28
Ac-L-Phe- L-Asn(Trt)- L-Tyr(dye)- 29 30 31 32
Figure 3.9.: Diamines 21 - 24 used as templates  for two-armed molecules and the
corresponding two-armed molecules 25 - 32 [58]
As arms we used the peptide from receptor 10, (Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)) as well
as the arm of 11 (Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)). We thus chose one representative
that bound to the peptides with both the cis- and the trans- template as well as its
diastereomer with changed configuration on the tyrosine that binds to peptides with the
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trans-diketopiperazine as backbone but not with the cis-diketopiperazine. In figure 3.9.,
the four templates and the resulting eight two-armed molecules are listed.
Unlike the two-armed molecules based on the diketopiperazine templates, 25 - 32 were
not synthesised step by step but the peptidic arms were synthesised separately and then
coupled to the diamines using either HATU or TBTU as coupling reagents (chapter 6.5.).
Screening against the deprotected tripeptide library 18 at concentrations of up to 500µM
revealed that all eight potential receptors showed no binding against any of the 24389
peptides within the library.
Thus the template is crucial for selective binding of peptides and exchanging the
diketopiperazine template by completely different diamines results in a complete loss of
binding ability.
However, already the relatively small change from the trans to the cis-template has a big
effect on the binding properties. The most dramatic difference between the trans- and cis-
receptors is the fact that only receptors based on the trans-template are binding to
peptides when the first amino acid of the arm has D-configuration. In order to understand
this phenomenon, conformational studies of the diketopiperazine templates were
performed.
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3. 8. Structural studies on the diketopiperazine receptors
In order to explain the binding results of the cis- and trans-diketopiperazine receptors we
now needed to answer the two following questions:
Firstly, is it possible to find a reasonable explanation for the worse binding properties of
the receptors based on the cis-diketopiperazine in comparison to the corresponding trans-
diketopiperazine diastereomers by analysing the structure of the two diastereomeric
templates?
Secondly, why are two armed molecules based on the cis-diketopiperazine template only
able to bind to peptides when the first amino acid has L-configuration?
Structural studies on the diketopiperazine template were thus performed in the solid state
as well as in solution by 1H-NMR spectroscopy.[52]
3. 8. 1. Structure of the template
The receptor prototypes are rather complex molecules which complicates the
conformational studies using 1H-NMR by overlapping signals. Furthermore, all attempts
to crystallise the receptor prototypes were unsuccessful. Because of these difficulties, we
decided to base our structural studies of the template on simpler model compounds. We
thus synthesised a couple of cis-diketopiperazine derivatives with different substituents
on Cγ. The preparation of the bis-azide 8 as well as the N-Boc-protected diamino-
diketopiperazine 9  has already been presented in chapter 3.2. The bis-acetyl
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diketopiperazine 33 was synthesised by reducing azide 8 in the presence of acetic
anhydride.
8: R = N3
 9: R = NHBoc
33: R = NHAc
34: R = NH2*HCl
35: R = NHCO(CH2)5 CH3
Figure 3.10.: cis-diketopiperazine model compounds
Ammoniumsalt 34 was prepared by the deprotection of 9 with HCl. Model compound 35
was synthesised by removing the Boc groups of bisBoc diketopiperazine 9 and reacted
with heptanoic acid anhydride. The corresponding model compounds 8', 9' and 33' - 35'
based on the trans-diketopiperazine (figure 3.11.) were obtained in an analogous way.[59]
 8': R = N3
 9': R = NHBoc
33': R = NHAc
34': R = NH2*HCl
35': R = NHCO(CH2)5CH3
Figure 3.11.: trans-diketopiperazine model compounds
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3. 8. 1. 1. Crystal structure of the bis-acetylated diketopiperazine templates
Crystals were obtained from the bis-acetylated derivatives 33  and 33 ' of both
diketopiperazine diastereomers. Figure 3.12. shows the crystal structures of the two
molecules.[60]
The conformation of the tricyclic skeleton of the two diastereomers is nearly identical.
The central six-membered ring of the diketopiperazine adopts boat conformation. The
pyrrolidine rings possess envelope (ECβ) conformations that are slightly perturbed to
twisted (CγTCβ) conformations in both compounds. However, the two structures differ
significantly in the orientation of the N-acetyl groups. In the cis-compound 33 they
occupy the pseudo-equatorial positions at Cγ, in the trans-compound 33' the pseudo-axial
positions. As a result, the distances between the two N- atoms and also the angle formed
between the two side chains and the tricyclic skeleton are considerably different in the
two diastereomers.  While the distance between the N-atoms of the two N-acetyl groups
is 8.7 Å in the crystal structure of the cis-template, this distance is almost 1 Å smaller in
the crystal structure of the trans-template, namely 7.8 Å. As a result, the angle between
the two Cγ-N bonds is much narrower in the trans-template. The trans-diketopiperazine
adopts a turn-like conformation, while the cis-diketopiperazine is a rather linear structural
element. This observation gives a first hint for the explanation of the different binding
properties of the cis- and trans-receptor prototypes: The trans-diketopiperazine directs
the two receptor arms into the same direction, thereby favouring an interaction with the
peptide. However, the unit cell of both crystal structures contains two nearly identical
molecules that are connected by two hydrogen bonds that stabilise these conformations.
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The structure in solution might therefore differ from the one observed in the crystal
structure. Thus conformational studies by 1H-NMR in solution were performed.
Figure 3.12.: Crystal structures of bis acetyl cis-diketopiperazine 33 and bis acetyl trans-
diketopiperazine 33'
3. 8. 1. 2. Conformation of the cis-template in solution
The structure in solution was investigated using one and two dimensional 1H-NMR
spectroscopy experiments. In all 1H-NMR spectra, only six spin systems were observed,
33
33'
34
indicating that all compounds possess C2-symmetry on the average time scale of the
NMR measurement. The unambiguous assignment of the proton signals was achieved
using a combination of COrrelated SpectroscopY (COSY) and either Nuclear Overhauser
Effect SpectroscopY (NOESY) or Rotational Overhauser Effect SpectroscopY (ROESY).
The Karplus curve[61] allows for a comparison between the 1H-1H coupling constants and
the expected torsion angles.
Table 3.4.: 1H-1H-coupling constants (Hz, ±0.1Hz) observed for cis-model compounds 8,
9 and 33 - 35 compared to the coupling constants that would be expected for the torsion
angles found in the crystal structure of 33
Torsion angle[a]
NMR,
3J(H,H)
8
NMR,
3J(H,H)
9
NMR,
3J(H,H)
33
NMR,
3J(H,H)
34
NMR,
3J(H,H)
35
X-ray
33[b]
3J(H,H)
exp.[c]
33
Hα-Cα-Cβ-Hβ 8.8 7.5 nd[d] nd[e] 7.7 30±8 6.5-8.5
Hα-Cα-Cβ-Hβ´ 5.7 7.5 nd[d] nd[e] 7.7 152±9 9.0-
11.5
Hβ-Cβ-Cγ-Hγ 5.6 7.5 nd[d] nd[e] 6.9 30±8 6.5-8.5
Hβ´-Cβ-Cγ-Hγ 4.5 7.5 nd[d] nd[e] 7.4 152±9 9.0-
11.5
Hγ-Cγ-Cδ-Hδ 5.6 6.7 5.9 nd[e] 6.9 17±7 7.5-9.5
Hγ-Cγ-Cδ-Hδ´ 3.8 6.0 3.7 nd[e] 6.0 139±8 6.5-9.5
[a] Hα, Hβ, Hγ, Hδ and Hβ´, Hδ´ respectively are on opposite faces of the pyrrolidine ring. [b] Average
over all torsional angles within the pyrrolidine rings of the two molecules in the asymmetric unit of the
crystal structure. [c] vicinal coupling constants expected for the conformation observed in the crystal
structure of 33. [d] The coupling constants could not be determined unambiguously due to overlapping
signals of Hα and Hγ as well as Hβ and Hβ´. [e] 34 is not soluble in chloroform
The coupling constants of the trans-diketopiperazine model compounds correspond very
well with the expected values from the crystal structure. Furthermore, neither the
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substituent on Cγ nor the solvent has a considerable influence on the structure. Thus, the
trans-diketopiperazine template is conformationally well defined and adopts the same
single conformation in solution as in the crystal.
In contrast to the trans-diketopiperazine, the configuration of the cis model compounds
do not match with the expected values from the cristal structure. Table 3.4. shows that
none of the coupling constants of the four model compounds soluble in chloroform lie
fully within the range that would be expected from the crystal structure of 33.
Particularly the azide 33 shows the biggest deviation. Compounds 9  and 35, whose
coupling constants are likewise, look more like the crystal structure although some of the
coupling constants still lie outside the expected range. Thus, the crystal structure is not
identical with the template structure in chloroform solution. As shown in figure 3.13. two
main conformations are conceivable for the cis-diketopiperazine: a conformation with the
substituents at Cγ in the pseudo equatorial positions ("pseudo-equatorial conformation")
as seen in the crystal structure and another one with pseudo-axial-positioned substituents
and ring flipped pyrrolidine moieties.
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N Hδ'
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Hδ'
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Hβ'
Figure 3.13.: Simplified conformational equilibr35um of the cis-diketopiperazine
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In table 3.5., the expected coupling constants for these two conformations as estimated by
the Karplus curve are listed. The most obvious differences exist for the coupling
constants between Hα and Hβ', Hγ and Hβ' as well as for Hγ and Hδ'. The torsion angle
for all three proton pairs changes from an angle of almost 180° at the pseudo equatorial
conformation to a nearly 90° angle at pseudo-axial conformation. This leads to a
difference in the coupling constants from >9 down to ≈ 0.
Table 3.5.: Expected  1H coupling constants for the two possible conformations of the cis-
diketopiperazine
Torsion angle[a] 3J(H,H) expected
pseudo equatorial
3J(H,H) exp.
pseudo axial
Hα-Cα-Cβ-Hβ 6.5-8.5 5.5-8.5
Hα-Cα-Cβ-Hβ´ 9.0-11.5 ≤ 2
Hβ-Cβ-Cγ-Hγ 6.5-8.5 4.0-7.0
Hβ´-Cβ-Cγ-Hγ 9.0-11.5 ≤ 2
Hγ-Cγ-Cδ-Hδ 7.5-9.5 4.5-7.5
Hγ-Cγ-Cδ-Hδ´ 6.5-9.5 ≤ 2
When the expected values from table 3.5. are compared to the experimental coupling
constants in chloroform, we clearly see that none of the two conformations can be used to
describe the situation in solution. For all four model compounds, the measured values are
approximately an average of the expected values for the two conformations.
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Figure 3.14.: NOE's observed for the cis-diketopiperazine model compounds 8, 9, 33 - 35.
The different values found for the model compounds indicate that the position of the
equilibrium depends on the substituents. While for all four compounds roughly a 1 : 1
equilibrium between the two conformers is observed the equilibrium lies slightly more on
the pseudo equatorial side for 9 and 35 compared to 8 and 33.
In order to investigate the influence of the solvent on the equilibrium all model
compounds were also measured in the more polar solvents d4-methanol and d8-DMSO. In
these solvents, the bis-amine 34 was also measured. In table 3.6. the coupling constants
of all model compounds in all three solvents are listed including the ones in chloroform.
For all compounds, the coupling constants measured in the two polar solvents methanol
and DMSO are almost identical. A significant difference to the values obtained in
chloroform is only observed for bis-acetyl diketopiperazine 33. The equilibrium for that
compound is shifted towards the pseudo equatorial conformation.
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Table 3.8.: 1H-1H-coupling constants (Hz, ±0.1Hz) observed for model compounds 8, 9,
33, 34  and 35  in the solvents CDCl3 (A), CD3OD (B) and d8-DMSO (C).
8 9 33 34 35
A B C A B C A B C A B C A B C
Hα-Cα-Cβ-Hβ 8.8 9.1 9.1 7.5 6.7 7.0 nd[d] 6.9 7.3 nd[e] 8.2 8.2 7.7 9.6 9.8
Hα-Cα-Cβ-Hβ´ 5.7 4.9 4.9 7.5 9.7 10.2 nd[d] 9.7 9.5 nd[e] 8.2 8.2 7.7 7.4 7.5
Hβ-Cβ-Cγ-Hγ 5.6 5.4 5.3 7.5 6.7 6.2 nd[d] 6.9 6.9 nd[e] 7.2 7.0 6.9 9.8 9.8
Hβ´-Cβ-Cγ-Hγ 4.5 3.9 3.6 7.5 9.7 10.2 nd[d] 9.7 9.7 nd[e] 8.0 7.0 7.4 6.9 6.8
Hγ-Cγ-Cδ-Hδ 5.6 5.3 5.2 6.7 7.8 8.2 5.9 7.9 7.8 nd[e] 7.2 7.2 6.9 7.6 7.6
Hγ-Cγ-Cδ-Hδ´ 3.8 3.1 2.8 6.0 7.8 8.5 3.7 7.7 7.6 nd[e] 5.7 5.1 6.0 7.9 7.8
[d] The coupling constants could not be determined unambiguously due to overlapping signals of Hα and
Hγ as well as Hβ and Hβ´. [e] 34 is not soluble in chloroform
In conclusion, the structural studies on the cis- and trans- diketopiperazines revealed that
the trans-diketopiperazine is conformationally defined and adopts a turn-like structure
with pseudo-axial standing substituents. For receptors built upon the trans-
diketopiperazine, this means, that the receptor arms are directed into the same direction
by the template. In contrast, the cis-diketopiperazine is flexible and the pseudo axial
conformation coexists with a conformation with pseudo equatorial standing substituents.
Thus, the observed different binding properties of cis- and trans-diketopiperazine based
receptor prototypes were rationalised based on structural studies on the two templates.
However there's still no explanation why we don't see any binding for the cis-
diketopiperazine based molecules when a D-tyrosine is the first amino acid while the
receptors have almost the same binding properties as the trans-receptors when L-tyrosine
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is the first amino acid. We thus analysed why the configuration of the first amino acid of
the arms has such a big influence on the binding properties of the receptors.
3. 8. 2.  How does the configuration of the first amino acid affect the structure of the
cis- template?
To find an explanation for the different binding properties of cis-diketopiperazine
receptors depending on the configuration of the first amino acid, conformational studies
in solution were performed. We decided to take a look at simple model compounds to
avoid solubility problems and to minimise overlapping of proton signals in the NMR-
spectra.
                     
N
HN N NH
O
O
H
H
36: AA1 = Ac-D-Tyr(OMe)
37: AA1 = Ac-L-Tyr(OMe)
AA1AA1
Figure 3.15.: Model compounds 36 and 37
The investigations were started with the diastereomeric pair 36 and 37 with either a Ac-L-
Tyr(OMe) or Ac-D-Tyr(OMe) respectively coupled to the cis-diketopiperazine. By
comparing the 1H-NMR spectra of 36 and 37 in chloroform, we observed a remarkable
difference in ppm for the proton signals Hβ' and Hδ'. In 36 these protons appear 0.52
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ppm or 0.23 ppm, respectively, further downfield compared to 37 (table 3.7.). The trend
is reverse for the other signals. These chemical shift differences indicate that the
conformation of the cis-diketopiperazine is influenced to a significant extent by the
configuration of the amino acid that is directly coupled to the diketopiperazine.
Table 3.7: 1H chemical shifts (δ in ppm) for the pyrrolidine ring protons of compounds 36
and 37 in chloroform. (36: R = NH-D-Tyr(OMe)Ac; 37: R = NH-L-Tyr(OMe)Ac)
Proton 36 37
α 4.26 4.14
β 2.42 2.22
β' 2.42 3.14
γ 4.35 4.09
δ 3.43 3.21
δ' 3.74 3.97
                   
N R
O
Hα
Hγ
Hδ'
Hδ
Hβ'Hβ
γ
δ
βα
In table 3.8. the mutual coupling constants between the pyrrolidine ring protons for
compounds 36 and 37 are listed together with the expected values for either the
conformation with pseudo equatorial or pseudo axial substituents. In addition the
coupling constants of the bis-azide 8 are listed.
These data show, that the conformation of 36 (D-Tyr(OMe) resembles the conformation
of bis-azide 8. The 1H-1H coupling constants of compound 37 however fit perfectly with
the values that would be expected for the pseudo-axial conformation. The coupling of
close to ~ 0 Hz for the couplings between Hγ and Hβ', Hγ and Hδ' as well as Hα and Hβ'
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indicate torsion angles of nearly 90°. This is only possible for the pseudo axial
conformation.
Table 3.8.: 1H-1H coupling constants for the pyrrolidine ring protons of compounds 36
and 37 and 8 in chloroform as well as the estimated values for the pseudo equatorial and
the pseudo axial conformation.
Torsion angle[a]
NMR, 3J(H,H)
36
(D-Tyr)
NMR, 3J(H,H)
37
(L-Tyr)
NMR, 3J(H,H)
8
(N3)
3J(H,H) exp.
pseudo
equatorial
3J(H,H)exp.
pseudo
axial
Hα-Cα-Cβ-Hβ 8.7 10.1 8.8 6.5-8.5 5.5-8.5
Hα-Cα-Cβ-Hβ´ 5.0 1.5 5.7 9.0-11.5 ≤ 2
Hβ-Cβ-Cγ-Hγ n.d.[b] 9.0 5.6 6.5-8.5 4.0-7.0
Hβ´-Cβ-Cγ-Hγ n.d.[b] 1.0 4.5 9.0-11.5 ≤ 2
Hγ-Cγ-Cδ-Hδ 5.9 9.0 5.6 7.5-9.5 4.5-7.5
Hγ-Cγ-Cδ-Hδ´ 3.3 1.0 3.8 6.5-9.5 ≤ 2
 [a] Hα, Hβ, Hγ, Hδ and Hβ´, Hδ´ respectively are on opposite faces of the pyrrolidine ring. [b] The
coupling constants could not be determined unambiguously due to overlapping signals of Hα and Hγ as
well as Hβ and Hβ´.
NOESY measurements confirmed this result by showing crosspeaks between Hβ and Hδ
as well as between Hβ' and Hδ' for 36. For 37, only a crosspeak between Hβ and Hδ is
observed but no crosspeak between Hβ ' and Hδ '. Thus model compound 37  is
conformationally much better defined than 36 and the pseudo axial conformation is
preferred.
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It was now interesting to see, if this stabilisation can also be observed for model
compounds with longer "arms". We thus synthesised two diastereomeric pairs of two-
armed molecules with two amino acids per arm (Figure 3.16.).
N
HN N NH
O
O
H
H
38:  Ac-D-Ser(OtBu)    D-Tyr(OMe)
39:  Ac-L-Ser(OtBu)     L-Tyr(OMe)AA
1AA1
AA2AA2 AA1AA2
40:  Ac-D-Ser(OtBu)      D-Leu 
41:  Ac-L-Ser(OtBu)       L-Leu
Figure 3.16.: Model compounds 38 - 41
In 38 and 39, D-Ser(Ot-Bu) or L-Ser(Ot-Bu) respectively is coupled as a second amino
acid after D-/L-tyrosine. To check, if the stabilisation effect can also be observed with a
different amino acid than tyrosine as first amino acid, D- or L-Tyr was substituted by D-
or L-Leu to yield 40 and 41. The NMR-spectra of 40 and 41 were measured in CDCl3
while for 38 and 39 5% d4-methanol had to be added because they were insoluble in pure
chloroform. A look at the chemical shifts of the proline signals of compounds 38 - 41
(table 3.9.) reveals a similar effect as for compounds 40 and 41. Proton signals Hβ' and
Hδ' appear more downfield in 39 than in 38 while the other protons appear more
highfield.
When the tyrosine is replaced by leucin the same trends are observed except for Hδ.
Unfortunately, not all the coupling constants of 38 - 41 could be determined due to
overlapping signals or unresolved couplings. In the NOESY spectra we observed a
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crosspeak between Hβ' and Hδ' not only for 38 but also for 39. The crosspeaks between
Hβ' and Hδ' as well as between Hβ and Hδ for 38 and 39 were integrated. Comparison of
the ratios revealed slightly higher population of the pseudo axial conformation for 39.
All these results indicate a stabilisation of the pseudo-axial conformation when the first
amino acid is L-configurated. This means, that the two-armed molecules based on the cis-
diketopiperazine look very much alike the trans-receptors with parallel receptor arms.
This would be a very reasonable explanation for the different binding behaviour of the
cis-receptors, depending on the configuration of the first amino acid.
Table 3.9.: 1H chemical shifts (δ in ppm) for the pyrrolidine ring protons of compounds
38 and 39 in chloroform. with 5% d4-MeOH and of compounds 40 and 41 in chloroform
Proton
38
(D-Ser-D-Tyr)
39
(L-Ser-L-Tyr)
40
(D-Ser-D-Leu)
41
(L-Ser-L-Leu)
α 4.26 4.17 4.35 4.22
β 2.44 2.32 2.60 2.38
β' 2.44 2.76 2.71 2.95
γ 4.30 4.15 4.30 4.23
δ 3.36 3.28 3.22 3.32
δ' 3.74 3.99 4.03 4.38
By measuring 1H-NMR at low temperature with model compounds 36 - 41, another
interesting effect was observed:  By cooling down to 225 K, the proton signals of 36 (D-
Tyr(OMe) started broadening while the signals of diastereomer 37 (L-Tyr(OMe)
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remained sharp showing the expected temperature shift. The signals of 36 had lost any
coupling pattern at this temperature while the coupling in 37 was still visible.
When the two-armed model compounds with two amino acids per arm 38 - 41 were
measured in chloroform at low temperature, even a stronger effect was observed (38 and
39 were measured in chloroform with 1% DMSO). The signals of the two compounds
with D-configurated amino acids 38 and 40 were broadening by cooling down to 265 K.
By further cooling down, the signals sharpened again, giving rise to two signal sets. One
set resembles the NMR-spectrum observed at room temperature with only three amide
protons as would be expected for a C2-symmetrical conformation. The second signal set
shows doubled peaks as would be expected for an asymmetric conformation. In contrast
to this dramatic temperature effect for the compounds with arms containing of D-amino
acids, no such effect was observed for 39 and 41 with arms containing L-amino acids. In
Figure 3.17., this different behaviour is illustrated by means of the amide NMR signals of
40 and 41 at different temperatures.
Figure 3.17.: 1H-NMR-spectra of 41 (left) and 40 (right) amide protons at different
temperatures
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By measuring 1H-NMR-spectra at different concentrations it was found, that the ratio
between the asymmetric and the symmetric signal set depends on the concentration. The
higher the concentration, the more dominant is the asymmetric signal set. On the other
hand, dilution of the sample down to a concentration of ≈  1mM results in total
disappearance of the asymmetric signal set. This indicates that an intermolecular
interaction occurs.
Thus, the pseudo axial conformation is especially stabilised when an L-amino acid is
attached to the template rather than a D-amino acid. Furthermore, dimerisation of model
compounds with D-amino acid in the arms was observed at low temperature but not with
two-armed molecules with L-amino acids.
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3. 9. Selective binding in water
The excellent binding selectivities of representatives of cis-receptors in chloroform is
very encouraging. Even more challenging is the binding of peptides in water.
Unfortunately none of the receptor prototypes 10 - 14 presented in chapter 3.3. is water
soluble, even after the hydrophobic trityl protecting groups of the asparagin or glutamine
residues were removed.
N
N
O O
NH
NH
H
H
AA1AA2AA3
AA1AA2AA3
    Ac-L-His            L-Asn        L-Tyr(dye)42
AA3                   AA2                AA1
O
N N N NO2dye =
Figure 3.18.: Receptor prototype 42
We exchanged the two phenylalanines of receptor 10 by more hydrophilic histidine
moieties in order to compensate the hydrophobicity of the dye. The resulting receptor 42
thus still possesses an aromatic side chain in the same position as 10 but the two
imidazole residues should render the molecule water-soluble. Indeed the deprotected
molecule 42 dissolved in water.[62] To investigate the binding properties of 42 in water,
polystyrene-based library 16 could not be used, since polystyrene beads don't swell in
water. Instead, a TentaGel[63]  based peptide library with three combinatorially varied
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positions was used. For each varied position, 31 different D- and L- amino acids were
used leading to a variety of 331 = 29791 different peptides. (For more details see chapter
3.1.)
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Figure 3.19.: General structure of the tripeptide library 43 on TentaGel [63] (AA1 - AA3
= Gly, L-Ala, D-Ala, L-Leu, D-Leu, L-Val, D-Val, L-Pro, D-Pro, L-Phe, D-Phe, L-Ser,
D-Ser, L-Thr, D-Thr,  L-Asn, D-Asn, L-Gln, D-Gln, L-His, D-His, L-Asp, D-Asp, L-Glu,
D-Glu, L-Lys, D-Lys, L-Arg, D-Arg, L-Cys, D-Cys)
When 42 (0.10 µM) was screened against library 43 in acetate buffer at pH 4.0, several
beads (ca. 10 %) turned feebly red indicating a selective binding of receptor 42 to
peptides.
Analysis of the peptides of 17 of the red beads revealed sequences either containing two
acidic amino acids (Glu or Asp) or an acidic amino acid in combination with a primary
amide (Gln or Asn). The selectivity observed is rather moderate and the observed
selectivities are not surprising, since the basic imidazole moiety of the receptor would be
expected to interact with acids.
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However, it could be shown, that the peptide binding ability of cis-diketopiperazine
receptors is not restricted to organic solvents. Also in water peptides are bound.
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4. Detection of Selective Peptide Damage by  the Fenton Reaction
4. 1. Synthesis of a fluorophore quencher library
To monitor the sequence dependence of the peptide damage caused by the Fenton
reaction we needed an appropriate detection method for selective peptide cleavage. Since
rational predictions of the cleavage selectivity are difficult, we wanted to address this
question by combinatorial chemistry. We used a library where the peptide is flanked by a
fluorophore on the side of the solid support and a quencher on the terminal side. Peptide
cleavage will thus lead to fluorescing beads (chapter 2. 3. 2.). For such a library, a potent
fluorophore-quencher system is needed, which works efficiently up to a distance of at
least 15 chemical bonds. A suitable system is the anthranilic acid nitrotyrosine pair
(figure 4.1.). The fluorophore anthranilic acid emits light at a maximum of 440nm when
irradiated at 320nm. The efficiency of nitrotyrosine to quench this fluorescence over a
distance of up to 10 amino acids has been demonstrated by Meldal et al. who used a
            
N
H
ONH2
HOOC
NH2
44
NH2
HOOC
OH
NO2
fluorophore
45
quencher
=  H-F-OH =  H-Q-OH
Figure 4.1.: The fluorophore and the quencher used for the library
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similar library to investigate the sequence selectivity of proteases.[47, 64] The anthranilic
acid can be coupled to the side chain amino group of lysine and is thus easily introduced
into a linear peptide.
The synthesis of the building blocks 48 and 49 (the Nα-FMOC protected forms of 44 and
45) that were used for the solid phase synthesis is shown in figure 4.2. Anthranilic acid
46 is first N-Boc protected. The acid group of 47 is then activated as a pentafluorophenyl
ester and coupled via an amide bond to the ε-amino group of Nα-FMOC protected lysine.
The quencher building block 50 was obtained in one step from nitrotyrosine using
FMOC-Cl.
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O
OH
NH
O
OH
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NHFmoca b, c
46 47 48
HO
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49 50
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Figure 4.2.: synthesis of the building blocks 48 and 50
In figure 4.3. the general structure of library 43 is shown. As solid phase resin we chose
amino functionalized TentaGel since it swells in water.[63]
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Edman degradation is ruled out for the analysis of peptides on fluorescing beads, since
the sequences of interest are not present anymore at the time of selection. Therefore
chemical tags were used for encoding of the library (chapter 2.2).[44]   
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Figure 4.3.: General structure of the fluorophore quencher library 43 (AA1 - AA3   =
Gly, L-Ala, D-Ala, L-Leu, D-Leu, L-Val, D-Val, L-Pro, D-Pro, L-Phe, D-Phe, L-Ser, D-
Ser, L-Thr, D-Thr,  L-Asn, D-Asn, L-Gln, D-Gln, L-His, D-His, L-Asp, D-Asp, L-Glu, D-
Glu, L-Lys, D-Lys, L-Arg, D-Arg, L-Cys, D-Cys)
As attachment site for the tags we could not use the peptide backbone because this would
have resulted in capping of a few percent of the peptides on each bead and therebye have
lead to ineffective quenching. Furthermore cleavage of the peptide would also result in
loss of the tags. As alternative attachment sites for the tags, we therefore coupled three
side-chain Alloc- protected lysines to the bead before the fluorophore was coupled. The
entire library synthesis was performed using the standard FMOC protocol. Following the
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fluorophore building block 48, a glycine moiety was coupled as a spacer. Starting from
precursor 51, we synthesised a library of combinatorially varied tripeptides.
Figure 4.4.: Synthesis of the fluorophore-quencher library  43
For each of the three varied positions, 31 different FMOC-protected D- and L-aminoacids
were used. This leads to a combinatorial variety of maximally 313=29791 peptides.
 All proteinogenic aminoacids except for methionine, isoleucine, tyrosine and
tryptophane were included in the library. Before quencher building block 50 was coupled,
another glycine spacer was introduced. The quencher was then acetylated as well as the
H2N
a: FMOC-Aminoacid-OH, DIC, HOBt, DCM
b: Piperidine, DMF (1:4)
coupling conditions:
H
N
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c: i): TFA, CH2Cl2. ii): allylchloroformiate, NEt3
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remaining amino groups of the tag-carrying lysines. Finally all of the sidechain protecting
groups were cleaved with TFA to complete library 43.
4. 2. Sequence selectivity of peptide damage under Fenton conditions
To test the sequence selectivity of peptide cvleavage under Fenton conditions we treated
the fluorophore quencher library 43 with iron(III), ascorbic acid and hydrogen peroxide.
Complexing of the library with FeCl3 (0.3M) followed by washing with H2O (5x) and
treatment with ascorbic acid (0.05M) and hydrogen peroxide (0.5M) resulted, after
quenching of the reaction by washing with water after 20 minutes, in several fluorescing
beads (Figure 4.5.).
          
a   b
Figure 4.5.: a: iron treated library after addition of  ascorbic acid (0.05 M) and
hydrogen peroxide (0.5 M) b: library without treatment
The reaction was then performed in different buffer systems. In table 1, the applied
reaction conditions are summarised together with the resulting contrast observed between
fluorescing and non fluorescing beads. As shown in table 4.1., the observed effect is
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highly pH dependent. At pH 5 or below, the contrast between fluorescing and non
fluorescing beads is biggest, while at higher pH's the effect becomes smaller until at pH >
6 almost no fluorescence is observed.
Table 4.1.: Effect of the pH / buffer system on the damage caused by the Fenton reaction.
Buffer pH Contrast
no buffer[a] 3.0 High
no buffer with 20µl HCl (1M) 4.5 High
acetate 5.0 High
MES 5.0 High
MES 5.9 Small
no buffer 6.0 Very small
HEPES 7.0 Very small
Tris 7.3 Very small
Tris 8.5 Very small
Procedure: Library beads were equilibrated with 0.3M FeCl3 solution and washed five times with water.
Then 650µl water was added followed by a solution of sodium ascorbate (0.1M) in 500µl of a specified
buffer and 100µl of 1M hydrogen peroxide. After 20 minutes, the reaction was quenched by washing with
water. [a]: Ascorbic acid was used instead of sodium ascorbate.
Control experiments showed that all three components are required to observe fluorescent
beads (table 4.2.). When either the ascorbate or the hydrogen peroxide is left out, no
fluorecent beads are observed.  The same is the case for library beads that are treated by
ascorbate and hydrogen peroxide without previous equilibration with iron(III). No
selectivity is observed when the beads are not washed after the equilibration with iron.
.
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Table 4.2.: Control experiments
Ascorbic Acid (0.05M) Hydrogen Peroxide (0.5M) Iron(III) Fluorescing beads?
YES YES YES YES
YES YES NO NO
YES NO YES NO
NO YES YES NO
Analysis of the sequences of 70 of the brightest fluorescing beads (table 4.3.) revealed
that almost all of the peptides on the selected beads contain two acidic amino acids
(glutamic acid and ascorbic acid). In 80% of the cases, the two acidic amino acids are in
successive positions, while in about 15% of the sequences, they are separated by another
random amino-acid.
Table 4.3.: Sequences on fluorescing beads (X = random amino acid)
AA3 AA2 AA1 Freq. Found
L/D-Asp/Glu L/D-Asp/Glu X 34 %
X L/D-Asp/Glu L/D-Asp/Glu 47 %
L/D-Asp/Glu X L/D-Asp/Glu 13 %
In order to explain these observations we hypothesised the following:
Peptides with two subsequent acidic amino acids are able to coordinate to iron as a
chelate complex. Thus, after washing the iron treated beads with water the iron
concentration on those peptides will be considerably higher than on peptides without this
motif. By the following addition of ascorbate and hydrogen peroxide, radicals are
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generated near these peptides. Therefore the extent of cleavage of these acid-rich peptides
should be higher.
In order to test this hypothesis, we first studied the complexation behaviour of model
peptides containing two subsequent acidic amino acids.  These experiments are described
in chapter 3.3. while in chapter 3.4. quantitative studies on the cleavage selectivity are
presented.
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4. 3. Iron complexation of peptides with two consequent acidic amino acids
To study the complex stability of peptides containing two subsequent acidic amino acids
with iron we performed experiments on solid phase and in solution.
4. 3. 1. Experiments on the solid phase
First we performed a complexation experiment with library 43. The library beads were
equilibrated with a 0.3 M iron(III)chloride solution and then washed five times with
water. To visualise the iron on the beads we then added a 1M KSCN solution to the
beads.
Figure 4.7.: Formation of the red iron rhodanide complex
Thiocyanate anions form red Fe(SCN)3 complexes with iron which was observed on
about 5 - 10 % of the beads (figure 4.8.). Analysis of the peptides on these red beads
revealed similar sequences (two subsequent acidic amino acids in most cases) as for the
fluorescing beads.
To quantify the complex stability we analysed how much Fe3+ remained on the beads
after complexation with iron. We thus synthesised two sequences on TentaGel following
a hexanoic acid spacer. In addition to Ac-L-Glu-L-Glu 52 the negative control Ac-Gly-
Gly 53 was synthesised.
3 SCN      +     Fe3+ Fe(SCN)3    (red)
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Figure 4.8.: library 43 after treatment with iron(III), washing with water and addition of
KSCN.
Both of these immobilised peptides were treated with a 0.3 M iron (III) solution. The
beads were then washed five times with water. The complex between the iron and the
peptide was broken by washing five times with 0.1 M HCl. The iron in the collected
acidic washing phases was then quantified by adding KSCN (1M) and measuring the UV
absorbtion of the red iron rhodanide complex at 480 nm. This allowed a estimation of the
iron content (table 4.4.).
In the case of the negative control peptide 53, only about 7% of iron was found compared
to the loading of the beads. On the other hand Ac-L-Glu-L-Glu 53 complexed iron to an
approximately equimolar extent.
Table 4.4.: Iron complexed by the peptides 52 and 53 by treating with excess iron and
washing with water. The values are given in % relative to the amount of peptides.
Ac-L-Glu-L-Glu 52 Ac-Gly-Gly 53
105 (± 5) % 7(± 5) %
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 Thus, a clear difference was found between the peptide containing two acidic amino
acids and the negative control.
To get an idea about the dimension of the complexation constant we equilibrated resins
52 and 53 with an equimolar amount of a 0.6 mM iron(III)chloride solution at pH 5 using
acetate buffer. After 30 hours of equilibration time, the iron remaining in solution was
measured as well as the iron on the bead (after washing with HCl).
From this data, the complex stability constant was calculated by:
where [iron] is the iron concentration measured in solution after equilibration and
[complex] is the concentration of the iron washed from the bead with HCl. The
concentration of the free peptide [peptide] is given by: [peptide0] -[complex] where
[peptide0] is calculated from the weighed sample of resin. We found a value in the range
of 3x103 for the Glu-Glu peptide 52 while the complex stability constant of the negative
control 53 was about two orders of magnitude smaller.
Table 4.5.: K values for 52 and 53 obtained by equilibration experiments on solid phase
(30 h equilibration of resin bound peptide with 1 eq iron(III)chloride (0.6 mM) in 0.5 M
acetate buffer pH 5. Values averaged over three experiments).
Complex stability constant K[a]
52 (L-Glu-L-Glu) 2900 (+/- 300)
53 (Gly-Gly) 55 (+/- 30)
[a] complex concentrtion and free iron concentration were obtained by measuring the iron concentrations
in solution and on the bead after equilibration (30 h).
K    =
[complex]
[peptide][iron]
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These results give us an idea about the dimension of the stability of the iron peptide
complex. The values are however not absolute since in the calculation no interference
from the buffer or the resin has been considered. Therefore these values can only be
compared when obtained under exactly the same conditions. A more accurate way to
determine the complex stability would be a pH-titration of the peptide in solution in the
presence of iron.
4. 3. 2. Complexation experiments in solution
For solution phase complexation experiments we synthesised peptide Ac-L-Glu-L-Glu-
NHPr 54.
                    54
N
H
H
N
N
H
O
O
O
HO
HO
O
O
 Figure 4.10.: Peptide 54 synthesised for solution phase studies of the iron complexation
By titration of 54 (2mM) with NaOH first in the absence of iron the pKa values were
determined to be 3.95 and 4.70 respectively, by using the program titfit.[65] The titration
61
yielded also the distribution of the species depending on the pH (figure 4.9.). This shows,
that at pH 5 the predominant form is the doubly deprotonated species with approximately
65 %, followed by the species with one deprotonated acid group (35 %), while the fully
protonated peptide is almost non-existent at that pH.
Figure 4.9.: Particle distribution of 54 depending on the pH as derived from titration
with NaOH.   (1) = fully protonated,   (2) = once deprotoneted,  (3) = fully
deprotonated.
Subsequently, we attempted to determine the complexation constant in solution by
titration of 54 in the presence of 0.9 eq FeCl3. However, precipitation of Fe(OH)3 at pH 4
in the course of the titration prevented the measurement with Fe3+. Instead, the titration
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was performed with FeCl2. Here, precipitation of Fe(OH)2 occurred only at pH 8 and
allowed for an estimation of the complexation constant in the range of 104. Typically, the
complexation constant is higher for iron(III) than for iron(II) by a factor of 10.[66]
We then measured the effect of iron on the peptide with 1H-NMR measurements by
titrating iron(III)chloride to an sample of 54.  It is known[67, 68] that the relaxation time is
shortened for protons close to a paramagnetic metal center. Indeed we observed  different
changes of the relaxation time for different protons indicating iron complexation.
However, the observed effect is too small to be analysed quantitatively.
The studies demonstrate that peptides with two subsequent acidic amino acids are able to
coordinate to iron stronger than peptides without this motif.
4. 4. Quantitative studies on the cleavage selectivity
To quantify the damage of Asp/Glu containing peptides compared to a negative control
we performed studies with the peptides bound to solid support and in solution.
For the solid phase studies we terminated the peptides with the fluorophore anthranilic
acid. Upon cleavage, the fluorophore is released into solution and can be quantified in
order to get relative cleavage and damage activities.
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4. 4. 1. Experiments on the solid phase
The Glu-Glu containing peptide 55 and a negative control peptide 56 where the glutamic
acid residues are replaced by glycines were synthesised on TentaGel.[63] and terminated
with the fluorophore anthranililc acid coupled to the side chain amino group of a lysine.
Ac-L-Lys(F)-Gly-Gly-Gly-L-Glu-L-Glu-εAhx-NH-
Ac-L-Lys(F)-Gly-Gly-Gly-Gly-Gly-εAhx-NH-
55
56
HN NH
O O NH2
L-Lys(F) =
= TentaGel
Figure 4.10.: Resin bound peptides 55 and 56 used for fluorospectrometric detection of
the peptide cleavage
To minimise quenching effects of the fluorescence by ascorbic acid or iron the
fluorescence measurement was performed at pH 4 in acetate buffer where quenching is
minimal.
Peptides 55 and 56 were both complexed with FeCl3 and washed thoroughly, followed by
addition of ascorbic acid (0.05 M pH 3.0) and hydrogen peroxide (0.5 M). After 20
minutes, the reaction was quenched by the addition of MnO2. Fluorescence of the
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Figure 4.11.: Fluorescence spectrum of the reaction mixtures of 55 (---) and the negative
control 56 (- -). Irradiation wavelength 320 nm).
solution was measured after removal of the resin by filtration. In figure 4.11. the
fluorescence spectra of the reaction mixture of resin 55 as well as of the negative control
56 are shown.
Clearly treatment of resin 55 bearing the Glu-Glu peptide releases much more of the
fluorophore into the solution than resin 56 containing two glycins instead. In fact, more
than 50 times more of the fluorophore is measured in the solution in case of 55 compared
to the negative control peptide 56. The experiment was also performed using 1 equivalent
of iron without washing between the complexation step and the addition of the reagents.
Under these more solution-like conditions, 55 still leads to an approximately five times
higher fluorescence of the resulting solution than 56.
This demonstrates, that the cleavage extent is much higher for peptides with two acidic
amino acids.
55
56
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 3. 4. 2. Experiments in solution
For the solution phase cleavage studies the fluorophore-marked peptides were prepared
on Wang resin and removed from the resin as propylamides 57 and 58.
Ac-L-Lys(F)-Gly-Gly-Gly-L-Glu-L-Glu-εAhx-NH-Pr
Ac-L-Lys(F)-Gly-Gly-Gly-Gly-Gly-εAhx-NH-Pr
57
58
Figure 4.12.: Peptides 57 and 58 for solution phase studies
The peptides were complexed with 3 eq of FeCl3 (30 mM), diluted with MES buffer pH 5
to a concentration of 1mM before sodium ascorbate and H2O2 were added. After 20
minutes, excess H2O2 was quenched with MnO2. After filtration, the reaction mixtures
were analysed by HPLC using a fluorescence detector. The HPLC analysis did not show
any new peaks with neither fluorescence nor UV detection (320 nm) but only a decrease
of the peaks corresponding to the peptides 57 and 58 respectively. Thus, the peptides are
damaged but no defined cleavage product was observed. This suggests, that the damaged
peptides are broken up in pieces too small to allow for their analysis by HPLC. As judged
by the decrease of the integrals of the signals detected at 320 nm (UV) the L-Glu-L-Glu
containing peptide 57 was damaged to an extent of approximately 35 % while the
negative control peptide 58 only was reduced by less than 10 %. Figure 4.13. shows the
averaged data depicted as columns. In figure 4.14. the HPLC chromatograms for the L-
Glu-L-Glu peptide 57 and negative control 58 untreated and treated with the Fenton
conditions are shown as an example.
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57 57' 58 58'
 Figure 4.13.: The relative extent of peptide damage by the Fenton reaction in solution as
determined by HPLC with UV detection (320 nm). 57 and 58 represent the untreated, 57'
and 58' the treated peptides. The percentages were calculated by averaging integrals of
the peptide peaks out of three experiments. The averages of 57 and 58 (untreated) are set
to 100% each.
Figure 4.14.: HPLC chromatograms (210 nm) of 57 untreated (upper left), 57’ treated
(upper right), 58 untreated (lower left), 58’ treated (lower right).
57 57’
58’58
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To take the results together: We have shown that peptides with two subsequent acidic
amino acids are damaged more than other peptides under Fenton conditions. The relative
cleavage yield is higher when the peptides are bound to the solid support than in solution.
We also demonstrated, that these peptides coordinate stronger to iron than peptides
without this motif. This can be interpreted that peptides are cleaved to a higher extent if
iron is in the vicinity of the peptide backbone.
68
5. Overall Conclusions and Outlook
This work presents a novel class of two-armed receptors that bind to peptides with high
sequence selectivity. These receptors are composed of a diketopiperazine derived from
hydroxyproline as a template and two peptidic arms. The excellent binding properties
have been rationalised by the analysis of the influence of the template structure on the
binding properties. Exchange of the diketopiperazine against other templates resulted in
an entire loss of intermolecular binding ability. Analysis of the diketopiperazine
conformation by X-ray crystal structure analysis and by 1H-NMR-spectroscopy revealed,
that diketopiperazine receptors with pseudo-axial standing substituents are excellent
templates for two armed receptors. These studies demonstrated that the template has the
largest impact on the binding properties. The second largest effect comes from the first
amino acid that is coupled to the template. The receptors are currently applied for the
development of sensors[69] and liquid crystallin materials70]  and might be used for the
development of diagnostics.
The second part shows by the use of a combinatorial fluorophore-quencher library, that
peptides containing two acidic amino acids are preferably cleaved under Fenton
conditions. Such peptides were shown to coordinate to iron more strongly than other
peptides. Due to the iron coordination, upon the addition of ascorbic acid and H2O2,
radicals are generated in the vicinity of the peptide. These peptides are therefore cleaved
more than peptides that are not able to coordinate to iron.
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The presented results are designed to serve as a starting point for the development of
selective proteolytic receptors. By coupling a proteolytically active metal complex (e.g.
Fe-EDTA)[71] to, for example a diketopiperazine receptor, peptides will not only be
bound, but, in a second step cleaved selectively (as shown in figure 5.)
Figure 5.: sequence selective cleavage of peptides as a two step process
peptide
binding
binding site active site
cleavage

Experimental Section
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6. Experimental part
6. 1. General aspects
6. 1. 1. Solvents and reagents
All materials and reagents were of the highest commercially available grade and used
without further purification as received from Fluka AG (Buchs, Switzerland), Aldrich
(Buchs, Switzerland), Bachem (Bubendorf, Switzerland) and NovaBiochem / Merck
Biosciences (Läufelfingen, Switzerland).
Solvents for chromatography and extractions were distilled prior to use. Further solvents
used for reactions correspond to the quality puriss, p. a., abs. For analytical and
preparative HPLC, HPLC-grade solvents were used. The water used for reactions and
HPLC was filtered over Barnstead ultrapure water system.
6. 1. 2. Materials and Instruments
Solvents were removed with a Büchi (Switzerland) rotary evaporator. For weighing
compounds and reagents Mettler (Switzerland) balances were used.
Finnigan MAT LCQ and TSQ 700 instruments were used for electrospray ionisation
(ESI) mass spectrometry.
6. 1. 3. Chromatographic methods
Analytical thin layer chromatography (TLC) was performed on Merck silica gel 60 F254
plates. Compounds were detected (if not visible by eye) at 254 nm (UV) or visualised
with ceric ammonium molybdate (CAM) or ninhydrin.
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For normal phase column chromatography sililca gel 60 from Merck (40 - 60 µm particle
size) was used and for eluting the compounds pressure (0.3 - 0.5 bar) was applied (flash
chromatography).
Analytical reversed phase HPLC (RP-HPLC) was performed on LiChrospher® 100 RP -
18 silica gel from Merck (5 µm particle size, 4x250 mm column) on a Waters alliance
2690  with a 996 photodiode array detector (PDA).
Gas chromatography of the tags was performed on a  Hewlett packard HP 6890 GC
system.
6. 1. 4. Spectroscopic methods
Ultra violet - visible absorption spectra were recorded  on a Perkin Elmer Lambda Bio 40
UV/VIS spectrometer using Hellma quartz cuvettes (10 mm light path). Fluorescence
spectra were recorded on a ISA Jobin Yvon-Spex FluoroMax-2 spectrometer using 10 mm
path length quartz cuvettes (Hellma).
Infrared spectra (IR) were measured on a Perkin Elmer 1600 Series FTIR in KBr (1%
w/w) or neat between NaCl-plates.
1H-Nuclear magnetic resonance spectroscopy (1H-NMR) was performed using either a
Varian Gemini (300 MHz), Bruker DPX-NMR (400 MHz), Bruker DRX-500 (500 MHz)
or a Bruker DRX-600 (600 MHz) spectrometer. Solvents for NMR were obtained from
Dr. Glaser AG (Basel, Switzerland) and Cambridge Isotope Laboratories (Andover, MA,
USA). If necessary for the interpretation correlated spectra like COSY, TOCSY, NOESY
and ROESY were recorded also.
Description: 1H-NMR (frequency, solvent, temperature): δH in ppm relative to residual
solvent peaks or trimethylsilyane (peak multiplicity: s = singlet, d = doublet, t = triplet, q
= quartet, quin = quintet, sext = sextet, m = multiplet, br = broad; coupling constants J in
Hertz)
13C- Nuclear magnetic resonance spectroscopy (13C -NMR) were 1H-decoupled and
recorded on a Varian Gemini 300 (75 MHz), Bruker DPX-NMR (100 MHz) or a Bruker
DRX-500 (125 MHz).
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6. 1. 5. Signature of the Proline Derivates
                                           
N R
O
Hα
Hγ
Hδ'
Hδ
Hβ'Hβ
γ
δ
βα
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6. 2. Synthesis of the cis-diketopiperazine template
6. 2. 1. N-Boc-trans-γ-hydroxy-L-proline methyl ester 5
10.54 g (45.6 mmol, 1 eq; CAS-Nr. 233663-27-9) of N-Boc-trans-γ-hydroxy-L-proline 4
was dissolved in 120 ml of methanol and a solution of 8.92 g (27.4 mmol, 0.6 eq) Cs2CO3
in 10 ml water was added. After stirring for 1 h at RT the methanol was removed in
vacuo. After it was coevaporated with toluol three times, the residue was suspendet in 30
ml DMF. Then after addition of 5.7 ml (91 mmol, 2 eq) methyliodide it was stirred one
hour at RT and 100 ml water and the same amount of Et2O was added to the mixture. The
waterphase was separated and extracted 7 times with 80 ml of Et2O. The organic phases
were washed with 50 ml of a saturated NaCl solution, dried over MgSO4 filtred and the
solvent was removed at reduced pressure to yield 11.00g (99%) of N -Boc-
trans−γ−hydroxy-L-proline methyl ester 5 as a yellowish oil. (1H NMR- and 13C NMR-
spectra show a double set of peaks (≈ 2 : 1) due to the s-cis and s-trans conformers
around the tertiary carbamate.)
C11H19NO5: 245.13
TLC: Pentane/EtOAc (2:1); Rf: 0.17 (Ninhydrin)
1H NMR (300 MHz, CDCl3, 25oC): δ (ppm) = 4.49 (s, br, 1H; Hγ), 4.40 (dd, J = 8.9 Hz,
1H; Hα), 3.73 (s, 3H; OCH3), 3.64 (dd, J = 5.7, 8.4 Hz, 1H; Hδ'), 3.50 (m, 1H; Hδ),
2.25-2.20 (m, 1H; Hβ'),  2.13-2.00 (m, 1H; Hβ),  1.48/1.37 (2s (1:2), 9H, t-Bu);
NBOC
COOH
HO
NBOC
CO2CH3
HO
1. Cs2CO3, H2O/MeOH
2. MeI, DMF
99%
4 5
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13C NMR (100.6 MHz, CDCl3, 25oC): δ (ppm) =  175.3, 175.1, 154.4, 153.6, 80.3,
71.0, 70.0, 57.8, 55.7, 55.1, 52.6, 52.3, 38.48, 35.3, 28.3, 28.1;
ESI-MS: m/z: calcd for C11H19NO5 [M+Na]+ 268; found 268.
6. 2. 2. N-Boc-cis-γ-azido-L-Proline-methylester 6
To a solution of 7.44 g (30.4 mmol, 1 eq) N-Boc-trans−γ−hydroxy-L-proline methyl ester
5 in 100 ml of CH2Cl2 5.1 ml (36 mmol, 1.2 eq) of NEt3 was added and the mixture was
cooled to 0°C. 2.9 ml (36 mmol, 1,2 eq) of mesylchloride was added, it was stirred  for
one hour and then washed with 50 ml saturated NaHCO3. The aquouos phase was
extracted twice with 50 ml CH2Cl2. The organic phases were dried over satureted NaCl
and MgSO4. After filtration and removal of the solvent, the mesylester was dissolved in
100 ml of DMF and 19.8 g (304 mmol, 10 eq) of NaN3 was added.  After stirring for 4 h
at 80°C water and Et2O (80 ml of each) was added. The water phase was separated and
extracted three times with 80 ml Et2O. The organic phases were washed with sat. NaCl
solution and dried over MgSO4. After removing of the solvent at reduced pressure, the
crude product (7.28 g) was purified by flash chromatography over silica gel (gradient of
CH2Cl2 / MeOH from 0 to 4% of methanol). This yielded 6.48 g (100%) of the N-Boc-
cis-γ-azido-L-Proline-methylester 6. (1H NMR- and 13C NMR- spectra show a double set
of peaks (≈ 2 : 1) due to the s-cis and s-trans conformers around the tertiary carbamate.)
NBOC
CO2CH3
HO
NBOC
CO2CH3
N3
1. MsCl, CH2Cl2/NEt3
2. NaN3, DMF
100%
5 6
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C11H18N4O4: 270.13
TLC: CH2Cl2/MeOH (25:1); Rf: 0.68 (Ninhydrin)
1H NMR (300 MHz, CDCl3, 25oC): δ (ppm) = 4.43 / 4.32 (2dd, J = 4.4 Hz, 8.8 Hz, 1H;
Hγ), 4.18-4.12 (m,  1H; Hα), 3.76 (s, 3H; OCH3), 3.78-3.68 (m, 1H; Hδ), 3.48 (ddd, J =
3.5 Hz, 11.0 Hz, 15.7 Hz, 1H; Hδ),  2.52-2.40 (m, 1H; Hβ),  2.21-2.14 (m, 1H; Hβ),  1.48
/ 1.42 (2s (1:1.5), 9H; t-Bu);
13C-NMR (75 MHz, CDCl3, 25oC): δ (ppm) = 172.2, 153.9, 153.4, 80.5, 59.2, 58.2, 57.7,
57.27, 51.2, 50.7, 36.0, 35.0, 28.2.
6. 2. 3. N-Boc-cis-γ-azido-L-Proline-pentafluorophenylester 7
2.00 g N-Boc-cis-4-azido-L-Proline-methylester 6 (7.40 mmol, 1 eq) was dissolved in a
1:1 mixture of THF and MeOH (50 ml). After the addition of 0.44 g NaOH (11.04 mmol,
1.5 eq) dissolved in water (1 ml) the mixture was stirred for 1.5 h at room temperature
and then carefully acidified with 1M HCl to pH 4.  EtOAc (100 ml) and water (50 ml)
were added and the mixture was extracted with additional 1M HCl (20 ml). The aqueous
layer was extracted with EtOAc (50 ml), the organic layers were washed with brine and
dried over MgSO4. Filtration and evaporation of the solvent at reduced pressure yielded a
colorless oil which was dissolved in CH2Cl2 (10 ml). Addition of pentafluorophenol (1.43
g, 7.77 mmol) and EDC (2.13 g, 11.11 mmol) yielded a solution which was stirred for 1 h
at room temperature and then extracted with water (50 ml) and EtOAc (100 ml). The
NBOC
CO2CH3
N3
NBOC
CO2C6F5
N3
1. NaOH, THF/MeOH/H2O
2. PFP, CH2Cl2/EDC
93%
6 7
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aqueous layer was extracted again with EtOAc (50 ml) and the organic layers were
washed with brine and dried over MgSO4. Filtration and removal of all volatiles at
reduced pressure yielded the pentafluorophenylester 7 (2.90 g, 6.87 mmol, 93%) as a
colorless oil. (1H NMR- and 13C NMR- spectra show a double set of peaks (≈ 2 : 1) due to
the s-cis and s-trans conformers around the tertiary carbamate.)
C16H15F5N4O4: 422.31
TLC: Pentane/EtOAc (5:1); Rf: 0.27 (Ninhydrin)
1H NMR (300 MHz, CDCl3, 25oC): δ (ppm) = 4.76 and 4.70 (2dd (1:2), J = 9.2 Hz, 3.2
Hz and 9.3 Hz, 2.8 Hz, 1H; Hα), 4.29 (m, 1H; Hγ), 3.76 (m, J = 11.9, 1H; Hδ), 3.63 and
3.54 (2dd (2:1), J = 11.8 Hz, 2.5 Hz and 11.3 Hz, 3.0 Hz, 1H; Hδ´), 2.68 - 2.37 (m, 2H;
Hβ,  Ηβ´), 1.49 und 1.46 (2s (1:2), 9H; t-Bu);
13C-NMR (100.5 MHz, CDCl3, 25oC): δ (ppm) = 168.3, 168.0, 153.9, 153.6, 143.5,
138.8, 81.9, 81.6, 60.8, 59.8, 57.7, 57.5, 51.7, 51.5, 36.9, 35.8, 28.7, 28.5;
FT-IR (NaCl, ν/cm-1): 2980, 2118, 1798, 1713, 1518, 1260;
ESI-MS: m/z: calcd for C16H15F5N4O4 [M+H]+ 423; found 423.
Elemental analysis: Calcd (%) for C16H15F5N4O4 (422.3):
C 45.51, H 3.58, N 13.27; found C 45.27, H 3.56, N 13.14.
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6. 2. 4. Cyclo-(cis-γ-N3-L-Pro)2 8
N-Boc-cis-γ-azido-L-Proline-pentafluorophenylester 7 (1.21 g, 2.87 mmol) was dissolved
in a 1 : 3 mixture of TFA and CH2Cl2 (10 ml) and allowed to stir at room temperature for
1.5 h. After removal of all volatiles at reduced pressure the oily residue was triturated
with Et2O (20 ml) to yield a white solid which was isolated by decantation followed by
removal of all residual volatiles in vacuo. The residue was dissolved in THF (10 ml),
Hünig`s base (2.00 ml, 11.48 mmol) was added and the mixture was stirred at room
temperature for 60 h. After removal of all volatiles at reduced pressure, flash
chromatography on silica gel (gradient of CH2Cl2 : MeOH from 100 : 0 to 100 : 6)
afforded the diketopiperazine 8 (0.19 g, 0.69 mmol, 47 %) as a colorless oil.
C10H12N8O2: 276.25
TLC: CH2Cl2/MeOH (10:1); Rf: 0.32 (Ninhydrin)
1H NMR (500 MHz, CDCl3, 25oC): δ (ppm) = 4.28 (dd, J = 8.8 Hz, 5.7 Hz, 2H; Hα),
4.20 (ψqd, J = 5.5 Hz, 4.0 Hz, 2H; Hγ), 3.81 (ddd, J = 12.4 Hz, 3.9 Hz, 1.2 Hz, 2H; Hδ´),
3.55 (dd, J = 12.4 Hz, 5.6 Hz, 2H; Hδ), 2.69 (dddd, J = 13.8 Hz, 5.7 Hz, 4.9 Hz, 1.2 Hz,
2H; Hβ´), 2.50 (ddd, J = 13.8 Hz, 8.8 Hz, 5.7 Hz, 2H; Hβ).
13C NMR (75.5 MHz, CDCl3, 25oC): ): δ (ppm) = 165.5, 58.2, 58.0, 50.3, 32.4;
FT-IR (NaCl, ν/cm-1): 2953, 2103, 1680, 1422, 1269.
N
N3
1. TFA, CH2Cl2
2. TAEA, THF
47%NBOC
CO2C6F5
N3
N
N3
O
O
H
H
7
8
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FAB-MS (NBA): m/z (%): [M+H]+ 277.
Elemental analysis calcd (%) for C10H12N8O2 (276.3): C 43.48, H 4.38, N 40.56; found C
43.33, H 4.54, N 40.26.
6. 2. 5. Cyclo-(cis-γ-NHBoc-L-Pro)2 9
N
BocHN
H2, Pd(C), (Boc)2O, MeOH
66%
N
NHBoc
O
O
H
H
N
N3
N
N3
O
O
H
H
8 9
Palladium on carbon (10%, 20 mg) was added to the solution of 0.25 g of the diazide 8
(0.91 mmol, 1 eq) and 0.79 g Boc2O (3.61 mmol, 4 eq) in MeOH (10 ml). The black
suspension was evacuated, flushed with hydrogen and allowed to stir for 4 h at room
temperature. After filtration over celite and removal of the solvent at reduced pressure,
the residue was purified by flash chromatography over silica gel (gradient of CH2Cl2 :
MeOH from 100 : 0 to 100 : 6) to afford the bis-N-Boc-protected diketopiperazine 9 (0.25
g, 0.59 mmol, 66 %) as a white solid.
C20H32N4O6: 424.23
TLC: CH2Cl2/MeOH (10:1); Rf: 0.18 (Ninhydrin)
1H NMR (300 MHz, CDCl3, 25oC): δ (ppm) =  5.30 (s (broad), 2H; NH), 4.27 (ψt, J =
7.8 Hz, 4H; Hα, Hγ), 3.73 (dd, J = 12.0 Hz, 7.0 Hz, 2H; Hδ), 3.43 (dd, J = 12.0 Hz, 6.5
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Hz, 2H; Hδ´), 2.55 (m, J = 13.6 Hz, 7.2 Hz, 2H; Hβ, 2.22 (dt, J = 13.5 Hz, 7.2 Hz,
2H; Hβ´), 1.44 (s, 18H; t-Bu);
13C NMR (100.5 MHz, 5% CD3OD in CDCl3, 25oC): δ (ppm) = 166.7, 155.9, 80.4,
59.3, 51.0, 48.9, 33.4, 28.7;
FT-IR (KBr): ν  = 3341, 2981, 1728, 1688, 1532, 1166.
ESI-MS: m/z: calcd for C20H32N4O5Na [M+Na]+ 447; found 447.
Elemental analysis calcd (%) for C20H32N4O6 + H2O (442.5): C 54.28, H 7.74, N 12.66;
found C 54.65, H 7.78, N 12.37.
6. 3. Synthesis of receptor precursor 17
6. 3. 1. Boc-Tyrosine(ODye)-Allylester 59
1.0 g (3.10 mmol, 1 eq) of BOC-D-Tyrosine-Allylester 15 was dissolved in 100 ml of
toluene and 0.98 g (3.10 mmol, 1 eq) of disperse red 1, 0.81 g of triphenyl phosphine and
BocHN
O
O
OH
BocHN
O
O
ODye
58 %
Dye-OH,
PPh3, DEAD, toluene
Dye-OH:
HO
N N
N NO2
15 59
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0.56 ml (3.10 mmol, 1 eq) of DEAD was added. After stirring for 24 hours at room
temperature, another 405 mg (0.5 eq) of triphenylphosphine and 0.3 ml (0.5 eq) of DEAD
was and the mixture was stirred for another 6 hours. Then, the toluene was removed
under reduced pressure and it was coevaporated twice with DCM. Purification of the
crude product by flash chromatography over silica gel (gradient: pentane:EtOAc from 3:1
to 2:1) yielded 1.1 g (58%) of 59.
C33H39N5O7: 617.69
TLC: CH2Cl2/MeOH (10:1); Rf: 0.71
1H-NMR:  (300MHz, CDCl3): δ= 8.33 (d, J = 8.5 Hz, 2H, ar-DR(o-NO2)), 7.92 (d, J =
8.7 Hz, 2H; ar-DR(m-NO2)), 7.91 (d, J = 9.0 Hz, 2H; ar-DR(m-amino)), 7.04 (d, J = 8.3
Hz, 2H; Tyr-Hδ), 6.81 (d, J = 9.1 Hz, 2H; Tyr-Hε), 6.81 (d, J = 9.1 Hz, 2H; ar-DR(o-
amino)), 5.93-5.82 (m, 1H; CH2CH=CH2), 5.31 (dd, J = 17.4, 1.0 Hz, 1H; CH2CH=CH2),
5.24 (dd, J = 10.2, 1.0 Hz, 1H; CH2CH=CH2), 4.94 (d, J = 7.0 Hz, 1H; NH), 4.60 (d, J =
5.7 Hz, 2H; CH2CH=CH2), 4.58-4.52 (m, 1H; Tyr-Hα) 4.16 (t, J  = 6.1 Hz, 2H;
OCH2CH2N), 3.85 (t, J = 5.9 Hz, 2H; OCH2CH2N), 3.61 (q, J = 7.0 Hz, 2H; NCH2CH3),
3.10-3.00 (m, 2H; Hβ), 1.41 (s, 9H; boc), 1.29 (t, J = 7.0 Hz, 3H; NCH2CH3);
ESI-MS: m/z: calcd for C33H39N5O7Na [M+Na]+ 640; found 640.
6. 3. 2. Boc-D-Tyrosine(ODye)-Allylester 59a
(59a was obtained analogue to the procedure described for 59 using BOC-D-Tyrosine-
Allylester 15a)
C33H39N5O7: 617.69
TLC: CH2Cl2/MeOH (10:1); Rf: 0.75
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1H-NMR:  (300MHz, CDCl3): δ= 8.32 (d, J = 9.0 Hz, 2H; ar-DR(o-NO2)), 7.93 (d, J =
9.1 Hz, 2H; ar-DR(m-NO2)), 7.93 (d, J = 9.1 Hz, 2H; ar-DR(m-amino)), 7.04 (d, J = 8.7
Hz, 2H; Tyr-Hδ), 6.82 (d, J = 9.4 Hz, 2H; Tyr-Hε), 6.81 (d, J = 8.7 Hz, 2H; ar-DR(o-
amino)), 5.94-5.80 (m, 1H; CH2CH=CH2), 5.31 (dd, J = 1.4, 17.2 Hz, 1H; CH2CH=CH2),
5.24 (dd, J = 1.2, 10.4, 1H; CH2CH=CH2), 4.94 (d, J = 7.0 Hz, 1H; NH), 4.60 (d, J = 5.8
Hz, 2H; CH2CH=CH2), 4.58-4.52 (m, 1H; Tyr-Hα), 4.16 (t, J = 5.9 Hz, 2H; OCH2CH2N),
3.85 (t, J = 5.8 Hz, 2H; OCH2CH2N), 3.62 (q, J = 7.1 Hz, 2H; NCH2CH3), 3.12- 2.95 (m,
2H; Hβ), 1.41 (s, 9H; boc), 1.29 (t, J = 6.9 Hz, 3H; NCH2CH3);
13C NMR (75 MHz, CDCl3, 25oC): δ (ppm) = 171.6, 157.5, 156.4, 151.5, 147.4, 143.6,
131.6, 130.5, 128.6, 126.7, 124.7, 122.5, 119.0, 114.5, 111.6, 79.9, 65.9, 65.3, 54.6, 50.0,
46.3, 37.5, 28.31, 12.4;
ESI-MS: m/z: calcd for C33H39N5O7Na [M+Na]+ 640; found 640.
6. 3. 3. Boc-Tyrosine(ODye)-Pentafluorophenylester 16
BocHN
O
O
ODye
BocHN
OC6F5
O
ODye
78 %
1. NaOH, THF/H2O/MeOH
2. C6F5OH, EDC, CH2Cl2
59 16
280mg (0.47 mmol, 1 eq) of BOC-L-Tyrosine(ODye)-Allylester 59 was suspended in a
1:1 mixture of THF and methanol and a solution of 28 mg (0.71 mmol, 1.5 eq) NaOH in
0.1 ml of water was added. The mixture was stirred at room temperature for 4 hours, then
20 ml of EtOAc was added. After extraction with 20 ml of 1M HCl the aquous phase was
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extracted twice with 20 ml of EtOAc. The organic layers were washed with brine and
dried over Na2SO4 and the solvent was removed at reduced pressure. The residue was
dissolved in 1 ml of DCM and 95 mg (0.52 mmol, 1.1 eq) of pentafluorophenol and 135
mg (0.71 mmol, 1.5 eq) of EDC was added. After 1 hour stirring at room temperature,
the solution was extracted with water (50 ml) and DCM (3*50 ml). The organic layers
were washed with brine and dried over Na2SO4. The volatiles were removed and the
product was purified over silica gel by flash chromatography (DCM) yielding 273 mg (78
%) of pentafluorophenylester 16.
C36H34F5N5O7: 743.24
1H-NMR:  (400MHz, CDCl3): δ= 8.31 (d, J = 8.5 Hz, 2H; ar-DR(o-NO2)), 7.91 (d, J =
9.1 Hz, 2H; ar-DR(m-NO2)), 7.90 (d, J = 9.1 Hz, 2H; ar-DR(m-amino)), 7.14 (d, J = 8.6
Hz, 2H; Tyr-Hδ), 6.87 (d, J = 8.6 Hz, 2H; Tyr-Hε), 6.81 (d, J = 9.8 Hz, 2H; ar-DR(o-
amino)), 4.95 (d, J = 8.6 Hz, 1H; NH), 4.86 (td, J = 7.5, 13.6 Hz, 1H; Tyr-Hα), 4.17 (t, J
= 6.3 Hz, 2H; OCH2CH2N), 3.86 (t, J = 6.3 Hz, 2H; OCH2CH2N), 3.61 (q, J = 7.1 Hz,
2H; NCH2CH3), 3.23 (dd, J =6.1, 14.1 Hz, 1H; Hβ), 3.16 (dd, J =6.1, 14.2 Hz, 1H; Hβ),
1.43 (s, 9H; boc), 1.29 (t, J = 7.1 Hz, 3H; NCH2CH3);
13C NMR (100.6 MHz, CDCl3, 25oC): δ (ppm) =  168.4, 157.8, 156.7, 151.2, 147.4,
143.7, 130.4, 127.3, 126.2, 124.6, 122.6, 114.7, 111.4, 80.6, 65.3, 54.4, 49.8, 46.2, 367.0,
28.2, 12.3;
6. 3. 4. Receptor precursor 17
N
BocHN
N
NHBoc
O
O
H
H
N
HN N NH
O
O
H
H
L-Tyr(Dye) L-Tyr(Dye)
Boc Boc
1. TFA, DCM
2. DIPEA, 
     Boc-L-Tyr(Dye)-PFP
75%
9 17
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To remove the Boc groups, 39 mg (92.6 µmol, 1 eq) of the bis-N-Boc-protected
diketopiperazine 9  were stirred at room temperature in 2 ml of a 1:3 mixture of TFA and
DCM. After 30 minutes, the volatile components were removed at reduced pressure and
the residue was tritureted with diethyl ether. Then 0.5 ml of DCM was added as well as
60µl (0.37 mmol, 4 eq) of DIPEA followed by 150 mg (0.23 mmol, 2.5 eq) of the
pentafluoro ester 16. After 3 hours the reaction mixture was filtered over silica gel
(gradient of CH2Cl2 : MeOH from 100 : 0 to 100 : 5). This yielded 92 mg (75 %) of 17.
C70H82N14O14: 1342.61
TLC: CH2Cl2/MeOH (10:1); Rf: 0.40
1H-NMR:  (400MHz, CDCl3): δ= 8.30 (d, J = 9.2 Hz, 2H, ar-DR(o-NO2)), 7.89 (d, J =
9.1 Hz, 2H; ar-DR(m-NO2)), 7.87 (d, J = 9.1 Hz, 2H; ar-DR(m-amino)), 7.03 (d, J = 8.5
Hz, 2H; Tyr-Hδ), 6.78 (d, J = 9.5 Hz, 4H; Tyr-Hε, ar-DR(o-amino)), 6.50 - 6.43 (m, 1H;
NH DKP), 5.27 - 5.20 (m, 1H; NH Boc), 4.43 - 4.30 (m, 1H; Tyr-Hα), 4.28 - 4.10 (m,
4H; DKP-Hα, DKP-Hγ, OCH2CH2N), 3.81 (t, J = 5.4 Hz, 2H; OCH2CH2N), 3.58 (q, J =
7.1 Hz, 2H; NCH2CH3), 3.60 - 3.50 (m, 1H; DKP-Hδ), 3.37 (dd, J = 3.1, 11.2 Hz, 1H;
DKP-Hδ),   2.94 (dd, J  = 6.9, 13.6 Hz, 1H; Tyr-Hβ), 2.87 (dd, J =6.7, 13.8 Hz, 1H; Tyr-
Hβ), 2.50 - 2.30 (m, 2H; DKP-Hβ), 1.37 (s, 9H; boc), 1.26 (t, J = 7.0 Hz, 3H; NCH2CH3);
13C NMR (100.6 MHz, CDCl3, 25oC): δ (ppm) =  171.7, 166.1, 159.5, 157.3, 156.7,
151.2, 147.3, 143.7, 130.4, 128.2, 126.2, 124.7, 122.6, 114.6, 111.4, 78.9, 65.3, 58.7,
56.5, 50.9, 50.1, 49.7, 46.1, 37.4, 30.9, 28.3, 12.3;
ESI-MS: m/z: calcd for C33H39N5O7Na [M+Li]+ 1349; found 1349.
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6. 4. Synthesis of dye marked cis-diketopiperazine receptor prototypes
6. 4. 1. A general protocol for the synthesis of two armed molecules
6. 4. 1. 1. Boc-deprotection of precursor 17
To 117 mg (89 mmol, 1 eq) of 17 2 ml of HCl (4M) in dioxane was added followed by
0.1 ml of methanol.  After stirring 1 hour at r.t. all volatiles were removed at reduced
pressure and the residue was triturated twice with diethyl ether. The red solid was then
dried in vacuo and dissolved in DCM with 50 ml DIPEA (267 mmol, 3eq). This solution
was then used for the next amino acid coupling.
6. 4. 1. 2. Coupling of N-α-Fmoc protected amino acids
The desired N-α-Fmoc Protected Amino Acid (3 eq) was added together with 3 eq of
EDC to a concetrated solution of the corresponding N-α deprotected educt (1 eq) in as
little DCM as possible (usually about 300 - 400 µl for 100 mg educt). The mixture was
stirred at r.t. until the reaction was complete (usually about 20 - 30 minutes). Then it was
extracted with DCM and 1M HCl. The aqueous layer was extracted twice more with
DCM and the organic phases were washed with brine and dried over Na2SO4. After
removal of the solvent at reduced pressure, the product was purified over silica gel
(gradient of DCM/MeOH from 100:0 to 90:10). This afforded the N-α-FMOC-protected
receptor precursor which was used without further purification.
6. 4. 1. 3. FMOC-deprotection
The N-α-FMOC-protected receptor precursor (1 eq) was dissolved in DCM and 50 eq
of TAEA were added. After 10 - 20 minutes the mixture was extracted three times with
brine and three times with phosphate buffer pH 5.5. The aqueous phases were extracted
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twice more with DCM and the organic layers were dried over Na2SO4. Removal of the
volatiles at reduced pressure yielded the corresponding free amine that was now
introduced to a further amino acid coupling or was acetylated. The coupling and FMOC-
deprotection cycles was repeated until the desired peptidic arms were assembled.
6. 4. 1. 4. Acetylation of the free amines
The corresponding free amine (1 eq) was dissolved in 1 ml of DCM and 3 eq of each
NEt3 and Ac2O was added.  After stirring of the mixture for 30 minutes the acetylated two
armed molecule was purified by flash chromatography and gel filtration (LH 20,
DCM/MeOH 90:10). The two armed molecules  10 - 14, 19 and 20 were isolated in
amounts of 20 - 40 mg (40 - 55 % from 9).
6. 4. 2. Receptor 10:
                                              
N
N
OO
H
H
NH
NH
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
C128H128N20O18: 2234.51
TLC: CH2Cl2:MeOH (10:1); Rf: 0.37
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1H NMR (500 MHz, 2% CD3OD in CDCl3, 25oC): δ = 8.32 (d, J = 9.0 Hz, 4H; dye),
7.99 (s, 2H; NH), 7.91 (d, J = 9.0 Hz, 4H; dye), 7.88 (d, J = 9.3 Hz, 4H; dye), 7.36 (d, J =
6.7 Hz, 2H; NH),  7.27 - 7.16 (m, 40H; trityl, Phe, NH), 7.09 (d, J = 7.0 Hz, 4H; Phe),
7.03 (d, J = 8.6 Hz, 4H; Tyr), 6.92 (d, J = 6.5 Hz, 2H; NH), 6.77 (d, J = 9.3 Hz, 4H; dye),
6.74 (d, J = 8.6 Hz, 4H; Tyr), 4.48 (m, 2H; Tyr-Hα), 4.36 (m, 6H; Pro-Hγ, Asn-Hα, Phe-
Hα), 4.17 (ψt, J = 8.0 Hz, 2H; Pro-Hα), 4.03 (t, J = 5.7 Hz, 4H;
 
OCH2CH2N), 3.74 (t, J =
5.7 Hz, 4H;
 
OCH2CH2N), 3.61 (m, 2H; Pro-Hδ), 3.55 (q, J = 7.1 Hz, 4H; CH2CH3), 3.23
(m, 2H; Pro-Hδ´), 3.06 (dd, J = 14.1 Hz, 4.9 Hz, 2H; Tyr-Hβ), 2.90 (m, 4H; Tyr-Hβ´,
Phe-Hβ), 2.78 (dd, J = 14.9 Hz, 5.7 Hz, 2H; Asn-Hβ), 2.65 (dd, J = 14.0 Hz, 9.9 Hz, 2H;
Phe-Hβ´), 2.56 (dd, J  = 14.9 Hz, 6.9 Hz, 2H; Asn-Hβ´), 2.38 (m, 2H; Pro-Hβ), 2.15 (m,
2H; Pro-Hβ´), 1.78 (s, 6H; COCH3), 1.25 (t, J  = 7.1 Hz, 6H; CH2CH3);
13C NMR (125.6 MHz, 2% CD3OD in CDCl3, 25oC): δ = 172.4, 171.6, 171.4, 170.7,
170.2, 166.0, 157.3, 156.8, 151.3, 147.3, 144.1, 143.4, 136.3, 130.3, 129.4, 129.0, 128.7,
127.8, 127.0, 126.3, 124.7, 122.6, 114.4, 111.4, 70.6, 65.2, 58.9, 55.2, 54.9, 51.1, 49.8,
49.2, 47.5, 46.0, 37.4, 36.9, 35.8, 32.3, 22.5, 12.2;
HRMS (ESI): m/z: calcd for C128H128N20O18 [M+2H]2+ 1117.4931; found 1117.4933.
6. 4. 3. Two armed molecule 11:
                                            
N
N
OO
H
H
NH
NH
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
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C128H128N20O18: 2234.51
TLC: CH2Cl2:MeOH (20:1); Rf: 0.19
1H NMR (500 MHz, 5% CD3OD in CDCl3, 25oC): δ = 8.31 (d, J = 9.1 Hz, 4H; dye),
7.90 (d, J = 9.1 Hz, 4H; dye), 7.85 (d, J = 9.2 Hz, 4H; dye), 7.26 - 7.12 (m, 36H; trityl,
Phe-6H,), 7.08 (d, J = 8.4 Hz, 8H; Tyr, Phe), 6.78 (d, J = 8.6 Hz, 4H; Tyr), 6.73 (d, J =
9.2 Hz, 4H; dye), 4.37 (m, 2H; Tyr-Hα), 4.27 (m, 4H; Asn-Hα, Phe-Hα), 4.07 (m, J =
6.0 Hz, 8H;
 
OCH2CH2N, Pro-Hα,  Pro-Hγ), 3.73 (t, J = 6.0 Hz, 4H; OCH2CH2N), 3.52 (q,
J = 7.1 Hz, 4H;
 
CH2CH3), 3.36 (d (broad), J = 9.7 Hz, 2H; Pro-Hδ), 3.18 (dd, J = 13.6
Hz, 6.7 Hz, 2H; Asn-Hβ), 3.10 (dd, J = 14.3 Hz, 4.2 Hz, 4H; Phe-Hβ, Tyr-Hβ), 2.92 (dd,
J = 13.6 Hz, 7.8 Hz, 2H; Asn-Hβ´), 2.75 (dd, J = 14.3 Hz, 9.7 Hz, 2H; Phe-Hβ´, Pro-
Hδ´), 2.64 (dd, J = 14.9 Hz, 5.9 Hz, 2H; Tyr-Hβ´), 2.27 (m, 4H; Pro-Hβ, Pro-Hβ´), 1.60
(s, 6H; COCH3), 1.21 (t, J  = 7.1 Hz, 6H; CH2CH3);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 172.1, 171.3, 171.1, 170.9,
170.7, 165.0, 157.1, 156.8, 151.3, 147.3, 144.2, 143.7, 136.0, 130.6, 129.8, 128.9, 128.9,
128.8, 127.9, 127.3, 127.0, 126.3, 124.7, 122.6, 114.4, 111.4, 70.8, 65.1, 58.2, 55.9, 50.9,
50.6, 49.8, 47.5, 46.0, 36.7, 35.4, 32.4, 22.9, 12.3;
HRMS (ESI): m/z: calcd for C128H128N20O18 [M+2H]2+ 1117.4931; found 1117.4937.
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6. 4. 4. Two-armed molecule 12:
                                  
N
N
OO
H
H
NH
NH
Ac-L-Asn(Trt)-L-Phe-D-Tyr(dye)
Ac-L-Asn(Trt)-L-Phe-D-Tyr(dye)
C128H128N20O18: 2234.51
TLC: CH2Cl2:MeOH (10:1); Rf: 0.46
1H NMR (500 MHz, 5% CDOD in CDCl3, 25oC): δ = 8.31 (d, J = 9.1 Hz, 4H; dye), 7.91
(d, J = 9.1 Hz, 4H; dye), 7.88 (d, J = 9.2 Hz, 4H; dye), 7.23 - 7.15 (m, 36H; trityl, Phe-
6H), 7.05 (d, J = 6.9 Hz, 4H; Phe), 6.78 (ψd, J = 9.1 Hz, 8H; dye, Tyr), 6.69 (d, J = 8.8
Hz, 4H; Tyr), 4.50 (ψt, J = 5.9, 2H; Asn-Hα), 4.39 (ψt, J = 7.3 Hz, 2H; Pro-Hγ), 4.32 (t,
J = 6.6 Hz, 2H; Tyr-Hα), 4.13 (t, J = 8.4 Hz, 2H; Pro-Hα), 4.07 (t, J = 6.0 Hz, 4H;
OCH2CH2N), 4.06 (m, 2H; Phe-Hα), 3.78 (t, J = 6.0 Hz, 4H; OCH2CH2N), 3.61 (dd, J =
12.0 Hz, 7.6 Hz, 2H; Pro-Hδ), 3.56 (q, J = 7.0 Hz, 4H;
 
CH2CH3), 3.30 (dd, J = 12.0 Hz,
7.6 Hz, 2H; Pro-Hδ´), 2.95 (dd, J = 13.4 Hz, 6.7 Hz, 2H; Phe-Hβ), 2.80 (dd, J = 13.4 Hz,
8.0 Hz, 2H; Phe-Hβ´), 2.74 (m, 8H; Tyr-Hβ,   Tyr-Hβ´, Asn-Hβ,  Asn-Hβ´), 2.42 (m, 2H;
Pro-Hβ), 2.27 (m, 2H; Pro-Hβ´), 1.77 (s, 6H; COCH3), 1.25 (t, J = 7.0 Hz, 6H; CH2CH3);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 171.8, 171.4, 171.1, 171.0,
170.3, 165.8, 157.3, 156.7, 151.2, 147.3, 144.1, 143.6, 136.6, 130.2, 129.3, 129.0, 128.6,
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128.5, 127.7, 126.9, 126.2, 124.6, 122.5, 114.2, 111.3, 70.5, 65.2, 58.6, 55.9, 54.5, 53.4,
50.2, 49.9, 49.7, 47.0, 46.0, 37.5, 36.3, 35.3, 32.6, 22.5, 12.1;
HRMS (ESI): m/z: calcd for C128H128N20O18 [M+2H]2+ 1117.4931; found 1117.4933.
6. 4. 5. Receptor 13:
                                          
N
N
OO
H
H
NH
NH
Ac-L-Phe-L-Gln(Trt)-L-Tyr(dye)
Ac-L-Phe-L-Gln(Trt)-L-Tyr(dye)
C128H128N20O18: 2262.56
TLC: CH2Cl2:MeOH (10:1); Rf: 0.49
1H NMR (500 MHz, CDCl3, 43oC): δ = 8.53 (s (broad), 2H, NH), 8.30 (d, J = 9.1 Hz,
4H; dye), 7.88 (d, J = 9.1 Hz, 4H; dye), 7.84 (d, J = 9.2 Hz, 4H; dye), 7.27 - 7.09 (m,
48H; trityl, Phe, Tyr-4H, NH-4H), 6.98 (s (broad), 2H, NH), 6.73 (ψd, J = 9.2 Hz, 8H;
Tyr, dye), 5.73 (s (broad), 2H, NH), 4.56 (m, 2H; Tyr-Hα), 4.41 (m, 2H; Pro-Hγ), 4.32
(m, 2H; Phe-Hα), 4.13 (m, 2H; Pro-Hα), 4.03 (m, 6H;
 
OCH2CH2N, Gln-Hα), 3.73 (t, J =
5.8 Hz, 4H;
 
OCH2CH2N), 3.71 (m, 2H; Pro-Hδ), 3.52 (q, J = 7.0 Hz, 4H; CH2CH3), 3.35
(dd, J = 11.3 Hz, 7.4 Hz, 2H; Pro-Hδ´), 3.25 (dd, J = 14.1 Hz, 3.7 Hz, 2H; Tyr-Hβ), 3.05
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(dd, J = 14.1 Hz, 4.5 Hz, 2H; Phe-Hβ), 2.83 (dd, J = 14.1 Hz, 10.1 Hz, 2H; Tyr-Hβ´),
2.67 (dd, J = 14.0 Hz, 9.9 Hz, 2H; Phe-Hβ´), 2.42 (m, 2H; Pro-Hβ), 2.34 (m, 2H; Pro-
Hβ´), 2.08 (m, 4H; Gln-Hγ, Gln-Hγ´), 1.87 (m, 2H; Gln-Hβ), 1.75 (m, 2H; Gln-Hβ´),
1.62 (s, 6H; COCH3), 1.22 (t, J = 7.1 Hz, 6H; CH2CH3);
13C NMR (125.6 MHz, CDCl3, 25oC): δ = 173.3, 172.9, 172.0, 171.3, 170.9, 165.8,
157.2, 156.8, 151.3, 147.4, 144.3, 143.7, 136.3, 130.4, 129.0, 128.8, 128.7, 128.0, 127.3,
127.1, 126.3, 124.7, 122.6, 114.3, 111.4, 70.8, 65.4, 58.9, 56.0, 54.8, 49.8, 49.4, 47.3,
46.1, 37.0, 36.1, 32.9, 25.8, 23.0, 12.3;
HRMS (ESI): m/z: calcd for C130H132N20O18 [M+2H]2+ 1131.5087; found 1131.5069.
6. 4. 6. Two armed molecule 14:
                                                
N
N
OO
H
H
NH
NH
Ac-L-Gln(Trt)-L-Phe-D-Tyr(dye)
Ac-L-Gln(Trt)-L-Phe-D-Tyr(dye)
C128H128N20O18: 2262.56
TLC: CH2Cl2:MeOH (10:1); Rf: 0.38
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1H NMR (500 MHz, 5% CD3OD in CDCl3, 25oC): δ = 8.31 (d, J = 9.1 Hz, 4H; dye),
7.91 (d, J = 9.1 Hz, 4H; dye), 7.88 (d, J = 9.2 Hz, 4H; dye), 7.29 - 7.15 (m, 36H; trityl,
Phe-6H), 7.05 (d, J = 7.1 Hz, 4H; Phe), 6.77 (d, J = 9.2 Hz, 4H; dye), 6.76 (d, J = 8.7 Hz,
4H; Tyr), 6.71 (d, J = 8.8 Hz, 4H; Tyr), 4.36 (m, 2H, Tyr-Hα), 4.32 (m, 2H, Pro-Hγ),
4.19 (ψt, J = 8.4 Hz, 2H; Pro-Hα), 4.09 (m, J = 5.8 Hz, 8H; Phe-Hα, OCH2CH2N, Gln-
Hα), 3.79 (t, J = 5.8 Hz, 4H;
 
OCH2CH2N), 3.61 (m, 2H; Pro-Hδ), 3.56 (q, J = 7.1 Hz, 4H;
CH2CH3), 3.47 (m, 2H, Pro-Hδ´), 2.97 – 2.90 (m, 4H, Phe-Hβ,  Tyr-Hβ), 2.79 (dd, J =
13.8 Hz, 8.2 Hz, 2H; Phe-Hβ´), 2.70 (dd, J = 13.8 Hz, 5.6 Hz, 2H; Tyr-Hβ´), 2.48 (m,
2H; Pro-Hβ), 2.20 (m, 6H; Pro-Hβ´, Gln-Hγ, Gln-Hγ´), 1.86 (s, 6H; COCH3), 1.80 (m,
4H, Gln-Hβ, Gln-Hβ´), 1.25 (t, J = 7.1 Hz, 6H; CH2CH3);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 172.7, 172.2, 171.7, 171.6,
171.1, 165.7, 157.3, 156.7, 151.3, 147.3, 144.3, 143.6, 136.8, 130.2, 129.0, 129.0, 128.6,
128.5, 127.8, 126.9, 126.8, 126.2, 124.6, 122.5, 114.4, 111.3, 70.5, 65.2, 58.6, 55.7, 54.4,
52.9, 49.5, 49.3, 47.1, 46.0, 36.2, 35.3, 32.8, 32.3, 26.7, 22.5, 12.2;
HRMS (ESI): m/z: calcd for C130H132N20O18 [M+2H]2+ 1131.5087; found 1131.5101.
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6. 4. 7. Two-armed molecule 19:
                                                  
N
N
OO
H
H
NH
NH
Ac-L-Asn(Trt)-L-Tyr(dye)
Ac-L-Asn(Trt)-L-Tyr(dye)
C160H152N24O18: 2697.17
TLC: CH2Cl2:MeOH (20:1); Rf: 0.13
1H NMR (500 MHz, 5% CD3OD in CDCl3, 25oC): δ = 8.33 (d, J = 9.1 Hz, 4H; dye),
7.92 (d, J = 9.1 Hz, 4H; dye), 7.90 (d, J = 9.2 Hz, 4H; dye), 7.71 (d, J = 6.9 Hz, 2H; NH
Asn),   7.29 - 7.16 (m, 30H, Trityl), 6.95 (d, J = 9.0 Hz, 2H; NH Tyr), 6.91 (d, J = 5.4 Hz,
2H; NH DKP), 6.80 (d, J = 8.5 Hz, 4H; Tyr), 6.79 (d, J = 9.2 Hz, 4H; dye), 6.63 (d, J =
8.7 Hz, 4H; Tyr), 4.93 - 4.88 (m, 2H; Tyr-Hα), 4.84 - 4.80 (m, 2H; Asn-Hα), 4.26 (dd, J
= 2.0, 8.8 Hz, 2H; Pro-Hα), 4.19 - 4.15 (m 2H; Pro-Hγ), 4.05 (t, J = 6.2 Hz, 4H;
OCH2CH2N), 3.78 (t, J = 6.2 Hz, 4H; OCH2CH2N), 3.76 (d, J = 12.6 Hz, 2H; Pro-Hδ'),
3.57 (q, J = 6.9 Hz, 4H;
 
CH2CH3), 3.32 (dd, J = 4.8, 12.4 Hz, 2H; Pro-Hδ), 3.01 (dd, J =
3.8, 15.0 Hz, 2H; Asn-Hβ), 2.64 (dd, J = 5.8, 15.1 Hz, 2H; Asn-Hβ), 2.57 (d, J = 14.1
Hz, 2H; Pro-Hβ'), 2.55 - 2.50 (m, 4H; Tyr-Hβ), 2.20 (ddd, J = 3.2, 5.5, 8.7 Hz, 2H; Pro-
Hβ), 1.77 (s, 6H; COCH3), 1.26 (t, J  = 7.0 Hz, 6H; CH2CH3);
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 13C NMR  (125.6 MHz, 5% CD 3OD in CDCl3, 25 oC): δ =  172.1, 172.0, 170.9, 170.8,
168.0, 157.1, 156.8, 151.3, 147.3, 144.3, 143.7, 130.1, 129.0, 128.8, 128.7, 127.9, 126.90,
126.3, 124.7, 122.6, 114.2, 111.4, 70.6, 65.1, 59.5, 53.4, 51.5, 50.6, 49.7, 48.6, 46.1, 35.8,
35.5, 30.7, 22.9, 12.3;
ESI-MS: m/z: calcd for C110H108N18O16 [M]+ 1938.8; found 1938.9.
6. 4. 8. Receptor 20:
N
N
OO
H
H
NH
NH
Ac-L-Asn(Trt)-L-Phe-L-Asn(Trt)-L-Tyr(dye)
Ac-L-Asn(Trt)-L-Phe-L-Asn(Trt)-L-Tyr(dye)
C174H168N24O22: 2647.28
TLC: CH2Cl2:MeOH (10:1); Rf: 0.35
1H NMR (500 MHz, 5% CD3OD in CDCl3, 25oC): δ = 8.31 (d, J = 9.0 Hz, 4H; dye),
7.90 (d, J = 9.0 Hz, 4H; dye), 7.87 (d, J = 9.2 Hz, 4H; dye), 7.71 (s, 2H; NH(Trt)), 7.61
(s, 2H; NH(Trt)), 7.23 - 7.10 (m, 66H; Trityl, Phe-6H), 7.07 (d, J = 6.7 Hz, 4H; Phe-Hδ),
7.02 (d, J = 8.6 Hz, 4H; Tyr-Hδ), 6.75 (d, J = 9.3 Hz, 4H; dye), 6.74 (d, J = 8.5 Hz, 4H;
Tyr-Hε), 4.46 (t, J = 6.6 Hz, 2H; Tyr-Hα), 4.38 (t, J = 6.2 Hz, 2H; Asn-Hα), 4.34 (t, J =
5.6 Hz, 2H; Asn-Hα), 4.32 - 4.25 (m, 4H; Pro-Hγ, Phe-Hα), 4.08 (t, J = 8.0 Hz, 2H; Pro-
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Hα), 4.02 (t, J = 5.8 Hz, 4H;
 
OCH2CH2N), 3.72 (t, J = 5.8 Hz, 4H; OCH2CH2N), 3.53 (q,
J = 7.1 Hz, 4H;
 
CH2CH3), 3.53 - 3.49 (m, 2H, Pro-Hδ), 3.17 (dd, J = 8.4, 11.5 Hz, 2H;
Pro-Hδ), 3.09 (dd, J = 4.2, 14.2 Hz, 2H; Phe-Hβ), 2.94 (dd, J = 6.2, 14.3 Hz, 2H; Tyr-
Hβ), 2.87 (dd, J = 7.2, 14.1 Hz, 2H; Tyr-Hβ), 2.70 (dd, J = 10.0, 14.1 Hz, 2H; Tyr-Hβ),
2.60 - 2.30 (m, 10H; Pro-2Hβ, Asn-8Hβ), 2.16 - 2.08 (m, 2H; Pro-Hβ), 1.76 (s, 6H, Ac),
1.23 (t, J  = 7.0 Hz, 6H; CH2CH3);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ =  171.7, 171.5, 171.3, 171.1,
170.8, 170.4, 170.1, 165.8, 157.3, 156.7, 151.3, 147.2, 144.1, 143.6, 136.5, 130.3, 129.1,
129.0, 128.6, 128.6, 128.5, 127.8, 127.8, 126.9, 126.8, 126.2, 124.6, 122.5, 114.3, 111.3,
70.5, 70.4, 65.1, 58.8, 54.8, 51.1, 50.5, 49.4, 49.1, 47.3, 45.9, 37.2, 36.9, 36.2, 35.9, 32.4,
22.6, 12.1;
ESI-MS: m/z: calcd for C174H168N24O22 [M + Na]+ 2968.3; found 2968.5.
96
6. 5. Synthesis of the two armed molecules 25 - 27 and 29 - 31 based on different
diamino templates[58]
6. 5. 1. Synthesis of the tripeptidic arms
The tripeptidic arms 60, 60', 61 and 61' were assembled starting from the corresponding
Nα-Boc-protected tyrosineesters 59, 59a, 59', and 59'a respectively following the
FMOC-amino acid coupling procedure as described for the receptor prototypes in chapter
6. 5. 1. 1. Tripeptidic arm Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)OAllyl 60:
C62H62N8O9: 1063.20
TLC: CH2Cl2:MeOH (25:1); Rf: 0.37
1H-NMR: (400MHz, CDCl3): δ = 8.32 (d, J  = 9.2 Hz, 2H; ar-DR(o-NO2)), 7.92 (d, J
= 9.1 Hz, 2H; ar-DR(m-NO2)), 7.89 (d, J = 9.1 Hz, 2H; ar-DR(m-Amino)), 7.45 (d, J =
7.0 Hz, 1H; NH(Tyr)), 7.33 (d, J = 7.0 Hz, 1H; NH(Asn)), 7.30 - 7.18 (m, 18H; Trt-ar,
3H-Phe,), 7.06 (d, J = 6.5 Hz, 2H; Phe-Hδ), 6.96 (d, J = 8.5 Hz, 2H;  Tyr-Hδ), 6.78 (d, J
= 9.7 Hz, 2H; ar-DR(o-Amino)), 6.73 (d, J = 8.6 Hz, 2H; Tyr-Hε), 5.87 (tdd, J = 5.5,
11.7, 16.1 Hz, 1H; CH2CH=CH2), 5.87 (s br, 1H; NH(Phe)), 5.27 (dd, J = 1.5, 17.1 Hz,
1H; CH2CH=CH2), 5.21 (dd, J = 1.1, 10.8 Hz, 1H; CH2CH=CH2),   4.66 - 4.57 (m, 3H;
Tyr-Hα, Asn-Hα,  Phe-Hα ), 4.05 (t, J = 5.9 Hz, 2H; OCH2CH2N), 3.77 (t, J = 6.1 Hz,
2H; OCH2CH2N), 3.58 (q, J = 7.1 Hz, 2H; NCH2CH3), 3.05 - 2.97 (m, 3H; Asn-Hβ, Phe-
Hβ, Tyr-Hβ), 2.87 (dd, J = 7.5, 13.1 Hz, 2H; Asn-Hβ', Phe-Hβ'), 2.54 (dd, J = 7.1, 15.5
Hz, 1H; Tyr-Hβ'), 1.79 (s, 3H; Acetyl), 1.27 (t, J = 7.0 Hz, 3H; NCH2CH3);
13C-NMR: (125.8 MHz, CDCl3): δ = 171.1, 170.7, 170.5, 170.2, 170.1, 156.8, 156.3,
151.3, 145.0, 144.3, 143.8, 136.0, 131.6, 130.4, 129.1, 128.5, 127.9, 127.1, 128.7, 126.3,
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124.5, 122.6, 118.6, 114.5, 111.4, 70.9, 65.9, 62.3, 54.2, 54.2, 53.4, 49.80, 46.1, 37.7,
36.8, 36.4, 23.0, 12.3;
6. 5. 1. 2. Tripeptidic arm Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)OAllyl 60':
C62H62N8O9: 1063.20
TLC: CH2Cl2:MeOH (25:1); Rf: 0.39
1H-NMR: (300MHz, CDCl3): δ = 8.32 (d, J  = 8.9 Hz, 2H; ar-DR(o-NO2)), 7.92 (d, J
= 9.0 Hz, 2H; ar-DR(m-NO2)), 7.89 (d, J = 9.1 Hz, 2H; ar-DR(m-Amino)), 7.51 (d, J =
7.7 Hz, 1H; NH(Tyr)), 7.30 - 6.93 (m, 22H; Trt-ar, Phe, Tyr-Hδ), 6.80 (d, J = 9.0 Hz, 2H;
ar-DR(o-Amino)), 6.77 (d, J = 8.3 Hz, 2H; Tyr-Hε), 5.88 - 5.73 (m, 1H; CH2CH=CH2),
5.25 (dd, J  = 1.4, 17.2 Hz, 1H; CH2CH=CH2), 5.16 (dd, J  = 1.1, 10.3 Hz, 1H;
CH2CH=CH2), 4.68 - 4.48 (m, 3H; Phe-Hα, Asn-Hα, Tyr-Hα), 4.11 (t, J = 5.8 Hz, 2H;
OCH2CH2N), 3.81 (t, J = 5.7 Hz, 2H; OCH2CH2N), 3.59 (q, J = 7.2 Hz, 2H; NCH2CH3),
3.07 (dd, J = 5.5, 14.0 Hz, 2H; Asn-Hβ, Phe-Hβ), 2.97 - 2.82 (m, 3H; Asn-Hβ, Phe-Hβ,
Tyr-Hβ), 2.46 (dd, J = 6.3, 15.3 Hz, 1H; Tyr-Hβ), 1.80 (s, 3H; Acetyl), 1.28 (t, J = 6.9
Hz, 3H; NCH2CH3);
13C-NMR: (125.8 MHz, CDCl3): δ = 171.6, 171.1, 170.9, 170.6, 170.4, 157.8, 157.2,
156.7, 151.7, 147.8, 144.6, 144.2, 136.5, 132.0, 130.9, 129.5, 129.2, 129.1, 128.4, 127.6,
127.5, 126.7, 125.1, 123.0, 119.2, 114.8, 111.8, 71.2, 66.3, 65.6, 61.8, 60.8, 55.2, 54.6,
50.3, 50.1, 46.5, 37.9, 37.4,  23.4, 12.7;
ESI-MS: m/z: calcd for C62H62N8O9Na [M+Na]+ 1086; found 1086.
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6. 5. 1. 3. Tripeptidic arm Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)OMe 61:
C60H60N8O9: 1037.17
TLC: CH2Cl2:MeOH (10:1); Rf: 0.49
1H-NMR: (500MHz, CDCl3): δ = 8.32 (d, J  = 9.1, 2H; ar-DR(o-NO2)), 7.92 (d, J =
9.1, 2H; ar-DR(m-NO2)), 7.89 (d, J = 9.2, 2H; ar-DR(m-Amino)), 7.49 (d, J = 7.3, 1H;
NH(Tyr)), 7.31 (d, J = 7.2, 1H; NH), 7.28-7.13 (m, 18H; ar H), 7.07 (d, J = 6.7, 2H; ar o-
Phe), 6.98 (s, 1H; NH(Trt)), 6.94 (d, J = 8.7, 2H; TyrHδ), 6.78 (d, J = 9.3, 2H; ar-DR(o-
Amino)), 6.74 (d, J = 6.7, 2H; Tyr-Hε), 4.66 (td, J = 3.4, 6.8, 1H; Tyr-Hα), 4.61-4.55 (m,
2H; Phe-Hα/ Asn-Hα), 4.04 (t, J  = 5.8, 2H; OCH2CH2N), 3.77 (t, J  = 5.8, 2H;
OCH2CH2N), 3.67 (s, 3H; OCH3), 3.57 (q, J = 7.1, 2H; NCH2CH3), 3.02 (dd, J = 3.5,
15.5, 1H; Tyr-Hβ), 3.00-2.95 (m, 2H; Asn-Hβ, Phe-Hβ), 2.89-2.84 (m, 2H; Asn-Hβ, Phe-
Hβ), 2.54 (dd, J = 6.5, 15.5, 1H; Tyr-Hβ), 1.78 (s, 3H; Acetyl), 1.27 (t, J = 7.1Hz, 3H;
NCH2CH3);
13C-NMR: (125.8 MHz, CDCl3): δ = 171.4, 171.2, 170.5, 170.2, 170.1, 157.4, 156.8,
151.3, 147.3, 144.2, 143.7, 136.0, 130.3, 129.1, 128.7, 128.0, 127.1, 128.4, 126.3, 124.7,
122.6, 114.4, 111.4, 70.8, 65.1, 54.2, 54.1, 52.3, 49.8, 49.5, 46.1, 37.6, 37.5, 36.5, 23.0,
12.3;
ESI-MS: m/z: calcd for C33H39N5O7Na [M+Na]+ 1060; found 1060;
6. 5. 1. 4. Tripeptidic arm Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)OMe 61':
C60H60N8O9: 1037.17
TLC: CH2Cl2:MeOH (10:1); Rf: 0.63
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1H-NMR: (500MHz, CDCl3): δ = 8.32 (d, J  = 9.1 Hz, 2H; ar-DR(o-NO2)), 7.92 (d, J
= 9.1 Hz, 2H; ar-DR(m-NO2)), 7.90 (d, J = 9.1 Hz, 2H; ar-DR(m-Amino)), 7.51 (d, J =
7.7 Hz, 1H; NH(Tyr)), 7.30 - 7.10 (m, 21H; Trt-ar, Phe, NH(Asn)), 7.03 (d, J = 8.7 Hz,
2H; Tyr), 6.79 (d, J = 9.3 Hz, 2H; ar-DR(o-Amino)), 6.77 (d, J = 8.6 Hz, 2H; Tyr-Hε),
5.90 (d, J = 6.8 Hz, 1H; NH(Phe)), 4.66 (ddd, J = 3.8, 6.2, 7.6 Hz, 1H; Tyr-Hα), 4.62
(ddd, J = 2.1, 5.7, 7.9 Hz, 1H; Asn-Hα), 4.54 (ddd, J = 3.9, 5.5, 6.8 Hz, 1H; Phe-Hα),
4.12 (t, J = 5.9 Hz, 2H; OCH2CH2N), 3.81 (t, J = 5.9 Hz, 2H; OCH2CH2N), 3.61 (s, 3H;
OCH3), 3.59 (q, J = 7.1 Hz, 2H; NCH2CH3), 3.08 (dd, J = 5.5, 10.1 Hz, 1H; Phe-Hβ),
3.05 (dd, J = 5.6, 10.1 Hz, 1H; Asn-Hβ), 2.91 (dd, J = 3.8, 15.3, 1H; Tyr-Hβ), 2.89 (dd, J
= 2.8, 10.1 Hz, 1H; Phe-Hβ'), 2.87 (dd, J = 2.1, 10.1 Hz, 1H; Asn-Hβ'), 2.46 (dd, J = 6.3,
15.3 Hz, 1H; Tyr-Hβ'), 1.80 (s, 3H; Acetyl), 1.27 (t, J = 7.0 Hz, 3H; NCH2CH3);
13C-NMR: (125.8 MHz, CDCl3): δ = 171.3, 171.2, 170.7, 170.2, 170.0, 157.4, 156.8,
151.3, 147.3, 144.2, 143.7, 136.1, 130.4, 129.0, 128.8,  127.9, 127.0, 128.6, 126.3, 124.7,
122.6, 114.4, 111.4, 70.7, 65.1, 54.8, 54.2, 52.2, 49.8, 49.7, 46.1, 37.51, 36.9, 22.9, 12.3;
ESI-MS: m/z: calcd for C33H39N5O7Na [M+Na]+ 1060; found 1060;
6. 5. 2. Ester cleavage of the arms and coupling to the diaminotemplates
For the synthesis of the two armed molecules 25 - 32, the methylester as well as the
allyester of the tripeptide were tried as starting material. The allylester can be cleaved
under milder conditions than the methylester and the amide coupling with the tripeptide-
acid arising from the allylester gave slightly purer products. However for some of the two
armed molecules purification by preparative HPLC was necessary, even after
optimisation of the coupling reaction.
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6. 5. 2. 1. General procedure for the ester cleavage of the tripeptide-allylester
The Tripeptide-allylester was dissolved in 4 ml of dry THF (ca. 4 ml for 100 mg of the
ester) together with 2.5 eq of pyrrolidine. The mixture was flushed for 20 minutes with
N2 and 0.01 eq of Pd(PPh3)4 was added. After stirring at r.t. for 30 minutes it was
extracted with DCM and 0.5 M H3PO4. After drying over Na2SO4 the solvent was
removed at reduced pressure to give the free acid in quantitative yield.
6. 5. 2. 2. General procedure for the ester cleavage of the tripeptide-methylester
1 eq of the tripeptide methylester was added to a solution of 1.8 eq KOSiMe3 in DCM
(ca. 5 ml per 100 mg tripeptide methylester). After three hours of stirring at room
temperature, it was washed twice with 30 ml of 1M HCl and filtered over silica gel
(gradient of DCM/MeOH from 95:5 to 85:15).
Ac-Phe-Asn(Trt)-Tyr(dye)OMe Ac-Phe-Asn(Trt)-Tyr(dye)OH
KOSiMe3  DCM
90%
Ac-Phe-Asn(Trt)-Tyr(dye)OAllyl Ac-Phe-Asn(Trt)-Tyr(dye)OH
Pd(PPh3)4
THF, Pyrrolidine
quant.
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6. 5. 2. 3. Coupling of the tripeptide arm acid to the diamines
-Determination of the optimal coupling conditions
Several conditions were tested for the coupling of the free acid of the tripeptidic arm to
the different diaminotemplates. To determine the best solvent and the best coupling
reagent preliminary test reactions were performed using ca. 1 mg of the tripeptide acid.
The coupling conditions leading to the least side products as detected by TLC were then
used for the synthesis of the corresponding two armed molecule. We tested the coupling
reagents DEPBT, EDC, TBTU, HATU as well as the solvents acetonitrile, DCM, THF,
toluene and acetone. In table 6.1., the best conditions found for each of the two armed
molecules are listed.
Table 6. 1.: Optimal coupling conditions for the two armed molecules 25 - 27 and 29 - 31
Two armed molecule coupling reagent solvent
23 TBTU DCM
24 TBTU DCM
25 HATU DCM
27 HATU Acetonitrile
28 HATU THF
29 HATU THF
Ac-L-Phe-L-Asn(Trt)-D/L-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-D/L-Tyr(dye)
NH2
NH2
NH
NH
2.1 eq Ac-L-Phe-L-Asn(Trt)-D/L-Tyr(dye)
DIPEA, coupling reagent, solvent
102
-General procedure of the coupling
1 eq of the tripeptide acid was dissolved in ca. 200 µl of the solvent (see table 6.1.) per 20
mg tripeptide. 0.45 eq of the diamine was added, followed by 1.1 eq of DIPEA and 1.1 eq
of the coupling reagent (see table 6.1.). After completion of the reaction (typically ca. 20
- 30 minutes) it was extracted with DCM, 1M HCl and brine. After drying over Na2SO4
the crude product was purified by flash chromatography over silica gel (gradient of
DCM/MeOH from 100:0 to 95:5) and gel filtration (LH 20, DCM/MeOH 90:10). When
required the products were further purified by preparative HPLC. Two armed molecules
25 - 27 and 29 - 31 were obtained in quantities of 15 - 30 mg with yields in the range of
70 - 90 %.
6. 5. 3. Two-armed molecule 25:
C124H126N18O16: 2124.44
TLC: CH2Cl2:MeOH (20:1); Rf: 0.20
1H NMR (500 MHz, 5% CD3OD in CDCl3, 25oC): δ = 8.31 (d, J = 9.1 Hz, 4H; dye),
7.90 (d, J = 9.1 Hz, 4H; dye), 7.87 (d, J = 9.1 Hz, 4H; dye), 7.23 - 7.11 (m, 42H; trityl,
Phe, 6 NH’s), 7.10 – 6.98 (m, 8H; Phe, Tyr), 6.73 (d, J = 8.7 Hz, 4H; Tyr), 6.72 – 6.67
(m, 4H; dye), 6.60 – 6.40 (m, 2H; NH Tyr), 4.76 – 4.60 (m, 4H; Asn-Hα, Phe-Hα), 4.45
– 4.30 (m, 2H; Tyr-Hα) ,  4.05 – 3.90 (m, 4H;
 
OCH2CH2N), 3.75 – 3.65 (m, 4H;
OCH2CH2N), 3.60 – 3.50 (m, 4H; CH2CH3), 3.50 – 3.40 (m, 2H, cHx), 3.05 – 2.92 (m,
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
HN
HN
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4H; Tyr-Hβ), 2.90 – 2.73 (m, 6H; Phe-Hβ, Asn-Hβ), 2.70 (dd, J = 14.3 Hz, 6.2 Hz, 2H;
Asn-Hβ´), 1.70 – 1.50 (m, 8H; cHx, COCH3), 1.73 (s, 6H; COCH3), 1.50 – 1.32 (m, 2H;
cHx), 1.22 (t, J  = 6.9 Hz, 6H; CH2CH3), 1.00 – 0.68 (m, 4H; cHx);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 171.2, 170.9, 170.6, 170.4,
170.1, 157.1, 156.8, 151.2, 147.3, 144.4, 143.7, 136.3, 130.7, 130.4, 130.2, 129.6, 129.5,
129.4, 129.2, 128.8, 128.7, 128.5, 128.3, 127.9, 126.9, 126.2, 124.7, 122.6, 114.3, 111.4,
70.8, 65.1, 54.8, 54.6, 54.3, 53.3, 49.7, 46.0, 38.9, 37.9, 36.5, 31.2, 24.3, 22.6, 12.2;
ESI-MS: m/z: calcd for C124H126N18O16Na [M+Na]+ 2147; found 2147.
6. 5. 4 Two-armed molecule 26:
C126H130N18O16: 2152.49
TLC: CH2Cl2:MeOH (20:1); Rf: 0.23
1H NMR (500 MHz, CDCl3, 25oC): δ = 8.61 (s, 2H, NH), 8.32 (d, J = 9.1 Hz, 4H; dye),
7.89 (d, J = 9.1 Hz, 4H; dye), 7.81 (d, J = 9.2 Hz, 4H; dye), 7.23 - 7.04 (m, 44H; 30 trityl,
10 Phe, 4 Tyr), 7.04 (d, J = 8.4 Hz, 4H; Tyr), 6.88 (d, J = 9.3 Hz, 4H; dye), 6.72 (d, J =
8.4 Hz, 4H; Tyr), 4.53 - 4.43 (m, 4H, Tyr-Hα,  Asn-Hα), 4.36 – 4.30 (m, 2H, Phe-H),
4.06 - 3.97 (m, 4H; OCH
2
CH2N), 3.79 – 3.75 (m, 4H; OCH2CH2N), 3.56 – 3.50 (m, 4H;
CH2CH3), 2.96 – 2.87 (m, 4H; Phe-Hβ , Tyr-Hβ ), 2.87 – 2.78 (m, 4H;
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
HN
H
N
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NHCH2(cyclohexyl)), 2.74 – 2.65 (m, 4H; Phe-Hβ, Tyr-Hβ), 2.63 – 2.52 (m, 2H; Asn-
Hβ ), 2.47 – 2.40 (m, 2H; Asn-Hβ), 1.72 (s, 6H; COCH3), 1.56 - 1.48 (m, 2H;
cyclohexyl), 1.48 - 1.42 (m, 2H; cyclohexyl), 1.27 - 1.16 (m, 2H; cyclohexyl), 1.13 (t, J =
8.4 Hz, 6H; CH2CH3), 1.00 - 0.91 (m, 1H; cyclohexyl), 0.58 - 0.51 (m, 2H; cyclohexyl),
0.34 - 0.29 (m, 1H; cyclohexyl);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 172.2, 170.9, 170.8, 170.0,
169.5, 157.3, 156.7, 152.0, 147.2, 145.1, 143.1, 138.2, 130.8, 130.3, 129.6, 128.9, 128.3,
127.8, 126.8, 126.5, 125.4, 122.9, 114.3, 112.1, 69.8, 65.7, 54.9, 54.4, 50.4, 49.6, 45.8,
43.1, 39.1, 37.9, 37.5, 30.4, 25.3, 22.9, 20.7, 12.4;
ESI-MS: m/z: calcd for C126H130N18O16Na [M+Na]+ 2175; found 2175.
6. 5. 5. Two-armed molecule 27:
C125H130N18O16: 2140.48
TLC: CH2Cl2:MeOH (10:1); Rf: 0.33
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-L-Tyr(dye)
HN
NH
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1H NMR (500 MHz, DMSO, 25oC): δ = 8.83 – 8.79 (m, 2H; Tyr-NH), 8.40 (d, J = 4.7
Hz, 2H; Asn-NH), 8.37 (d, J = 9.1 Hz, 4H; dye), 8.04 (m, 2H; Phe-NH), 7.94 (d, J = 9.1
Hz, 4H; dye), 7.83 (d, J = 9.2 Hz, 4H; dye), 7.72 (t, J = 5.9 Hz, 2H; Tyr-NH), 7.62 (t, J =
5.1 Hz, 2H; NH), 7.27 - 7.12 (m, 40H; trityl, Phe), 7.08 (d, J = 8.6 Hz, 4H; Tyr), 6.86 (d,
J = 9.4 Hz, 4H; dye), 6.74 (d, J = 8.7 Hz, 4H; Tyr), 4.56 – 4.48 (m, 4H; Phe-Hα, Asn-
Hα), 4.32 (td, J = 7.1 Hz, 4.5 Hz, 2H; Tyr-Hα), 3.95 (t, J = 6.6 Hz, 4H;
 
OCH2CH2N),
3.69 (t, J = 5.1 Hz, 4H;
 
OCH2CH2N), 3.50 (q, J = 6.6 Hz, 4H; CH2CH3), 3.06 (dd, J = 5.8
Hz, 5.4 Hz, 4H; heptyl), 3.01 (dd, J = 12.4 Hz, 2.1 Hz, 2H; Phe-Hβ), 2.88 – 2.74 (m, 4H;
Asn-Hβ, Tyr-Hβ), 2.71 – 2.55 (m, 6H; Asn-Hβ´, Phe-Hβ ´, Tyr-Hβ´), 1.71 (s, 6H;
COCH3), 1.49 (quint, J = 6.9 Hz, 4H; heptyl),  1.24 – 1.15 (m, 4H; heptyl), 1.13 (t, J =
7.0 Hz, 6H; CH2CH3), 1.10 – 1.02 (m, 2H; heptyl);
13C NMR (125.6 MHz, 5% DMSO in CDCl3, 25oC): δ = 171.5, 170.5, 170.1, 169.7,
169.1, 156.7, 156.2, 151.6, 146.9, 144.7, 142.8, 138.1, 130.0, 129.2, 128.6, 128.0, 127.5,
126.4, 126.2, 126.1, 125.0, 122.5, 114.0, 111.7, 69.4, 65.2, 54.4, 53.8, 49.7, 49.1, 45.3,
44.4, 38.4, 37.9, 36.2, 29.2, 28.7, 26.1, 26.0, 22.4, 12.0;
ESI-MS: m/z: calcd for C125H130N18O16Na [M+Na]+ 2162; found 2162.
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6. 5. 6. Two-armed molecule 29:
C124H126N18O16: 2124.44
TLC: CH2Cl2:MeOH (20:1); Rf: 0.20
1H NMR (500 MHz, 5% CD3OD in CDCl3, 25oC): δ = 8.32 (d, J = 9.1 Hz, 4H; dye),
7.91 (d, J = 9.1 Hz, 4H; dye), 7.89 (d, J = 9.3 Hz, 4H; dye), 7.24 - 7.10 (m, 44H; trityl,
Phe, Tyr), 6.79 (d, J = 9.3 Hz, 4H; dye), 6.74 (d, J = 8.5 Hz, 4H; Tyr), 4.57 (t, J = 6.0 Hz,
2H; Asn-Hα), 4.50 (dd, J = 9.6 Hz, 4.2 Hz, 2H; Phe-Hα), 4.45 (dd, J = 8.7 Hz, 5.4 Hz,
2H; Tyr-Hα), 4.07 (t, J = 5.8 Hz, 4H;
 
OCH2CH2N), 3.79 (t, J = 5.8 Hz, 4H; OCH2CH2N),
3.58 (q, J = 7.1 Hz, 4H;
 
CH2CH3), 3.41 (m, 2H, cHx), 3.10 (m, 4H; Phe-Hβ, Tyr-Hβ),
2.95 (dd, J = 13.1 Hz, 8.7 Hz, 2H; Tyr-Hβ´), 2.75 (dd, J = 14.0 Hz, 10.0 Hz, 2H; Phe-
Hβ´), 2.73 (dd, J = 14.4 Hz, 5.7 Hz, 2H; Asn-Hβ), 2.64 (dd, J = 14.5 Hz, 6.0 Hz, 2H;
Asn-Hβ´), 1.75 (m, 2H; cHx), 1.73 (s, 6H; COCH3), 1.56 (m, 4H; cHx), 1.26 (t, J  = 7.1
Hz, 6H; CH2CH3), 1.06 (m, 2H; cHx);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 171.9, 171.5, 170.8, 170.5,
170.0, 157.3, 156.8, 151.4, 147.3, 144.3, 143.7, 136.7, 130.4, 129.7, 129.0, 128.7, 128.6,
127.8, 126.9, 126.8, 126.3, 124.7, 122.6, 114.5, 111.4, 70.4, 65.2, 55.5, 54.9, 52.9, 50.3,
49.8, 46.1, 45.1, 37.8, 37.2, 36.4, 31.7, 29.7, 24.4, 22.7, 12.2;
HRMS (ESI): m/z: calcd for C124H126N18O16 [M+2H]2+ 1062.4872; found 1062.4882.
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
HN
HN
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6. 5. 7. Two-armed molecule 30:
C126H130N18O16: 2152.49
TLC: CH2Cl2:MeOH (20:1); Rf: 0.19
Not all the NMR - signals of the isomeric mixture could be assigned unambigously
1H NMR (500 MHz, CDCl3, 25oC): δ = 8.35 (2d, J = 9.2 Hz, 4H; dye), 7.91 (2d, J = 9.1
Hz, 4H; dye), 7.88 (2d, J = 9.3 Hz, 4H; dye), 7.27 - 7.13 (m, 44H; 30 trityl, 10 Phe, 4
Tyr), 6.76 (2d, J = 9.9 Hz, 4H; dye), 6.72 (d, J = 8.6 Hz, 4H; Tyr), 4.57 - 4.40 (m, 6H,
Phe-Hα,   Tyr-Hα,  Asn-Hα), 4.06 - 3.97 (m, 4H; OCH
2
CH2N), 3.77/3.74 (2t, J = 5.6 Hz,
4H;
 
OCH
2
CH2N), 3.56/3.55 (2q, J = 7.4 Hz, 4H; CH2CH3), 3.28 - 3.14 (m, 2H, Tyr-H),
3.12 - 2.97 (m, 4H, NHCH2(cyclohexyl), Phe-Hβ), 2.97 - 2.81 (m, 4H, Phe-Hβ, Tyr-Hβ),
2.69 (s br, 2H, Asn-Hβ), 2.60 - 2.50 (m, 4H, Asn-Hβ, NHCH2(cyclohexyl)), 1.75/1.74
(2s, 6H, COCH3), 1.68 - 1.55 (m, 2H, cyclohexyl), 1.49 - 1.40 (m, 2H, cyclohexyl), 1.33
- 1.15 (m, 2H, cyclohexyl), 1.28 - 1.23 (m, 6H; CH2CH3), 1.05 - 0.95 (m, 1H,
cyclohexyl), 0.71 - 0.55 (m, 2H, cyclohexyl), 0.20 - 0.27 (m, 1H, cyclohexyl);
13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 174.0, 172.0, 171.9, 171.8,
171.0, 170.9, 170.8, 170.3, 170.2, 157.2, 157.1, 156.8, 151.3, 147.3, 144.7, 144.6, 143.7,
136.2, 130.3, 130.0, 129.0, 128.7, 127.7, 127.1, 126.3, 124.7, 122.7, 114.3, 111.4, 70.6,
65.1, 55.5, 50.4, 50.3, 50.2, 49.8, 46.1, 45.7, 37.9, 36.9, 36.4, 30.5, 30.2, 29.3, 25.2, 23.3,
22.6, 22.5, 21.0, 12.2.
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
HN
H
N
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ESI-MS: m/z: calcd for C126H130N18O16Na [M+Na]+ 2175; found 2175.
6. 5. 8. Two-armed molecule 31:
C125H130N18O16: 2140.48
TLC: CH2Cl2:MeOH (20:1); Rf: 0.17
1H NMR (500 MHz, CDCl3, 25oC): δ = 8.64 (s, 2H; Tr-NH), 8.41 (d, J = 7.9 Hz, 2H;
Asn-NH), 8.35 (d, J = 9.1 Hz, 4H; dye), 8.13 (d, J = 7.9 Hz, 2H; Phe-NH), 7.93 (d, J =
9.1 Hz, 4H; dye), 7.84 (d, J = 9.3 Hz, 4H; dye), 7.79 (d, J = 8.3 Hz, 2H; Tyr-NH), 7.72 (t,
J = 5.5 Hz, 2H; NH), 7.25 - 7.13 (m, 40H; trityl, Phe), 7.07 (d, J = 8.7 Hz, 4H; Tyr), 6.91
(d, J = 9.3 Hz, 4H; dye), 6.75 (d, J = 8.7 Hz, 4H; Tyr), 4.52 (m, 2H; Phe-Hα), 4.47 (m,
2H; Asn-Hα), 4.32 (m, 2H; Tyr-Hα), 4.07 (t, J = 5.2 Hz, 4H;
 
OCH2CH2N), 3.81 (t, J =
5.2 Hz, 4H;
 
OCH2CH2N), 3.56 (q, J = 7.0 Hz, 4H; CH2CH3), 2.93 (m, 8H; Phe-Hβ, Tyr-
Hβ, heptyl), 2.72 (dd, J = 9.7 Hz, 3.9 Hz, 2H; Phe-Hβ´), 2.68 (dd, J = 12.9 Hz, 3.7 Hz,
2H; Tyr-Hβ´) 2.60 (m, 2H; Asn-Hβ), 2.49 (m, 2H; Asn-Hβ´), 1.74 (s, 6H; COCH3), 1.24
(m, 6H; heptyl), 1.16 (t, J = 7.0 Hz, 6H; CH2CH3), 1.11 (m, 4H; heptyl);
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
Ac-L-Phe-L-Asn(Trt)-D-Tyr(dye)
HN
NH
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13C NMR (125.6 MHz, 5% CD3OD in CDCl3, 25oC): δ = 172.8, 171.3, 171.1, 170.3,
169.8, 157.0, 156.7, 151.6, 147.8, 145.3, 143.2, 138.7, 130.8, 130.1, 129.4, 128.5, 128.4,
127.9, 127.4, 126.2, 124.9, 122.4, 113.8, 111.6, 70.5, 65.1, 54.4, 54.0, 51.1, 50.1, 49.1,
45.1, 38.6, 38.5, 37.3, 28.8, 28.6, 26.2, 11.9;
HRMS (ESI): m/z: calcd for C125H130N18O16 [M+2H]2+ 1070.5029; found 1070.5034.
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6. 6. Synthesis of the diketopiperazinemodels 33 - 35
6. 6. 1. Synthesis of bis-acetyl diketopiperazine 33
In 1 ml MeOH, 61 mg (221 µmol, 1 eq) of bis-azido diketopiperazine 8 was dissolved
and 5 mg of palladium on carbon was added. The black suspension was evacuated,
flushed with hydrogen and allowed to stir for 1.5 h at room temperature. Then, 207 ml
(2.2 mmol, 10 eq) of acetic anhydride was added and stirred for another 30 minutes. After
filtration over celite and removal of the solvent at reduced pressure, the product was
purified by precipitation with Et2O (4 times).  This afforded 58 mg (85%) bisacetylated
diketopiperazine 33 as a white solid. Crystals were obtained by diffusion of Et2O into a
solution of 33 in EtOAc and a trace of CH2Cl2.
C14H20N4O4 : 308.33
TLC: CH2Cl2/MeOH (10:1); Rf: 0.35 (Ninhydrin)
1H NMR (500 MHz, CDCl3, 25oC): δ = 6.08 (d, J = 6.1 Hz, 2H; NH), 4.33 (ψτ, J = 6.8
Hz, 2H; Hα), 4.41 (ψtq, J = 5.9 Hz, 3.8 Hz, 2H; Hγ), 3.78 (dd, J = 12.3 Hz, 3.7 Hz, 2H;
Hδ´), 3.57 (dd, J = 12.3 Hz, 5.9 Hz, 2H; Hδ), 2.52 – 2.49 (m, 4H; Hβ´, Hβ), 1.91 (s, 6H;
CH3);
13C NMR (100.5 MHz, CDCl3, 25oC): δ = 170.2, 167.1, 59.2, 51.4, 48.3, 32.2, 23.1;
FT-IR (KBr, ν/cm-1): 3446, 3292, 3071, 1661, 1549, 1446.
N
HN N NH
O
O
H
H
N
N3
N
N3
O
O
H
H
1. H2, Pd(C), (Boc)2O, MeOH
2. Ac2O
85%
O O
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FAB-MS (NBA): m/z: (%): calcd for C20H33N4O5 [M+H]+ 309; found 309.
Elemental analysis: Calcd (%) for C20H32N4O6 + H2O (442.5): C 54.28, H 7.74, N 12.66;
found C 54.42, H 7.70, N 12.57.
1H NMR (500 MHz, CD3OD, 25oC): δ = 4.45 (ψt, J = 7.6 Hz, 2H; Hα), 4.48 (m, J = 9.6
Hz, 7.7 Hz, 2H; Hγ), 3.81 (dd, J = 11.8 Hz, 7.9 Hz, 2H; Hδ), 3.27 (dd, J = 11.8 Hz, 7.7
Hz, 2H; Hδ´), 2.53 (dt, J = 12.7 Hz, 6.9 Hz, 2H; Hβ), 2.10 (dt, J = 12.7 Hz, 9.7 Hz, 2H;
Hβ´), 1.94 (s, 6H; CH3);
1H NMR (500 MHz, d6-DMSO, 25oC): δ = 8.08 (d, J = 6.8 Hz, 2H; NH), 4.37 (dd, J =
9.3 Hz, 7.5 Hz, 2H; Hα), 4.30 (dtt, J = 9.6 Hz, 7.7 Hz, 6.8 Hz, 2H; Hγ), 3.60 (dd, J = 11.4
Hz, 7.8 Hz, 2H; Hδ), 3.12 (dd, J = 11.4 Hz, 7.6 Hz, 2H; Hδ´), 2.34 (dt, J = 12.4 Hz, 6.9
Hz, 2H; Hβ), 2.05 (dt, J = 12.4 Hz, 9.8 Hz, 2H; Hβ´), 1.80 (s, 6H; CH3);
6. 6. 2. Synthesis of bis-ammoniumsalt 34
The Boc-protected diamine 6 (24 mg, 56mmol, 1 eq) was dissolved in 4 M HCl in
dioxane (1 ml) and allowed to stir at room temperature for 15 min. After removal of all
volatiles at reduced pressure the solid residue was triturated with Et2O (2 ml) to yield a
white solid which was isolated by decantation followed by removal of all residual
volatiles in vacuo.
C10H18Cl2N4O2: 297.18
N
H2N
N
NH2
O
O
H
H
N
BocHN
N
NHBoc
O
O
H
H
quant.
1. HCl 4M  in Dioxan
HCl HCl
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1H NMR (500 MHz, CD3OD, 25oC): δ = 4.57 (ψt, J = 8.2 Hz, 2H; Hα), 4.02 (dq, J = 7.2
Hz, ≈6 Hz, 2H; Hγ), 3.81 (dd, J = 12.5 Hz, 7.2 Hz, 2H; Hδ), 3.74 (dd, J = 12.5 Hz, 5.7
Hz, 2H; Hδ´), 2.73 (dt, J = 13.6 Hz, 7.4 Hz, 2H; Hβ), 2.42 (dt, J = 13.6 Hz, 7.9 Hz,
2H; Ηβ´).
1H NMR (500 MHz, d6-DMSO, 25oC): δ = 8.51 (s (broad), 4H; NH), 4.45 (ψt, J = 8.2
Hz, 2H; Hα), 3.85 (m (broad), 2H; Hγ), 3.61 (dd, J = 12.2 Hz, 5.1 Hz, 2H; Hδ´), 3.58
(dd, J = 12.2 Hz, 7.2 Hz, 2H; Hδ), 2.53 (dt, J = 12.8 Hz, 7.4 Hz, 2H; Hβ), 2.26 (dt, J =
12.8 Hz, 7.7 Hz, 2H; Hβ´);
13C NMR (100.5 MHz, d6-DMSO, 25oC): δ = 165.4, 66.3, 57.9, 48.7, 48.1, 31.3.
ESI-MS: m/z: calcd for C10H16N4O2 [M+H]+ 225; found 225;
6. 6. 3. Synthesis of bis-octyl diketopiperazine 35
58 mg (136 µmol, 1 eq) of bis-Boc protected diketopiperazine 9  was dissolved in 2 ml of
4M HCl in dioxane and 0.4 ml of methanol. After stirring 30 minutes at r.t. the solvent
was evaporated and the residue was dissolved in 1.5 ml of CH2Cl2. After the addition of
132 mg (547 mmol, 4 eq) of oenanth acid anhydride and 0.11 ml (821 mmol, 6 eq) of
N
HN N NH
O
O
H
H
N
BocHN N NHBoc
O
O
H
H
1. HCl 4M in Dioxan
2. (C6H13CO)2O, NEt3, CH2Cl2
66%
O O
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NEt3 the solution was stirred at r.t. for 30 minutes. Then it was extracted twice by 30 ml
of AcOEt and 15 ml of 1M NaOH. The organic layers were washed over 15 ml of sat.
NaCl, dried over Na2SO4 and the solvent was removed in vacuo. The crude product was
purified by flash chromatography over silica gel (gradient of CH2Cl2 / MeOH from 0 to
10% of methanol) to yield 40 mg (66%) of Cyclo-(trans-γ-NHCOC6H13-L-Pro) 35.
C24H38N4O4: 448.60
TLC: CH2Cl2/MeOH (20:1); Rf: 0.22 (Ninhydrin)
1H NMR (500 MHz, CDCl3, 25oC): δ = 6.48 (d, J = 6.9 Hz, 2H; NH), 4.54 (m, J = 6.8
Hz, 2H; Hγ), 4.33 (t, J = 7.7 Hz, Hα), 3.71 (dd, J = 12.0 Hz, 6.9 Hz, 2H; Hδ), 3.50 (dd, J
= 12.0 Hz, 6.0 Hz, 2H; Hδ´), 2.51 (ddd, J = 13.5 Hz, 7.7 Hz, 6.9 Hz, 2H; Hβ), 2.29 (dt, J
= 13.4 Hz, 7.4 Hz, 2H; Hβ´), 2.14 (ψt, J = 7.4 Hz, 4H; CH2), 1.57 (m, 4H; CH2), 1.29 (m,
12H; CH2), 0.88 (t, J = 7.0 Hz, 6H; CH3);
1H NMR (500 MHz, CD3OD, 25oC): δ = 4.48 (m, J = 7.7 Hz, 2H; Hγ), 4.46 (ψt, J = 7.4
Hz, Hα), 3.81 (dd, J = 11.7 Hz, 7.9 Hz, 2H; Hδ), 3.27 (dd, J = 11.7 Hz, 7.7 Hz, 2H; Hδ´),
2.53 (dt, J = 12.7 Hz, 6.8 Hz, 2H; Hβ), 2.17 (ψt, J = 7.5 Hz, 4H; CH2), 2.10 (dt, J = 12.7
Hz, 9.7 Hz, 2H; Hβ´), 1.59 (m, 4H; CH2), 1.31 (m, 12H; CH2), 0.90 (t, J = 7.1 Hz, 6H;
CH3);
1H NMR (500 MHz, d6-DMSO, 25oC): δ = 8.00 (d, J = 6.8 Hz, 2H; NH), 4.37 (ψt, J =
8.4 Hz, Hα), 4.29 (m, J = 9.1 Hz, 7.7 Hz, 2H; Hγ), 3.60 (dd, J = 11.4 Hz, 7.8 Hz, 2H;
Hδ), 3.11 (dd, J = 11.4 Hz, 7.6 Hz, 2H; Hδ´), 2.33 (dt, J = 12.4 Hz, 6.8 Hz, 2H; Hβ), 2.04
(ψt, J = 7.4 Hz, 4H; CH2), 1.93 (δt, J = 12.4 Hz, 9.7 Hz, 2H; Hβ´), 1.47 (m, 4H; CH2),
1.23 (m, 12H; CH2), 0.86 (t, J = 7.0 Hz, 6H; CH3);
13C NMR (100.5 MHz, CDCl3, 25oC): δ = 173.5, 166.6, 59.1, 50.7, 47.5, 36.4, 32.7,
31.5, 28.9, 25.5, 22.4, 14.0;
ESI-MS: m/z: calcd for C24H39N4O4 [M+H]+ 449; found 449.
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6. 7. Synthesis of two armed model compounds 36 - 41
Two armed molecules 36 - 41 were obtained following the general procedure described
in chapter 6. 4. 1. starting with bis-Boc protected diketopiperazine 9.
6. 7. 1. Two armed molecule 36
C34H42N6O8: 662.73
TLC: CH2Cl2:MeOH (10:1); Rf: 0.15 (UV)
1H NMR (500 MHz, CDCl3, 25oC): δ = 7.06 (d, J = 8.5 Hz, 4H; Tyr-Hδ), 6.98 (d, J =
6.2 Hz, 2H; NH-DKP), 6.80 (d, J = 8.6 Hz, 4H; Tyr-Hδ), 6.25 (d, J = 7.7 Hz, 2H; NH-
Tyr), 4.48 (q, J = 7.4 Hz, 2H; Tyr-Hα), 6.58 (q, J = 3.0 Hz, 2H; Pro-Hγ), 4.26 (dd, J =
5.0, 8.7 Hz, 2H; Pro-Hα), 3.74 (dd, J = 1.5, 12.0 Hz, 2H; Pro-Hδ), 3.76 (s, 3H; OCH3),
3.43 (dd, J = 5.6, 12.3 Hz, 2H; Pro-Hδ), 3.02 (dd, J = 6.8, 14.1 Hz, 2H; Tyr-Hβ), 2.94
(dd,  J = 7.3, 14.0 Hz, 2H; Tyr-Hβ'), 2.45 - 2.39 (m, 4H; Pro-Hβ), 1.93 (s, 6H; COCH3);
13C-NMR: (75 MHz, CDCl3 +1%d4-MeOH): δ =  171.2, 170.5, 166.3, 151.4, 130.1,
128.8, 113.8, 58.0, 55.2, 53.9, 50.0, 48.8, 36.2, 31.7, 23.3.
ESI-MS: m/z: calcd for C34H42N6O3Na [M+Na]+ 685; found 685;
6. 7. 2. Two armed molecule 37
C34H42N6O8: 662.73
TLC: CH2Cl2:MeOH (10:1); Rf: 0.15 (UV)
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1H NMR (500 MHz, CDCl3, 25oC): δ = 7.77 (d, J = 4.3 Hz, 2H; NH-DKP), 7.04 (d, J =
8.6 Hz, 4H; Tyr-Hδ), 6.73 (d, J = 8.7 Hz, 4H; Tyr-Hε), 6.04 (d, J = 7.5 Hz, 2H; NH-
Tyr), 4.72 (q, J = 7.5 Hz, 2H; Tyr-Hα), 4.14 (dd, J = 1.5, 10.1 Hz, 2H; Pro-Hα), 4.09
(ddd, J = 4.5, 9.0, 9.0 Hz, 2H; Pro-Hγ), 3.79 (dd, J = 1.0, 12.2 Hz, 2H; Pro-Hδ'), 3.74 (s,
3H; OCH3), 3.21 (dd, J = 4.5, 12.2 Hz, 2H; Pro-Hδ), 3.14 (dd, J = 1.0, 14.3 Hz, 2H;
Pro-Hβ'),3.03 (dd,  J = 67.6, 14.0 Hz, 2H; Tyr-Hβ), 2.86 (dd,  J = 7.5, 14.0 Hz, 2H; Tyr-
Hβ'), 2.23 (ddd, J = 5.1, 10.3, 15.3 Hz, 2H; Pro-Hβ), 1.95 (s, 6H; COCH3);
13C-NMR: (75 MHz, CDCl3 +5%d4-MeOH): δ =  171.3, 170.9, 170.6, 158.4, 149.6,
130.2, 128.8, 114.1, 58.9, 55.3, 51.4, 47.9, 36.8, 23.1;
ESI-MS: m/z: calcd for C34H42N6O3Na [M+Na]+ 685; found 685;
6. 7. 3. Two armed molecule 38
C48H48N8O12: 949.10
TLC: CH2Cl2:MeOH (10:1); Rf: 0.10 (UV)
1H NMR (500 MHz, CDCl3 + 5%d4-MeOH, 25oC): δ = 7.53 - 7.50 (m, 2H; NH), 7.41
(d, J = 6.8 Hz, 2H; NH), 7.01 (d, J = 7.2 Hz, 2H; NH), 6.93 (d, J = 8.4 Hz, 4H; Tyr-Hδ),
6.75 (d, J = 8.6 Hz, 4H; Tyr-Hε), 4.38 - 4.29 (m, 6H, Tyr-Hα, Ser-Hα, Pro-Hγ), 4.26
(dd, J = 7.3, 7.3 Hz, 2H; Pro-Hα), 3.74 - 3.72 (m, 2H; Pro-Hδ), 3.73 (s, 6H; OCH3),
3.62 (dd, J = 4.3, 8.9 Hz, 2H; Ser-Hβ), 3.39 - 3.33 (m, J = 2H; Pro-Hδ), 3.27 (dd, J =
8.8, 8.8 Hz, 2H; Ser-Hβ') 2.95 (dd, J = 6.6, 13.6 Hz, 2H; Tyr-Hβ), 2.83 (dd, J = 7.4,
13.9 Hz, 2H; Tyr-Hβ'), 2.48 - 2.42 (m, 4H; Pro-Hβ), 1.97 (s, 6H; COCH3), 1.19 (s,
18H, OtBu);
13C-NMR: (75 MHz, CDCl3 +5%d4-MeOH): δ =  171.5, 171.2, 170.4, 165.6, 158.6,
129.9, 128.4, 114.0, 75.0, 61.3, 58.3, 55.5, 55.2, 52.5, 51.2, 47.6, 35.7, 32.1, 27.4, 22.8.
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ESI-MS: m/z: calcd for C48H48N8O12: Na [M+Na]+ 972; found 972;
6. 7. 4. Two armed molecule 39
C48H48N8O12: 949.10
TLC: CH2Cl2:MeOH (10:1); Rf: 0.10 (UV)
1H NMR (500 MHz, CDCl3+5%d4-MeOH, 25oC): δ = 7.84 (d, J = 8.6 Hz, 2H; Ser-
NH), 7.51 (d, J = 5.5 Hz, 2H; Tyr-NH), 7.27 - 7.25 (m, 2H; DKP-NH), 6.83 (d, J = 8.6
Hz, 4H; Tyr-Hδ), 6.68 (d, J = 8.7 Hz, 4H; Tyr-Hε), 4.45 - 4.36 (m, 4H, Tyr-Hα, Ser-
Hα) 4.17 (dd, J = 3.1, 10.1 Hz, 2H; Pro-Hα), 4.15 (m, 2H, Pro-Hγ), 3.99 (dd, J = 0.3,
12.0 Hz, 2H; Pro-Hδ'), 3.69 (s, 6H; OCH3), 3.64 (dd, J = 4.2, 8.9 Hz, 2H; Ser-Hβ), 3.41
(dd, J = 9.0, 9.0 Hz, 2H; Ser-Hβ'), 3.28 (dd, J = 4.7, 11.8 Hz, 2H; Pro-Hδ), 2.94 (dd, J =
7.4, 13.8 Hz, 2H; Tyr-Hβ), 2.79 - 2.71 (m, 4H; Tyr-Hβ', Pro-Hβ'), 2.32 (ddd, J = 5.3,
10.1, 14.2 Hz 2H; Pro-Hβ), 1.97 (s, 6H; COCH3), 1.27 (s, 18H, OtBu);
13C-NMR: (75 MHz, CDCl3 +5%d4-MeOH): δ =  171.9, 171.8, 169.9, 166.1, 160.0,
129.9, 130.0, 128.4, 114.2, 74.9, 61.3, 57.7, 55.5, 55.1, 50.1, 49.2, 48.0, 35.8, 33.0,
27.4, 22.9;
ESI-MS: m/z: calcd for C48H48N8O12: Na [M+Na]+ 972; found 972.
6. 7. 5. Two armed molecule 40
C40H68N8O10: 821.02
TLC: CH2Cl2:MeOH (10:1); Rf: 0.17 (Ninhydrin)
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1H NMR (500 MHz, CDCl3, 25oC): δ = 7.88 (d, J = 6.8 Hz, 2H; Pro-NH), 7.85 (d, J =
7.8 Hz, 2H; Leu-NH), 7.39 (d, J = 7.0 Hz, Ser-NH), 4.48 (ddd, J = 10.0 Hz, 7.1 Hz, 4.3
Hz, 2H; Ser-Hα), 4.35 (dd, J = 10.5 Hz, 4.3 Hz, 2H; Pro-Hα), 4.30 (m, 2H; Pro-Hγ),
4.20 (q, J = 7.7 Hz, 2H;
 
Leu-Hα), 4.03 (d (broad), J = 12.1 Hz, 2H; Pro-Hδ´), 3.66 (dd,
J = 8.7 Hz, 4.3 Hz, 2H; Ser-Hβ), 3.30 (dd, J = 9.8 Hz, 9.0 Hz, 2H; Ser-Hβ´), 3.22 (dd, J
= 12.1 Hz, 3.6 Hz, 2H; Pro-Hδ), 2.71 (ddd, J = 14.3 Hz, 4.0 Hz, ≈ 1.5 Hz, 2H; Pro-
Hβ´), 2.60 (ddd, J = 14.4 Hz, 10.8 Hz, 6.8 Hz, 2H; Pro-Hβ), 2.09 (s, 6H; COCH3), 1.65
(dt, J = 13.3 Hz, 7.0 Hz, 2H; Leu-Hβ), 1.52 (m, J = 6.6 Hz, 2H; Leu-Hγ), 1.41 (dt, J =
13.3 Hz, 7.1 Hz, 2H; Leu-Hβ´), 1.26 (s, 18H; tBu), 0.82 (2t, J = 6.6 Hz, 12H; Leu-Hδ,
Leu-Hδ´);
13C NMR (125.6 MHz, CDCl3, 25oC): δ = 172.0, 171.9, 170.3, 165.5, 75.1, 61.4, 58.1,
52.4, 52.0, 51.9, 47.6, 39.1, 32.0, 27.5, 24.6, 23.0, 22.3, 22.2;
ESI-MS: m/z: calcd for C40H63N3O10Na [M+Na]+ 843; found 843;
6. 7. 6. Two armed molecule 41
C40H68N8O10: 821.02
TLC: CH2Cl2:MeOH (10:1); Rf: 0.15 (Ninhydrin)
1H NMR (500 MHz, CDCl3, 25oC): δ = 8.01 (d, J = 8.3 Hz, 2H; Leu-NH), 7.93 (d, J =
5.2 Hz, 2H; NH), 7.75 (d, J = 7.3 Hz, Ser-NH), 4.53 (ddd, J = 9.9 Hz, 7.5 Hz, 4.3 Hz,
2H; Ser-Hα), 4.38 (dd, J = 11.8 Hz, 1.6 Hz, 2H; Pro-Hδ´), 4.29 (yq, J = 7.8 Hz, 2H;
Leu-Hα), 4.23 (q (broad), J = 4.8 Hz, 2H;
 
Pro-Hγ), 4.22 (d (broad), J = 11.0 Hz, 2H;
Pro-Hα), 3.65 (dd, J = 8.8 Hz, 4.3 Hz, 2H; Ser-Hβ), 3.42 (ψt, J = 9.3 Hz, 2H; Ser-Hβ´),
3.32 (dd, J = 11.8 Hz, 4.4 Hz, 2H; Pro-Hδ), 2.95 (dd, J = 14.4 Hz, ≈ 1.5 Hz, 2H; Pro-
Hβ´), 2.38 (ddd, J = 14.4 Hz, 11.0 Hz, 5.1 Hz, 2H; Pro-Hβ), 2.07 (s, 6H; COCH3), 1.66
(ddd, J = 13.8 Hz, 7.1 Hz, 6.6 Hz, 2H; Leu-Hβ), 1.52 (m, J = 6.6 Hz, 2H; Leu-Hγ), 1.40
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(m, J  = 13.5 Hz, 7.5 Hz, 2H; Leu-Hβ´), 1.27 (s, 18H; tBu), 0.82 (2t, J = 6.6 Hz, 12H;
Leu-Hδ, Leu-Hδ´);
13C NMR (125.6 MHz, CDCl3, 25oC): δ = 171.3, 171.3, 169.9, 166.4, 75.1, 61.2, 57.7,
52.0, 51.9, 50.3, 48.2, 39.1, 33.4, 27.5, 24.7, 23.1, 22.4, 22.2;
ESI-MS: m/z: calcd for C40H63N3O10Na [M+Na]+ 843; found 843;
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6. 8. Synthesis of two armed molecule 42
The side chain protected two armed molecule 42' was obtained following the general
procedure described in chapter 6. 4. 1. starting with bis-Boc protected cis-
diketopiperazine 9.
6. 8. 1. Two-armed molecule 42':
C160H152N24O18: 2699.07
TLC: CH2Cl2:MeOH (20:1); Rf: 0.13
1H NMR (500 MHz, CDCl3, 25oC): δ = 8.31 (d, J = 9.0 Hz, 4H; dye), 7.90 (d, J = 9.0
Hz, 4H; dye), 7.89 (d, J = 9.2 Hz, 4H; dye), 7.54 - 6.93 (m, 70H; Trityl, NH, His-Hε),
6.89 (d, J = 8.6 Hz, 4H; Tyr), 6.78 (d, J = 9.3 Hz, 4H; dye), 6.58 (d, J = 8.7 Hz, 4H; Tyr),
6.57 (s, 2H; His-Hδ), 4.64 - 4.57 (m, 2H; Tyr-Hα), 4.53 (q, 2H, J = 5.5 Hz; Asn-Hα),
4.32 - 4.27 (m, 4H; Pro-Hγ, His-Hα), 4.09 (t, J = 7.8 Hz, 2H; Pro-Hα), 4.02 (t, J = 5.9
Hz, 4H;
 
OCH
2
CH2N), 3.77 (t, J = 5.8 Hz, 4H; OCH2CH2N), 3.66 - 3.61 (m, 2H; Pro-Hδ'),
3.57 (q, J = 7.2 Hz, 4H;
 
CH2CH3), 3.35 - 3.28 (m, 2H; Pro-Hδ), 3.11 (dd, J = 5.0, 14.5
Hz, 2H; Tyr-Hβ), 2.86 (dd, J = 5.8, 14.6 Hz, 2H; His-Hβ), 2.76 (dd, J = 9.14, 14.0 Hz,
2H; Tyr-Hβ), 2.71 (dd, J = 4.4, 14.8 Hz, 2H; His-Hβ), 2.66 - 2.58 (m, 2H; Asn-Hβ), 2.54
N
N
OO
H
H
NH
NH
Ac-L-His(Trt)-L-Asn(Trt)-L-Tyr(dye)
Ac-L-His(Trt)-L-Asn(Trt)-L-Tyr(dye)
120
- 2.46 (m, 2H; Asn-Hβ), (td, J = 1.9, 5.0 Hz, 4H; Pro-Hβ), 1.89 (s, 6H; COCH3), 1.26 (t,
J  = 6.9 Hz, 6H; CH2CH3);
 13C NMR  (125.8 MHz, 5% CD 3OD in CDCl3, 25 oC): δ = 171.6, 171.4,  171.1, 170.4,
170.1, 166.1, 156.9, 156.8, 151.3, 147.4, 144.2, 143.7, 138.6, 135.5, 130.0, 129.7, 128.65,
128.2, 128.0, 126.3, 124.7, 122.6, 120.6, 114.2, 111.4, 70.8, 65.1, 58.9, 54.5, 53.5, 51.5,
50.2, 49.8, 47.2, 46.1, 37.3, 35.3, 32.5, 30.3, 23.1, 12.3;
ESI-MS: m/z: calcd for C160H152N24O18 [M+Na]+ 2720.2; found 2720.6;
6. 8. 2. Two-armed molecule 42:
N
N
OO
H
H
NH
NH
Ac-L-His(Trt)-L-Asn(Trt)-L-Tyr(dye)
Ac-L-His(Trt)-L-Asn(Trt)-L-Tyr(dye)
N
N
OO
H
H
NH
NH
Ac-L-His-L-Asn-L-Tyr(dye)
Ac-L-His-L-Asn-L-Tyr(dye)
TFA, H2O, TIS
quant.
42' 42
15 mg (5.6 µmol, 1 eq) of the side chain protected two armed molecule  42’ were
dissolved in 1 ml TFA containing 2.5% of water and 2.5% of TIS. After 20 minutes of
stirring at r.t., the volatiles were removed at reduced pressure and the residue was
triturated three times with diethylether and excess ether was evaporated in vacuo. This
yielded 9.5 mg (100%) of the deprotected receptor 42.
C84H96N24O18: 1729.81
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1H NMR (500 MHz, DMSO, 25oC): δ = 8.36 (d, J = 9.1 Hz, 4H; dye), 8.24 (d, J = 7.0
Hz, 2H; NH-Asn), 8.14 (d, J = 8.2 Hz, 2H; NH-His), 8.10 (d, J = 8.6 Hz, 2H; NH-Tyr),
7.93 (d, J = 9.1 Hz, 4H; dye), 7.84 (d, J = 9.2 Hz, 4H; dye), 7.47 (s, 2H, NHδ-Asn), 7.14
(s, 2H; His-Hε), 7.10 (d, J = 8.5 Hz, 4H; Tyr-Hδ),6.98 (s, 2H; His-Hδ), 7.92 (d, J = 9.4
Hz, 4H; dye), 6.81 (d, J = 8.7 Hz, 4H; Tyr-Hε), 4.57 (dd, J = 5.6, 7.8 Hz, 2H; His-Hα),
4.48 (dd, J = 7.4, 9.1 Hz, 2H; Asn-Hα), 4.40 - 4.26 (m, 6H; Pro-Hα, Pro-Hγ, Tyr-Hα),
4.12 (t, J = 5.4 Hz, 4H;
 
OCH
2
CH2N), 3.82 (t, J = 5.4 Hz, 4H; OCH2CH2N), 3.58 (q, J =
7.3 Hz, 4H;
 
CH2CH3), 3.57 - 3.53 (m, 2H; Pro-Hδ'), 2.98 - 2.88 (m, 6H; Pro-Hδ, His-Hβ,
Tyr-Hβ), 2.82 (dd, J = 8.4, 15.3 Hz, 2H; His-Hb'), 2.76 (dd, J = 8.2, 13.4 Hz, 2H; Tyr-
Hβ'), 2.58 - 2.50 (m, 4H; Asn-Hβ), 2.42 (dd, J = 6.6, 15.4 Hz, 2H; Asn-Hβ'),  2.34 - 2.27
(m, 2H; Pro-Hβ'), 1.93 - 1.84 (m, 2H; Pro-Hβ), 1.81 (s, 6H; COCH3), 1.17 (t, J  = 7.3 Hz,
6H; CH2CH3);
13C-NMR: (125.8 MHz, DMSO): δ =  172.2, 171. 3, 171.2, 170.9, 170.1, 165.9,
157.3, 156.6, 152.1, 147.3, 143.2, 138.9, 135.8, 130.7, 130.2, 126.6, 125.5, 122.9, 120.6,
114.5, 112.2, 65.7,  58.8, 55.0, 52.2, 50.1, 49.6, 48.1, 46.9, 46.6, 37.2, 37.1, 33.1, 28.9,
23.0, 12.5;
ESI-MS: m/z: calcd for C84H96N24O18 [M+Na]+ 1752; found 1752;
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6. 9. Synthesis of the building blocks for the fluorophore quencher library
6. 9. 1. Synthesis of N-Boc-anthranilic acid 47
Anthranilic acid 46 (10 g, 72.9 mmol, 1 eq) was dissolved in 30 ml DMF and 19.91 g
(91.2 mmol, 1.25 eq) of Boc2O and 19.33 ml (109.5 mmol, 1.5 eq) NEt3 was added. After
stirring 24 hours, the solvent was removed at reduced pressure. The residue was
dissolved in 20 ml of CH2Cl2 and extracted 10 times with 40 ml of saturated potassium
carbonate. All the aquous phases were acidified with 60 ml 2M HCl each and extracted
three times with 60 ml Et2O. After removal of the solvent, the product was precipitated
with pentane to yield 9.5 g (55%) of 47.
C12H15NO4 : 237.25
TLC: EtOAc Rf:0.58 (Ninhydrin)
1H NMR (300 MHz, CDCl3, 25oC): δ (ppm) = 10.03, (s, 1H; NH), 8.47 (d, J = 7.5 Hz,
1H; H ar o-carbonyl), 8.10 (d, J = 8.0 Hz, 1H; H ar o-amino), 7.57 (t, J = 7.3
Hz, 1H; H ar p-carbonyl), 7.04 (t, J = 8.2 Hz, 1H; H ar p-amino), 1.55 (s, 9H;
t-Bu);
13C NMR (100.5 MHz, CDCl3, 25oC): δ (ppm) = 172.2, 152.8, 142.9, 135.6, 131.9,
121.3, 118.9, 80.8, 28.3;
NH2
O
OH
NH
O
OH
O
46
Boc2O, NEt3, DMF
O
47
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ESI-MS: m/z: calcd for C12H15NO4Na [M+Na]+ 260; found 260.
elemental analysis calcd (%) for C12H15NO4 (237.26): C 60.75, H 6.37, N 5.90; found C
60.70, H 6.35, N 5.88.
6. 9. 2. Synthesis of N-Boc-anthranilic acid pentafluorophenylester 47'
3.01 g (12.7 mmol, 1 eq) of 47 was dissolved in 30 ml of absolute DCM followed by 2.45
g (13.3 mmol, 1.05 eq) pentafluorophenol and 3.65 g (19.05 mmol, 1.5 eq) EDC. The
solution was stirred for 1 hour and then extracted with 80 ml water and 80 ml Et2O. After
purification over silica gel (Pentane:Ethyl acetate 20:1) 3.2 g (63%) of 47' were obtained.
C18H14F5NO4 : 403.30
TLC: CH2Cl2/MeOH (50:1); Rf: 0.80 (Ninhydrin)
1H NMR (400 MHz, CDCl3, 25oC): δ (ppm) = 9.74, (s, 1H; NH), 8.55 (d, J = 9.2 Hz, 1H;
H ar o-carbonyl), 8.24 (d, J = 7.9 Hz, 1H; H ar o-amino), 7.65 (t, J = 9.0 Hz,
1H; H ar p-carbonyl), 7.11 (t, J = 8.2 Hz, 1H; H ar p-amino), 1.51 (s, 9H; t-
Bu);
13C NMR (75 MHz, CDCl3, 25oC): δ (ppm) = 164.1,  152.4, 143.7, 136.5, 131.68,
121.5, 119.1, 111.0, 81.1, 18.2;
NH
O
O
O
C6F5OH, EDC, CH2Cl2
NH
O
OH
O
47
F
F
F
F
F
O O
47'
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ESI-MS: m/z: calcd for C18H14F5NO4Na [M+Na]+ 426; found 426;
6. 9. 3. Synthesis of fluorophore building block 48
FMOC-Lys(BOC)-OH (3.70 g, 7.90 mmol, 1 eq) was dissolved in a 1:1 mixture of TFA
and CH2Cl2 and stirred at room temperature for 1 hour. After removal of the volatile
components, the residue was triturated three times with Et2O. The Boc-deprotected lysine
was then dissolved in 15 ml of DMF and 3.2 g (7.90 mmol, 1 eq) of
pentafluorophenylester 47' as well as 8.7 ml (79 mmol, 10 eq) N-methylmorpholine were
added. After stirring the mixture for 1 hour, it was extracted with 20 ml of EtOAc and 20
ml of water. The organic layers were washed with sat. NaCl solution, dried over Na2SO4
and the solvent was removed under reduced pressure. Purification over silica gel
(gradient of CH2Cl2 / MeOH from 0 to 5% of methanol) yielded 4.03 g (87%) of 48.
C33H37N3O7 : 587.66
TLC: CH2Cl2/MeOH (10:1); Rf: 0.37 (Ninhydrin)
1H NMR (400 MHz, CDCl3, 25oC): δ = 10.04 (s, 1H, NHBoc), 9.80 (s br, 1H, OH), 8.25
(d, J = 7.9 Hz, 1H; H ar o-carbonyl), 7.72 (d, J = 7.5 Hz, 2H, Fmoc-H(ar)), 7.54 (d, J =
7.2 Hz, 2H, Fmoc-H(ar)), 7.42 - 7.28 (m, 4H, H ar o-amino, H ar p-carbonyl, Fmoc-
2H(ar)), 7.26 (t, J = 7.6 Hz, 2H, Fmoc-H(ar)), 6.85 (dd, J = 7.7 Hz, 7.7 Hz 1H; H ar p-
amino), 6.64 (t, J = 4.9 Hz, 1H, NH-Lysε), 5.61 (d, J = 8.2 Hz, 1H, NH-Lysα), 4.42 -
4.28 (m, 3H; Lys-Hα, FMOC-CH2), 4.16 (t, J = 7.1 Hz, 1H, FMOC-CH), 3.42 - 3.28 (m,
FmocHN NHBoc
OHO
FmocHN N
H
OHO
O NHBoc1. TFA/ CH2Cl2 (1:1)
2. 47', NMM, DMF
48
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2H; Lys-ε), 1.94 - 1.82 (m, 1H; Lys-β), 1.78 - 1.70 (m, 1H; Lys-β'), 1.68 - 1.52 (m, 2H;
Lys-δ), 1.50 (s, 9H, Boc), 1.45 - 1.37 (m, 2H; Lys-γ);
13C NMR (75 MHz, CDCl3, 25oC): δ = 175.8, 169.2, 156.3, 153.2,  143.6, 143.5, 141.2,
139.6, 132.2, 127.7, 127.0, 126.8, 124.9, 121.5, 120.2, 119.9, 80.4, 67.1, 53.4, 46.9, 39.5,
31.9, 31.5, 28.5, 28.2;
ESI-MS: m/z: calcd for C33H37N3O7 [M+Na]+ 610; found 610.
Elemental analysis: Calcd (%) for C33H37N3O7 (587.7):
C 67.45, H 6.35, N 7.15; found C 67.37, H 6.38, N 7.07.
6. 9. 4. Synthesis of quencher building block 50
1.35 g of Nitrotyrosine 49 (7.73 mmol, 1 eq) was dissolved in 10 ml dioxane and 20 ml
10% aquous Na2CO3 solution. A solution of 2.0 g (7.73 mmol, 1 eq) of FMOC-Cl in 20
ml dioxane was added and the mixture was allowed to stir at room temperature for two
hours. After extracting with 20 ml of EtOAc and 20 ml of 0.1 M HCl, the organic layers
were washed with sat. NaCl solution, dried over Na2SO4 and the solvent was removed
under reduced pressure. Purification over silica gel (gradient of CH2Cl2 / MeOH from 0 to
5% of methanol) yielded 1.70  g (49%) of 50.
C24H20N2O7 : 448.42
FMOCCl, Na2CO3
HO
O2N CO2H
NH2 HO
O2N CO2H
NHFMOCH2O, Dioxane
49 50
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TLC: CH2Cl2/MeOH (10:1); Rf: 0.31 (Ninhydrin)
1H NMR (300 MHz, DMSO, 25oC): δ = 7.86 (d, J = 8.4 Hz, 2H, Fmoc-H(ar)), 7.85 (s,
1H, H ar o-NO2), 7.76 (d, J = 8.2 Hz, 2H, H ar p-NO2), 7.62 (d, J = 7.0 Hz, 2H, Fmoc-
H(ar)), 7.47 - 7.33 (m, 3H, NH, Fmoc-2H(ar)), 7.27 (td, J = 7.3, 7.3 Hz, 2H, Fmoc-
H(ar)), 7.06 (d, J = 8.2 Hz, 1H; H ar m-NO2), 4.29 - 4.09 (m, 4H, Hα, FMOC-CH2,
FMOC-CH), 3.09 (dd, J = 4.1, 13.7 Hz, 1H, Hβ), 3.85 (dd, J = 10.9, 13.5 Hz, 1H, Hβ);
13C NMR (75 MHz, DMSO, 25oC): δ = 174.0, 157.0, 151.9, 144.7, 141.7, 137.2, 137.0,
130.2, 128.6, 128.0, 126.5, 126.2, 121.1, 120.0, 66.6, 56.2, 47.5, 36.0;
ESI-MS: m/z: calcd for C33H37N3O7 [M+Na]+ 610; found 610.
Elemental analysis: Calcd (%) for C33H37N3O7 (587.7):
(+1/2 H2O) C 63.02, H 4.63, N 6.12; found C 62.64, H 4.38, N 5.97.
127
6. 10. Solid Phase Peptide Synthesis (SPPS)
6. 10. 1. General FMOC-Strategy for Peptide Synthesis on Solid Support
Exemplified by the Synthesis of Ac-L-Glu-L-Glu-εAhx-Resin
6. 10. 1. 1. FMOC-Amino Acid Coupling onto Amino-Functionalized Resin
300 mg (0.078 mmol) of amino methyl polystyrene resin (TentaGel, purchased by Rapp
Polymere, loading 0.26 mmol/g) was placed in a 25 ml Merrifield vessel and washed
three times with DCM (10 ml) for 1 minute. The resin is suspended in the smallest
amount of dry DCM that still allows efficient shaking (4 ml) and 83 mg (234 µmol, 3 eq)
of FMOC-εAhx was added. After the addition of  a solution of 32 mg (234 µmol, 3 eq) of
HOBt in 200 µl of DMF the mixture was agitated for 2 minutes. Then 36 µl (234 µmol, 3
eq) of DIC is added and the mixture was shaken for 2 hours. The resin was then washed
five times with DMF and five times with DCM for 1 minute each. Then the absence of
free amino groups was ensured by performing the Kaiser test with a small amount of
beads. A negative Kaiser test indicates that no more free amino groups are present and
thus the coupling has been exhaustive. However, if the Kaiser test was positive, the
coupling had to bee repeated until no more free amino groups were detected.
6. 10. 1. 2. FMOC-Deprotection
After washing the FMOC-functionalized resin three times with DMF, it was shaken twice
with 8 ml of a 4:1 mixture of DMF and Piperidine first for five and then a second time for
ten minutes. Then it was washed five times with DMF  and five times with DCM. The
successful deprotection of the FMOC-group was confirmed by the Kaiser test.
Steps 6. 10. 1. 1. and 6. 10. 1. 2. were repeated until the desired peptide sequence was
accomplished
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6. 10. 1. 3. Acetylation of free amines
The resin was suspended in 5 ml of dry DCM and 54 µl (390 µmol, 5 eq) of Et3N are
added followed by 37 µl (390 µmol, 5 eq) of Ac2O. After shaking the mixture for 1 hour,
it was washed three times with DMF and five times  with DCM. The completion of the
reaction was confirmed by a negative Kaiser test.
6. 10. 1. 4. Cleavage of the side-chain protecting groups
The side-chain protecting groups are removed by shaking the resin twice with 10 ml of a
1:1:0.1 mixture of TFA, DCM and TIS first for 2 minutes and then for 1 hour. The resin
is then washed five times with DCM, five times with a 4:1 mixture of DCM / Et3N
followed by another five times with DCM. Then the resin is dried in vacuo and stored at
4°C.
6. 10. 2. General FMOC-Strategy for Solid Phase Peptide Synthesis  on Wang Resin
Exemplified by the Synthesis of Ac-L-Glu-L-Glu-NHPr
6. 10. 2. 1. Coupling onto Hydroxy-Functionalized Resin
If an amino acid had to be coupled to hydroxy-functionalized resin as Wang resin, it was
proceeded as described in 6.10.1.1. but 0.05 eq of DMAP was added to the reaction
mixture. To ensure optimal reaction yields, the coupling to the resin was repeated twice
and the loading after the coupling was determined by cleavage of the FMOC group of an
aliquot and quantify by UV-measurement.
The rest of the peptide synthesis was performed according to 6. 10. 1. 1. - 6. 10. 1. 3.
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6. 10. 2. 2. Cleavage from the Resin as Propyl Amide
After washing three times with DCM the resin was dried in vacuo and placed in a 50 ml
round bottom flask with magnetic stirrer and 10 ml of DCM and 5 ml of propylamine was
added. After stirring for 72 hours the mixture was filtered and all the volatiles were
removed at reduced pressure. The peptide was purified by extraction with DCM, HCl
(0.5%) and brine. (If the peptides were water soluble gel filtration (LH 20, DCM/MeOH
90:10) was used for purification instead of extraction). Drying over Na2SO4 and
evaporation of the solvent yielded 240 mg (0.51 mmol) of the propylamide of the side
chain protected diamine.
6. 10. 2. 3. Removal of the Side Chain Protecting Groups
123 mg (0.26 mmol, 1 eq) of the side chain protected peptide was placed into a 25 ml
round bottom flask and dissolved in 5ml of TFA containing 2.5% water and 2.5 % TIS.
After 1 hour of stirring at r.t. the TFA was removed at reduced pressure and the peptide
was purified by precipitating five times with diethyl ether and adjacent drying at reduced
pressure. If necessary the peptide was further purified by preparative HPLC.
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6. 11. Synthesis of the fluorophore quencher library 43 using oxidative cleavable
tags
6. 11. 1. Synthesis of library precursor 51
25 g (6.5 mmol, 1 eq) of amino functionalized PEG-PS resin (TentaGel loading 0.26
mmol/g) was placed in a 500 ml Merrifield shaking vessel and washed three times with
CH2Cl2 (100 ml). Then three NεBoc-NαFMOC protected lysin moieties were coupled
according to 6.10.1.1. and 6.10.1.2. The Lys(Boc)-groups were removed by shaking
twice (2 minutes and 1 hour) with a mixture of CH2Cl2 and TFA (3:1) with subsequent
washing of the beads six times with CH2Cl2, twice with CH2Cl2 : NEt3 (9:1) and again six
times with CH2Cl2. The free lysine ε-amino groups were then Alloc protected by
suspending the resin in 50 ml DCM and adding allylchloroformiate (10.15 ml, 95.5
mmol, 15 eq) and NEt3 (19.96 ml, 143 mmol, 22 eq). The coupling was repeated twice
until the Kaiser test was negative.  After FMOC-deprotection (see 6.10.1.2.), the
fluorophore building block 6 was coupled (4.99 g, 8.5 mmol, 1.33 eq) according to
6.10.1.1. followed by another FMOC-deprotection and coupling of FMOC-Glycin-OH
(5.68 g, 19.11 mmol, 3 eq) was coupled to yield library precursor 5.
H2N
51
H
N
N
H
H
N
FmocHN
AllocHN
HN
O
O
O
O
NHBoc
3
H
N
N
H
AllocHN
O 3
Fmoc
H
N
N
H
BocHN
O 3
Fmoc
2x (a, b)
a
2x (b, a)c
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6. 11. 2. Split-and-mix synthesis of the combinatorially varied peptide sequence
6. 11. 2. 1. Deprotection of the lysine Nε-Alloc protecting groups
The resin with library precursor 5 (25 g, 6.37 mmol, 1 eq) was placed in a 250 ml
Merrifield vessel and washed three times with 100 ml DCM. Then it was washed again
under nitrogen using 100 ml dry DCM. Then the resin was suspended in 50 ml of dry
DCM in a nitrogen athmosphere and 1.50 g (5.7 mmol, 0.9 eq) of PPh3 and 4.01 g (28.7
mmol,  4.5 eq) of dimedone was added followed by 220.7 mg (0.063 mmol, 0.01 eq) of
Pd(PPh3)4.  After shaking for 20 minutes it was washed five times with DMF and three
times with DCM. Successful deprotection of the alloc groups was confirmed by Kaiser
test.
6. 11. 2. 2. Splitting and Encoding
The alloc deprotected resin was devided into 31 equal portions of 806 mg (0.21 mmol)
and each portion was placed into a 25 ml Merrifield shaking vessel. After washing three
times with 10 ml of DCM, the resin was suspended in 10 ml of dry DCM. 4 mol % of
oxidative cleavable tags (See 6.11.2.5) were dissolved in 200µl of DMF and added to the
resin followed by 56 mg (420µmol, 50 eq) of HOBt per tag dissolved in 200µl of DMF.
To ensure an equal distribution of the tags, the mixture was then shaken vigorously for
five minutes and 132µl (840µmol, 100 eq) of DIC per tag were added and each mixture
was agitated immidiately after the addition. After shaking the reaction mixtures over
night, they all were washed ten times with DMF.
6. 11. 2. 3. Check of Successful Encoding and Alloc Protection
From each reaction vessel three beads were separated and each single bead was placed
into a 25 ml micropipette that was then sealed at one end.  (H.P. Nestler, Paul A. Bartlett,
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W.C. Still, J.O.C. 1994, 59, 4723 - 4724) The beads were washed three times with water,
then 1 µl of 0.5 M ceric ammonium nitrate  in 1 : 1 water : acetonitrile and 3 µl of hexane
were added and the micropipette was sealed at the other end.  After treating in a sonic
bath for 2 hours the released tags were extracted into the hexane phase by centrifugating
the capillary several times. The tag alcohols were silylated and the corresponding
trimethylsilylethers were analysed by ECGC.  If the amount of tags was insufficient, the
tag coupling process was repeated, otherwise the resin was washed three times with DCM
and the remaining free Nε-aminogroups were alloc protected by suspending the resin in 5
ml of DCM and adding 130ml (0.99mmol, 4.5 eq) of NEt3 followed by 100µl (0.99mmol,
4.5 eq) of  allyl chloroformiate. After shaking for 1 hour and washing five times with
DCM, it was made sure by Kaiser test, that no more free amino groups were present.
6. 11. 2. 4. FMOC-Deprotection and Amino Acid Coupling
The α−FMOC group was removed according to 6.10.1.2.  Then the amino acid coupling
was performed following the general protocol described in chapter 6.10.1.1. using 3 eq of
each amino acid (see 6.11.2.5. for details), 84 mg (0.617 mmol, 3 eq) of HOBt and 100µl
(0.617 mmol, 3 eq) of DIC. Each coupling was repeated twice to ensure complete
coupling. After that, the resin was combined in a 250 ml Merrifield vessel.
The steps 6. 11. 2. 1. to 6. 11. 2. 4. were repeated twice with with different sets of tags
leading to a library with 313 = 29791 members.
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6. 11. 2. 5. Tags used for the Fluorophore Quencher Library
1st step: (CH2)12-2-4-5-Cl3  (4.33 mg,  8.40 µmol) = tag No 1
(CH2)9-Cl5   (4.56 mg,  8.40 µmol) = tag No 2
(CH2)10-Cl5   (4.68 mg,  8.40 µmol) = tag No 3
(CH2)11-Cl5  (4.79 mg,  8.40 µmol) = tag No 4
(CH2)12-Cl5   (4.91 mg,  8.40 µmol) = tag No 5
2nd step: (CH2)9-2-4-5-Cl3  (3.98 mg,  8.40 µmol) = tag No 1
(CH2)10-2-4-6-Cl3  (4.10 mg,  8.40 µmol) = tag No 2
(CH2)10-2-4-5-Cl3  (4.10 mg,  8.40 µmol) = tag No 3
(CH2)11-2-4-6-Cl3  (4.22 mg,  8.40 µmol) = tag No 4
(CH2)11-2-4-5-Cl3  (4.22 mg,  8.40 µmol) = tag No 5
3rd step: (CH2)7-2-4-6-Cl3  (3.74 mg,  8.40 µmol) = tag No 1
(CH2)7-2-4-5-Cl3  (3.74 mg,  8.40 µmol) = tag No 2
(CH2)8-2-4-6-Cl3  (3.86 mg,  8.40 µmol) = tag No 3
(CH2)8-2-4-5-Cl3  (3.86 mg,  8.40 µmol) = tag No 4
(CH2)9-2-4-6-Cl3  (3.98 mg,  8.40 µmol) = tag No 5
O
H3CO
CO2H
(CH2)n Aryl
n = 7 - 12
Cl
Cl
Cl
Cl
Cl
Cl
ClCl
Cl
ClCl
Aryl =
2,4,6-Cl3 2,4,5-Cl3Cl5
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Encoding sheme and amounts of amino acids used
 Tag No 1 Tag No 2 Tag No 3 Tag No 4 Tag No 5 amino acid 0.617 mmol
1 0 0 0 0 Gly 183 mg
0 1 0 0 0 L-Ala 192 mg
0 0 1 0 0 D-Ala 192 mg
0 0 0 1 0 L-Val 209 mg
0 0 0 0 1 D-Val 209 mg
1 1 0 0 0 L-Leu 218 mg
1 0 1 0 0 D-Leu 218 mg
1 0 0 1 0 L-Phe 239 mg
1 0 0 0 1 D-Phe 239 mg
0 1 1 0 0 L-Ser 236 mg
0 1 0 1 0 D-Ser 236 mg
0 1 0 0 1 L-Thr 245 mg
0 0 1 1 0 D-Thr 245 mg
0 0 1 0 1 L-Asn 368 mg
0 0 0 1 1 D-Asn 368 mg
1 1 1 0 0 L-Gln 377 mg
1 1 0 1 0 D-Gln 377 mg
1 1 0 0 1 L-Asp 254 mg
1 0 1 1 0 D-Asp 254 mg
1 0 1 0 1 L-Glu 262 mg
1 0 0 1 1 D-Glu 262 mg
0 1 1 1 0 L-Lys 289 mg
0 1 1 0 1 D-Lys 289 mg
0 1 0 1 1 L-Pro 208 mg
0 0 1 1 1 D-Pro 208 mg
1 1 1 1 0 L-His 382 mg
1 1 1 0 1 D-His 382 mg
1 1 0 1 1 L-Arg 409 mg
1 0 1 1 1 D-Arg 409 mg
0 1 1 1 1 L-Cys 361 mg
1 1 1 1 1 D-Cys 361 mg
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6. 11. 2. 6. Fluorophore-quencher library 43
H
N
R0: tag / Ac
R1-3: aminoacid sidechains
N
H
H
N
N
H
H
N
N
H
H
N
R0HN
HN
O
O
O
O
O
O
R1
R2
R3
O
NH2
3
= Tenta Gel
N
H
H
N
OHO2N
O
O
O
After removal of the FMOC-group of the third combinatorially varied amino acid
FMOC-Glycin followed by the quencher building block 50 was coupled according to 6.
10. 1. 1. and 6. 10. 1. 2. The alloc groups were deprotected as described in 6. 11. 2. 1. and
the free amino groups were acetylated according to 6. 10. 1. 3. Finally the terminal
FMOC groups were removed and the according amino groups were acetylated as well.
After deprotection of the side chain protecting groups the resin was washed three times
with DCM, three times with methanol, six times with 0.1 M NaOH, again three times
with methanol and three times with DCM. Then the resin was dried at reduced pressure
and library y was stored at 4°C.
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6. 12. Analytical data of the model peptides 54' , 54, 57 and 58
6. 12. 1. Ac-L-Glu(Ot-Bu)-L-Glu(Ot-Bu)-NHPr 54'
C23H41N3O7 : 471.59
TLC: CH2Cl2/MeOH (10:1); Rf: 0.52 (Cer)
1H NMR (400 MHz, CDCl3, 25oC): δ = 7.52 (d, J = 7.5 Hz, 1H; NH Glu), 6.91 (d, J = 5.9
Hz, 1H; NH Glu), 6.73 (t, J = 5.7 Hz, 1H; NH Pr), 4.40 (ψtd, J = 5.7, 7.2 Hz, 1H; Glu-
Hα), 4.31 (ddd, J = 5.2, 6.2, 8.2 Hz, 1H; Glu-Hα), 3.20 (ψtd, J = 5.9, 7.5 Hz, 2H;
NHCH2CH2CH3), 2.49 - 2.25 (m, 4H; Glu-Hγ), 2.13 - 1.92 (m, 4H; Glu-Hβ), 2.04 (s, 3H;
Ac), 1.53 (ψ q, J  = 7.0 Hz, 2H; NHCH2CH2CH3), 0.91 (t, J  = 7.2 Hz, 3H,
NHCH2CH2CH3);
13C-NMR: (100.6 MHz, CDCl3, 25oC): δ =  173.3, 173.2, 171.3, 170.8, 170.6, 81.0,
80.9,  53.7, 52.8, 41.2, 31.9, 31.8, 28.0, 28.0, 27.3, 27.2, 23.1, 22.5, 11.3;
ESI-MS: m/z: calcd for C23H41N3O7 [M+Na]+ 494; found 494.
Elemental analysis: Calcd (%) for C23H41N3O7 (471.60):
C 58.58, H 8.76, N 8.91; found C 58.57, H 8.54, N 8.75.
6. 12. 2. Ac-L-Glu-L-Glu-NHPr 54
C15H25N3O7 : 359.38
1H NMR (400 MHz, DMSO, 25oC): δ = 8.04 (d, J = 7.2 Hz, 1H; NH Glu), 7.93 (d, J =
8.2 Hz, 1H; NH Glu), 7.77 (t, J = 5.7 Hz, 1H; NH Pr), 4.21 - 4.13 (m, 2H; Glu-Hα), 2.98
(m, 2H; NHCH2CH2CH3), 2.24 - 2.15 (m, 4H; Glu-Hγ), 1.91 - 1.63 (m, 4H; Glu-Hβ),
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1.83 (s, 3H; Ac), 1.53 (td, J = 7.3, 14.6 Hz, 2H; NHCH2CH2CH3), 0.80 (t, J = 7.6 Hz, 3H,
NHCH2CH2CH3);
13C-NMR: (100.6 MHz, CDCl3, 25oC): δ =  174.4, 174.3, 171.7, 171.1, 170.1, 52.6,
52.4, 40.7, 30.6, 30.5, 27.7, 27.6, 22.9, 22.7, 11.7;
ESI-MS: m/z: calcd for C15H25N3O7 [M-H]- 358; found 358;
6. 12. 3. Ac-F-Gly-Gly-Gly-L-Glu-L-Glu-Ahx-NHPr 57
C40H62N10O13 : 890.98
1H NMR (500 MHz, d4-MeOH, 25oC): δ = 7.55 (d, J = 7.9 Hz, 1H; H ar o-carbonyl),
7.32 (ψt, J = 7.6 Hz, 1H; H ar p-carbonyl), 6.95 (d, J = 7.9 Hz, 1H; H ar o-amino), 6.89
(d, J = 6.6 Hz 1H; H ar p-amino), 4.34 - 4.30 (m, 2H; Glu Ha's), 4.26 (dd, J = 5.8, 8.5 Hz,
1H; Lys-α), 3.95-3.83 (m, 6H; Gly-α), 3.36 (t, J = 6.8 Hz, 2H; Lys-ε), 3.21 - 3.12 (m,
2H; Ahx-ε), 3.11 ((ψt, J = 7.2 Hz, 2H; NHCH2CH2CH3), 2.45-2.35 (m, 4H; Glu-γ), 2.17
(t, J = 7.5 Hz, 2H; Ahx−α), 2.17-2.07 (m, 2H; Glu-β), 2.03 - 1.92 (m, 2H; Glu-β), 1.98
(s, 3H; Ac), 1.89 - 1.81 (m, 1H; Lys−β), 1.77 - 1.68 (m, 1H; Lys-β), 1.64 (ψq, J = 7.0 Hz,
2H; Lys-δ), 1.60 (ψq, J = 7.6 Hz, 2H; Ahx-β), 1.54 - 1.42 (m, 6H; NHCH2CH2CH3, Ahx-
δ, Lys-γ), 1.36 - 1.29 (m, 2H; Ahx-γ), 0.91 (t, J = 7.5 Hz, 3H, NHCH2CH2CH3);
13C NMR (100.5 MHz, d4-MeOH, 25oC): δ =  175.2, 175.1, 174.7, 174.6, 174.1, 172.6,
172.3, 172.0, 171.2, 171.1, 170.9, 146.4, 131.9, 127.8, 126.5, 119.8, 119.7, 54.0, 53.4,
53.0, 42.5, 42.4, 40.7, 38.9, 38.8, 35.6, 30.8, 29.9, 29.8,  28.6, 28.5,  26.6, 26.0, 25.3,
22.8, 22.2, 21.0, 10.3;
ESI-MS: m/z: calcd for C40H62N10O13 [M+]+ 891; found 891.
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RP-HPLC: retention time: 19.6 minutes (gradient: water (+ 0.1 % TFA): acetonitrile (+
0.1 % TFA) 100:0 -> 60:40 in 30 minutes).
6. 12. 4. Ac-F-Gly-Gly-Gly-Gly-Gly-Ahx-NHPr 58
C34H54N10O9 : 746.41
1H NMR (500 MHz, D2O, 25oC): δ = 7.25 (dd, J = 1.3, 7.6 Hz, 1H; H ar o-carbonyl),
7.18 (td, J = 1.5, 8.2 Hz, 1H; H ar p-carbonyl), 6.74 (d, J = 8.1 Hz, 1H; H ar o-amino),
6.69 (td, J = 1.2, 8.6 Hz, 1H; H ar p-amino), 4.12 (dd, J = 5.8, 8.5 Hz, 1H; Lys-α), 3.86 -
3.70 (m, 10H; Gly-α), 3.22 (t, J = 6.7 Hz, 2H; Ahx-ε), 3.03 (t, J = 7.3 Hz, 2H; Lys-ε),
2.97 ((t, J = 6.9 Hz, 2H; NHCH2CH2CH3), 2.06 (t, J = 6.3 Hz, 2H; Ahx−α), 1.86 (s, 3H;
Ac), 1.75 - 1.66 (m, 1H; Lys−β), 1.66 - 1.56 (m, 1H; Lys-β), 1.54 - 1.46 (m, 2H, Ahx-δ),
1.45 - 1.39 (m, 2H, Ahx-β), 1.37 - 1.29 (m, 6H; NHCH2CH2CH3, Lys-γ, Lys-δ), 1.16 -
1.09 (m, 2H; Ahx-γ), 0.72 (t, J = 7.4 Hz, 3H, NHCH2CH2CH3);
13C NMR (100.5 MHz, D2O, 25oC): δ =  175.8, 175.4, 175.2, 172. 2, 172.1, 172.0, 171.9,
132.4, 128.0, 118.7, 118.3, 54.0, 46.6, 42.4, 41.0, 39.1, 39.0, 35.6, 30.3, 27.9, 25.3, 25.0,
22.2, 21.7, 21.5, 10.5.
ESI-MS: m/z: calcd for C34H55N10O9 [M+1]+ 747; found 747;
RP-HPLC: retention time: 18.4 minutes (gradient: water (+ 0.1 % TFA): acetonitrile (+
0.1 % TFA) 100:0 -> 60:40 in 30 minutes)
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6. 13. Studies on the sequence dependence of peptide cleavage caused by the Fenton
reaction
6. 13. 1. Combinatorial assay with fluorophore-quencher library 43
In a 2 ml siringe with filter frit, ca. 10 mg of library 43 was weighted. It was washed
twice with water, followed by 1 ml of a 0.3 M FeCl3 solution (10 seconds). It was washed
five times with water. The iron complexed beads were placed into a 1.5 ml Eppendorff
tube and dried in a Speedvac.Then, 2 mg beads were placed in an Eppendorff tube and
650 µl water was added, followed by 500 µl of 0.1 M ascorbic acid solution and 100 µl of
1 M hydrogen peroxide (final pH of the reaction mixture: 3.0). After 20 minutes, the
reaction was quenched by washing five times with water. The beads were then studied
under a fluorescence microscope.
6. 13. 2. Solid phase complexation assay (excess)
The resin (0.23 mmol/g) with the peptide of interest (52 or 53) was first dried over high
vacuum.  Then ca. 15 mg (3.5 µmol) was weighed into a 5 ml syringe containing a filter
frit. The resin was washed five times with water and then equilibrated for 10 seconds
with 2 ml of a 0.3 M solution of FeCl3 in water. The resin was then washed six times with
2 ml water each. Then it was  washed 10 times with 2 ml of 0.1 M HCl each. The acidic
washing phases were collected in a 25 ml graduated flask, 1250 µl of 1M KSCN was
added and it was filled up to the mark with 0.1 M HCl and UV was measured at 480 nm
to determine the iron content.
6. 13. 3. Solid phase complexation assay (equilibration)
After drying over high vacuum, ca. 8 mg (1.8 µmol) of the resin bound (0.23 mmol/g)
peptide of interest (52 or 53) was weighed into a 5 ml syringe containing a filter frit.
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After the addition of 3 ml (1 eq) of a 0.6 mM solution of iron(III)chloride in  0.5 M MES
(pH 5.0) or 0.5 M acetate (pH 5.0) respectively it was equilibrated for 24 hours. Then the
reaction solution was filtered into a 25 ml graduated flask. Into the flask ca. 20 ml of 0.1
M HCl was added followed by 1250 µl of 1M KSCN and it was filled up to the mark
with 0.1 M HCl. The UV of this solution was measured at 480 nm to determine the iron
concentration in the solution.
The iron content of the resin was determined by washing the resin 10 times with 2 ml of
0.1 M HCl each. The washing phases were collected in a 25 ml graduated flask, 1250 µl
of 1M KSCN was added and it was filled up to the mark with 0.1 M HCl and UV was
measured at 480 nm.
6. 13. 4. Quantitative study of the cleavage by fluorescence spectroscopy
Into a sirynge (2 ml) with filter frit ca. 1 mg of the resin carrying the peptide of interest
(55 or 56) was exactly weighted. The resin was equilibrated with 1 ml 0.3 M FeCl3 and
washed five times with water. The iron complexed resin was then equilibrated for 20
minutes with 0.05 M ascorbic acid and 0.5 M hydrogen peroxide in a final volume of
1000 µl. After 20 minutes, the beads were removed by filtering and it was washed with
250 µl of water. Ca. 5 mg MnO2 was added to the reaction mixture. After 5 minutes, the
MnO2was removed by zentrifugation. 1000 ml of the solution was taken and placed into a
fluorescence cuvette followed by 2000 ml of 0.5 M acetate buffer (pH 4) and measuring
of the fluorescence with 320 nm exitation energy.
 6. 13. 5. Quantitative study of the cleavage in solution
From a stock solution, 0.05 µmol of the peptide of interest (57 or 58) was placed into a 1
ml eppendorf tube. After removal of the solvent on a speed vac, 5 µl (0.15 µmol, 3 eq) of
a 30mM solution of iron in 0.5 M MES (pH 5.0) was added. After five minutes 100 µl of
0.5 M MES (pH 5.0) and 35 µl of water was added and it was waited for another five
141
minutes. Then 100 µl (0.5 µmol, 10 eq) of a 5mM sodium ascorbate solution in water
was added followed immediately by 10 µl (10 µmol, 200 eq) of 1M hydrogen peroxide.
After 20 minutes of reaction time, ca. 5 mg of MnO2 was added and it was waited 5
minutes before the reaction mixture was filtered and injected into HPLC.
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Listing of the Sequences Found in the Screenings of the Peptide Libraries
Sequences found in the screening against side chain deprotected acetylated tripeptide
library 18 on polystyrene in chloroform
Receptor 10 (2 assays)
AS3 AS2 AS1 found
D-Val D-Val D-His 4x
D-Val D-Ala D-His 3x
D-Ala D-Val D-His 2x
D-Ala L-Asn L-Ala 2x
D-Ala L-Asn L-Val 2x
D-Phe D-Ala D-His 2x
D-Phe D-Phe D-His 2x
D-Phe D-Val D-His 2x
D-Ala D-Ala D-His
D-Ala L-Asn Gly
D-Ala L-Leu D-His
D-Asn D-Leu D-Val
D-Asn D-Phe D-Val
D-Asn D-Val Gly
D-Gln D-Leu D-His
D-Leu D-Phe D-His
D-Leu D-Val D-His
D-Phe D-Leu D-His
D-Thr D-Val D-His
D-Val D-Leu D-His
D-Val L-Ala D-His
L-Ala L-Asn Gly
L-His D-Leu D-Val
Receptor 13 (2 assays)
AS3 AS2 AS1 found
D-Val D-Phe D-His 4x
D-Val D-Leu D-His 3x
D-Val D-Val D-His 2x
D-Gln D-Phe D-Val 2x
D-Phe D-Phe D-His
L-Ala L-Gln D-Ala
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D-Phe D-Ala D-His
D-Ala D-Phe D-His
D-Gln D-Val D-Leu
Receptor 20 (2 assays)
AS3 AS2 AS1 found
L-Asn L-Phe L-Asn 3x
L-Asn L-Val L-Asn
L-Asn L-Leu L-Asn
L-Asn L-Ala L-Asn
D-Leu D-Asn D-Phe
D-Val D-Asn D-Asn
L-Val L-Ala D-Ser
Gly L-Ala L-Asn
D-Asn L-Val L-Asn
Sequences found in the screening against the fluorophore-quencher library 43 in water
Receptor 47
AA3 AA2 AA1
L-Asp L-Asp D-Lys
D-Glu D-Glu Gly
D-Asn L-Asp L-Asn
D-Asp D-Phe L-Asn
L-Glu L-Glu Gly
L-Phe L-Asp L-Asp
L-Glu D-Arg D-Phe
L-Thr D-Asp L-Asn
L-Asp L-Gln L-Asp
D-Asp L-Asp L-Glu
L-Asp L-Gln L-Glu
L-Asp L-Leu D-Asn
L-Ser L-Glu L-Asn
D-Glu D-Arg D-Leu
D-Asp L-Asp L-Glu
L-Glu D-Glu L-Ala
L-Asn D-Asp Gly
150
Sequences found by applying the Fenton reaction to fluorophore-quencher library 43
AA3 AA2 AA1
D-Lys L-Asp L-Asp
L-Lys D-Asp L-Asp
L-Gln L-Asp D-Asp
L-Pro L-Asp L-Glu
Gly L-Asp L-Glu
L-Thr L-Asp D-Glu
L-Cys D-Asp D-Glu
D-Cys D-Glu L-Asp
D-Leu L-Glu L-Asp
L-Gln L-Glu D-Asp
L-Pro D-Glu L-Asp
D-Ser L-Glu D-Glu
L-Phe L-Glu D-Glu
L-Asn D-Glu L-Glu
D-Asn D-Glu L-Glu
D-Gln D-Glu L-Glu
Gly D-Glu L-Glu
L-Phe D-Glu D-Glu
L-Asp L-Asp L-Lys
L-Asp D-Asp L-Gln
L-Asp D-Asp L-Pro
L-Asp L-Glu D-Ala
L-Asp D-Glu L-Ala
L-Asp D-Glu D-Cys
D-Asp L-Asp Gly
D-Asp L-Glu L-Leu
D-Asp L-Glu L-Cys
L-Glu L-Asp D-Glu
L-Glu L-Asp L-Thr
L-Glu D-Asp D-Leu
L-Glu D-Asp D-Pro
D-Glu L-Glu D-Cys
D-Glu D-Glu L-His
L-Asp L-Cys L-Glu
D-Asp D-Ser D-Asp
L-Glu L-Thr L-Asp
L-Glu D-Gln D-Asp
L-Glu D-Gln L-Glu
D-Glu D-Ala L-Glu
D-Asp L-Ala L-Asn
L-Glu L-Gln D-Asp
D-Glu L-Ser L-Ala
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